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B Summary - English 
Upon synthesis, nascent polypeptide chains are subject to major rearrangements of their side 
chains to obtain an energetically more favorable conformation in a process called folding. About 
one third of all cellular proteins pass through the secretory pathway and undergo oxidative 
folding in the endoplasmic reticulum (ER). During oxidative folding, the conformational 
rearrangements are accompanied by the formation of disulfide bonds – covalent bonds between 
cysteine side chains that form upon oxidation. Protein disulfide isomerase (PDI) assists in the 
folding of substrates by catalyzing the oxidation of pairs of cysteine residues and the 
isomerization of disulfide bonds as well as by acting as chaperones. In addition to PDI itself, a 
family of related ER-resident proteins has formed. All PDI family members share the thioredoxin 
fold in at least one of their domains and exhibit a subset of the PDI activities. Despite many 
studies, the role of most PDI family members remains unclear.  
The project presented in this thesis was aimed to establish tools for the biochemical 
characterization of single members of the PDI family and their role in the folding process. A 
combination of fluorescence based assays was developed to selectively study single functions of 
PDI family members and relate their properties of either catalysis of oxidation or catalysis of 
isomerization or chaperone activity to the rest of the protein family. A binding assay using 
isothermal titration calorimetry (ITC) was established to complement the activity assays. Using 
ITC we could show for the first time that members of the PDI family can distinguish between 
folded and unfolded proteins selectively binding the latter. The unique information provided by 
this method also revealed a two-site binding of unfolded proteins by PDI itself. 
In addition to the functional characterization, experiments were conducted to further investigate 
the oligomeric state of PDI. We could show that the equilibrium between structurally different 
states of PDI is heavily influenced by the redox state of the protein and its environment. This 
new data could help to further our understanding of the interplay between oxidases like PDI and 
their regenerative enzymes like Ero1, which may be governed by structural changes in response 
to the change in redox status. Another structural approach was the screening of all investigated 
PDI family members for suitable crystallization conditions. As a result of this screening we 
could obtain protein crystals of human ERp27 and were able to solve the structure of this protein 
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with X-ray crystallography. The structure gives insight into the mechanisms of substrate binding 
domains within the PDI family and helps to understand the interaction of ERp27 with the redox 
active ERp57. In collaboration with the group of Heike Hermanns we could further show the 
physiological importance of this interaction under oxidative stress. 
In conclusion, the project presented in this thesis provides novel tools for an extensive analysis 
of the activities of single PDI family members as well as a useful set of methods to characterize 
novel oxidoreductases and chaperones. The initial results obtained with the our novel methods 
are very promising. At the same time, the structural approach of this project could successfully 
solve the structure of a PDI family member and give information about the interplay within the 
PDI family. 
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C Zusammenfassung - Deutsch 
Neu gebildete Polypeptidketten arrangieren schon direkt nach ihrer Synthese die Seitenketten 
ihrer Aminosäuren um, damit sie einen energetisch günstigeren Zustand erlangen. Diesen 
Umlagerungsprozess nennt man Proteinfaltung. Schätzungsweise ein Drittel aller zellulären 
Proteine werden über den sekretorischen Transportweg geschleust und durchlaufen die oxidative 
Proteinfaltung im endoplasmatischen Retikulum (ER). Während der oxidativen Faltung werden 
zusätzlich zur Umlagerung von Seitenketten auch Disulfidbrücken gebildet. Dies sind kovalente 
Bindungen zwischen Zystein-Seitenketten durch Oxidation entstehen. Protein Disulfid Isomerase 
(PDI) unterstützt die Faltung von Proteinen im ER indem es die Oxidation zweier Zystein-
Seitenketten katalysiert. Neben der Oxidation katalysiert PDI ebenfalls die Isomerisierung von 
fehlverknüpften Disulfidbrücken und wirkt als Chaperon der Aggregation entgegen. Im Laufe 
der Evolution hat sich zusätzlich zu PDI eine Gruppe verwandter ER-lokalisierter Proteine 
gebildet. Diese Mitglieder der PDI-Familie weisen alle das Thioredoxin-Faltungsmotiv in 
mindestens einer ihrer Domänen auf und besitzen mindestens eine der drei PDI-Aktivitäten. 
Trotz eingehender Untersuchung ist die Rolle der meisten dieser PDI Familienmitglieder 
weiterhin unklar. 
Im Rahmen des Projekts, welches dieser Dissertation zugrunde liegt, wurden Methoden zur 
biochemischen Charakterisierung einzelner Mitglieder der PDI-Familie, und deren Rolle im 
Faltungsprozess, entwickelt. Eine Kombination von Fluoreszenzexperimenten wurde etabliert 
mit der selektiv einzelne Aktivitäten von Faltungshelfern analysiert und qualitativ in die PDI-
Familie eingeordnet werde können. Diese fluoreszenzbasierten Methoden wurden durch 
isothermale Titrationkalorimetrie (ITC) ergänzt. Mit ITC konnten wir als Erste zeigen, dass PDI-
Familienmitglieder gefaltete von ungefalteten Proteinen unterscheiden können und letztere 
selektiv binden. Die zusätzlichen Informationen, die in einem ITC-Experiment gewonnen 
wurden, zeigten, dass PDI mit Substraten mit Hilfe von zwei unterschiedlichen Bindungsstellen 
interagiert. 
Neben der funktionellen Analyse der PDI-Familie wurde Experimente durchgeführt um den 
oligomeren Zustand von PDI näher zu untersuchen. Wir konnten zeigen, dass das Gleichgewicht 
zwischen strukturell verschiedenen Zuständen entscheidend vom Redox-Status von PDI abhängt. 
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Diese neuen Daten werfen ein neues Licht auf die Interaktion zwischen Oxidasen wie PDI und 
ihren regenerativen Enzymen wie Ero1. Diese Interaktion könnte sehr wohl durch strukturelle 
Veränderungen, ausgelöst durch Redox-Reaktionen, reguliert werden. Als weiteren strukturellen 
Ansatz zur Erforschung der PDI-Familie wurden alle verwendeten Familienmitglieder auf 
aussichtsreiche Kristallisationsbedingungen hin untersucht. Durch dieses Screening konnte 
ERp27 kristallisiert und seine Struktur durch Röntgenkristallografie aufgeklärt werden. Die so 
gewonnene Struktur gibt Aufschluss über die Mechanismen der Substratbindung in der PDI-
Familie und hilft ebenfalls dabei, die Interaktion zwischen ERp27 und dem redoxaktiven ERp57 
besser zu verstehen. Auf Grund dieser Daten konnten wir gemeinsam mit der Gruppe von Heike 
Hermanns die physiologische Bedeutung dieser Interaktion bei oxidativem Stress aufzeigen. 
Zusammenfassend konnten im Rahmen dieses Projektes neue Werkzeuge zur eingehenden 
Analyse der PDI-Familie etabliert werden, welche auch zur Charakterisierung neuer 
Oxidoreduktasen und Chaperone verwendet werden können. Die ersten Ergebnisse die mit Hilfe 
dieser neuen Methoden gewonnen werden konnten sind vielversprechen. Gleichzeitig konnten 
wir mit ERp27 die Struktur eines weiteren PDI-Familienmitgliedes lösen und so weitere 
Einblicke in das komplexe Netzwerk der PDI-Familie gewinnen. 
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1. Introduction 
 
1.1 On proteins, structures and energy landscapes 
Proteins are the key to life. An organism’s genetic information for the most part either specifies 
the amino acid sequence of proteins or regulates the spatial or temporal distribution of protein 
production. Proteins are extremely versatile and are utilized for functions as different as 
structural support, movement, recognition, coordination of cellular events and exchange of 
information between cells. With very few exceptions, every biochemical reaction within a cell is 
catalyzed by a protein. No matter the task in an organism, one will find proteins involved in it. In 
the face of this multitude and variety of tasks, it comes as a surprise that proteins themselves are 
assembled from only twenty different building blocks: the proteogenic amino acids.  
By linking together amino acids in different combinations, proteins with diverse biochemical 
properties and functions are generated. Proteins binding transition states of reactants for example 
catalyze the corresponding reactions by lowering the activation energy. Proteins are assembled at 
the ribosome as polypeptide chains. These strings of amino acids are defined by the sequence of 
its residues, also known as the primary structure. In vivo, polypeptide chains do not keep this 
thread-like form. Instead, at a first level of higher order structure neighboring amino acids 
interact to form three-dimensional patterns, also known as the secondary structure. These 
patterned groups in turn interact with each other forming a complex three-dimensional tertiary 
structure. In many cases protein molecules become subunits in a stable protein complex. Such an 
arrangement is called the quaternary structure. This process of rearranging the relative 
orientation of residues to each other from the primary structure into a stable tertiary structure is 
called protein folding. The tertiary structure of a protein is more important in determining a 
protein’s function than the exact sequence of amino acids, as the tertiary structure determines the 
spatial arrangement of certain key residues. Independent studies [1-3] have found very similar 
structures, when investigating proteins which perform the same function (Fig. 1.1). 
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Despite originating from completely unrelated life forms, proteins performing an identical task 
usually share similar structures. On the other hand, two protein molecules might share the same 
amino acid sequence, but while one fulfils a vital role in the cell, the second may even be 
harmful to the organism due to a different fold. Multiple medical conditions are known to be 
caused by incorrect folding. Alzheimer’s disease is probably the most prominent example of an 
illness caused by the misfolding and subsequent aggregation of two proteins, amyloid-beta and 
tau, in the brain. [4] The build-up of protein aggregation – visible as amyloid plaques - finally 
leads to the pruning of neuronal connections and eventually cell death. Another publicly well-
known disease caused by protein misfolding is the Creutzfeldt-Jakob disease, which was covered 
extensively in the media in the 1990ies. Here prions – protein molecules with an alternative 
stable fold – act as chaperones convert their correctly folded forms into the prion fold [5]. 
Eventually, as the concentration of the misfolded prion form rises, the prions aggregate causing 
apoptosis. The difference in secondary and tertiary structure alone renders one a functional part 
of the cell and the other an infectious and pathogenic agent. These examples highlight the 
importance of protein folding to transform a newly translated polypeptide chain into a functional 
protein. 
Figure 1.1 – Structure and function 
 
Models of thioredoxins from Homo sapiens (green – 1ERU), Mycobacterioum tuberculosis 
(blue – 2I1U) and Chlamydomonas reinhardtii (red – 1DBY) were generated from coordinate 
files retrieved from the protein data base. Each protein performs the task of reducing protein 
disulfide bonds and all three proteins adopt the thioredoxin consisting of a central β-sheet 
which is flanked by two helices on each side. In all three proteins the active site (highlighted 
in yellow stick model) is located at the same position at the beginning of a helix. 
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A protein is able to fold because two bonds per residue within the polypeptide backbone are 
flexible and can rotate (see Figure 1.2). This flexibility allows the peptide chain to adopt many 
different conformations. Yet, as shown by X-ray diffraction analysis of crystallized proteins, 
most proteins only adopt a limited number of folded, native conformations, and single domain 
proteins usually only have one single native conformation [6]. At a conference in 1969 Cyrus 
Levinthal [7, 8] presented a calculation for the case of a small protein with 100 amino acids. 
Even if each amino acid of the hypothetical model is limited to only three different 
conformations and the interconversion of structures takes place with the speed of the fastest 
known biochemical reaction (1013/s, the reaction velocity for the hydration of carbon dioxide), 
the average time needed for folding would be 1.6x1027 years as there would be 3100 or 5x1047 
possible structures. The problem of the folding time of a small protein with limited 
conformations exceeding the age of the universe was termed the Levinthal paradox. In contrast, 
Barnase (Bacillus amylofaciensis Rnase, 110 amino acids) has been shown experimentally to 
fold with a half time of 50 ms [9]. This discrepancy between theoretical calculation and 
experimental observation shows that protein folding cannot succeed by randomly trying out 
every possible conformation. Anfinsen and coworkers could show [10] using RNAseA as a 
model, that proteins which were unfolded using chaotrope agents such as urea will reacquire 
their native conformation when the denaturing agent is removed. This refolding occurs in the 
absence of cellular factors demonstrating that the primary structure contains all relevant 
information for folding. Despite more than fifty years of research since those initial experiments, 
Figure 1.2 – Schematic of a peptide backbone 
The bonds involving the Cα atom are free to rotate. Thus the 
orientation of the amino acid in relation to its neighbors is 
defined by the diherdral angles ψ and φ. Due to the partial 
double bond character (dashed line) the peptide bond is fixed 
and cannot rotate. While both bonds can rotate freely, not all 
combinations of angles are possible due to sterical hindrance 
and unfavorable bond angles. The favored and disfavored 
combinations for amino acids are displayed in a 
Ramachandran plot. 
 
(Modified from Wikimedia Commons: 
Protein_backbone_PhiPsiOmega_drawing.jpg)  
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the prediction of a structure ab-initio from just its sequence of amino acids cannot be done with 
certainty.  
Any transition between two states depends on the energy gradient between those states. As the 
conformational change of a protein within the cell happens at constant temperature and pressure, 
the Gibbs free energy is used to describe the thermodynamic potential of a conformation. 
Folding is driven by the fact that an unfolded protein has a higher free energy than the folded 
state, which is stabilized by – among others – hydrogen bonds and hydrophobic interactions [11]. 
The previously discussed Levinthal paradox is based on the assumption that only the final native 
conformation possesses a lower free energy and that all non-native states are equal in their 
thermodynamic potential. The paradox breaks down, when the different free energies are 
attributed to folding intermediates [12]. Today the predominant model for protein folding is the 
energy landscape model. As two amino acids are brought into close proximity by their shared 
peptide bond, their bonds will rotate in a way that optimizes the interaction between them. Thus, 
there are many concurrent micro-folding processes as each amino acid accommodates to its 
micro environment, thus lowering the global free energy of the macro molecule, albeit at the 
level of kBT [13]. In parallel there is also a similar process to minimize the free energy between 
non-neighboring residues. Between those two often competing processes, some states are 
generated with an even lower free energy, from which, through rearrangement of larger segments 
of the protein, even more energetically favorable states emerge. When plotting all possible 
conformational states against their free energy, the energy landscape for a given sequence is 
generated. As this would require an n-dimensional plot (with n being the number of amino acids) 
and it is currently beyond our possibilities to accurately determine the free energy of fleeting 
Figure 1.3 – The ‘energy funnel’ 
3D model of a hypothetical energy landscape of a 
protein undergoing protein folding. The Gibbs’ free 
energy is plotted on the vertical axis. Proteins with 
energetically unfavorable conformations (red regions in 
the catchment area) move towards more lower energy 
states through a series of intermediate conformations. 
The blue center point with the lowest free energy 
corresponds to the native conformation of the protein. 
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folding intermediates, the landscape is usually visualized in the form of an energy funnel with 
the native conformation at its center (see Figure 1.3 - Taken from [14]) 
Such a funnel directs all possible conformations within its catchment area towards the central 
conformation with the lowest free energy within a short time. Experimental work with random 
and designed amino acid sequences show that such a smooth funnel with a single minimum is the 
exception rather than the rule [15, 16]. This stems from the fact that polypeptides are an 
inherently frustrated system, meaning that it is not possible for each functional group to attain its 
optimal environment. As an example, the hydrogen-bonded interactions of the peptide backbone 
favor the continuation of an α-helix, as the end of a helix contains unsatisfied hydrogen bonds. 
Yet a helix must be broken, as the hydrophobic interactions of apolar side chains require that the 
polypeptide chain folds back onto itself. This thermodynamic frustration often causes sequences 
to contain special amino acids to initiate or terminate helices, where side chains either provide 
additional hydrogen bonds or, in the case of proline at the start of helices, do not feature a 
nitrogen atom with hydrogen bond potential to reduce the frustration [17]. Spatial constraints are 
an additional source of frustration. Often the ideal thermodynamic arrangement is impossible due 
to the fact that polypeptides are a chain and single residues cannot move independently. This 
geographic frustration results in local minima that are similar in their free energy and structure, 
but are divided by a high energy barrier [12] and are thus not interconvertible. This leads to the 
formation of folding pathways, where few well-folded and energetically favorable intermediates 
compete for less folded intermediates. Depending on the topography of such a rough energy 
landscape, local minima can either lead on towards the folded state, or can represent a kinetic 
trap (as it has been mapped out for bovine pancreatic trypsin inhibitor, BPTI [18]). Statistical 
models such as those proposed by Bryngelson and Wolynes [19] postulate, that most local 
energy minima are way points on the path towards a native conformation as the folding molecule 
minimizes frustration. 
 
Besides the roughness of an energy landscape, its ‘depth’ – the difference in free energy (∆G) 
between the unfolded and the fully folded state – is also a very important characteristic of a 
protein. The amount of this free energy difference is directly related to the stability of a protein 
[20]. Stable proteins remain in their native conformation over a wide range of temperature, pH or 
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ionic strength. Naturally proteins have to balance competing needs. While they have to be stable 
enough to attain and retain their functional conformation at physiological conditions, very stable 
enzymes would be unable to undergo functionally relevant conformational changes needed e.g. 
for substrate binding. Also the function of a protein itself usually reduces stability, as binding 
interfaces for interaction partners or substrates as well as catalytic residues need to be present at 
a higher free energy level to thermodynamically favor the substrate-bound state [21]. With all 
those constraints on protein stability it is not surprising that enzymes are usually very well 
adapted to the physiological conditions inside the cell. This also highlights the importance of 
cellular homoestasis, as many proteins depend on a stable constitution of the solvent in order to 
remain in their native state. 
 
In conclusion, the shape and structure are the defining features of a protein. Made up from a 
limited variety of amino acids, proteins fold along the gradient of free energy, gradually 
optimizing the environment of their functional groups. A defined fold is a necessity, but protein 
stability is usually not the primary feature, a given sequence is selected throughout the course of 
evolution. Therefore the energy landscape is rarely a smooth funnel towards a single minimum 
as shown in Figure 1.3. Experimental work on β-barrel folds [22, 23] revealed that even with 
sequences designed to fold smoothly, the energy landscape is rather rough and contains many 
local energy minima. This roughness results from geometric constrains and competing but 
mutually exclusive tendencies to saturate hydrogen bonds and avoid solvent contact by apolar 
groups. In such a rough energy landscape, unfolded polypeptides are forced into defined 
pathways usually leading towards the native state. Once folded, the energy barriers surrounding 
the native state keep a protein folded and functional. Thus, proteins rely on a gradient of free 
energy not only to fold properly, but also to remain folded. As the energy landscape is shaped 
not only by the sequence, but also by environmental factors such as temperature, pH and ionic 
strength among others, cellular homeostasis is very important to keep proteins functional. 
 
 
1.2 Redox chemistry and its application to proteins 
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As previously discussed, proteins fold because their native state is favored energetically. The 
free energy difference between the unfolded and the folded state dictates the stability of a 
protein, which is correlated with the ability to retain its 3D structure under stress. This stress can 
be induced through a rise in temperature, a shift in pH or ionic strength, or a change in the 
solvent content, like the addition of ethanol or chaotropic agents. While proteins within the cell 
benefit from a stable and controlled environment maintained in the cytosol, there are many 
functional proteins on the outside of the cell wall or plasma membrane. These proteins need to 
keep a functional conformation under a wide variety of conditions that the cell can only 
influence to a limited degree. Therefore proteins working on the outside usually contain 
stabilizing features that raise energy barriers in order to lock a peptide chain in its functional 
state. 
The energy gain through the optimal arrangement of residues is relatively small, usually on the 
order of kBT [24], which corresponds to 4.11×10-21 J per residue or 2.48 kJ/mol at standard 
conditions. On the other hand, the binding enthalpy for a covalent bond between atoms ranges 
between 146 kJ/mol and 945kJ/mol [25], so with the introduction of covalent bonds between 
residues, a structure can be stabilized significantly. The most prominent bond utilized for protein 
stability is the disulfide bond. Cysteine residues carry a terminal free thiol group that is 
susceptible to oxidation under physiological conditions. Two cysteine residues with their thiol 
groups in proximity can transfer electrons to a suitable acceptor and form a disulfide bond – a 
covalent linkage between their side chains. Once formed, it requires either extremely high 
energies or a suitable redox reaction to break such a bond. Thus, disulfide bonds raise energy 
barriers to trap a protein in its native conformation. Due to their nature as a redox sensitive bond, 
they are reversible, they will only form once the protein is in an oxidative environment and they 
can be removed through reduction with a suitable electron donor. 
The redox potential within the cell is regulated to keep the proteins in the proper redox state. 
Eukaryotic cells generally maintain a reducing environment in the cytoplasm with regard to their 
proteins. To keep the cysteines of a protein reduced, a buffer system of the oxidized and reduced 
forms of the tri-peptide glutathione is used. Upon spontaneous oxidation of protein cysteines, the 
resulting disulfide bond is reduced by the enzyme thioredoxin with electrons supplied by reduced 
glutathione which itself becomes oxidized and forms a disulfide bond. The dimeric glutathione is 
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then reduced by the enzyme glutathione reductase which uses the reductant NADH generated by 
the catabolic branch of the metabolism to regenerate the reduced glutathione. Therefore proteins 
localized in the cytosol, the nucleus or other reducing environments have evolved to be 
functional with their cysteines in the reduced state.  
In contrast to the cell interior, the environment of cells is usually oxidizing with regard to 
proteins due to the presence of molecular oxygen. This means that extracellular proteins or the 
extracellular portions of membrane spanning proteins usually feature disulfide bonds in their 
functional conformation. In order to have properly disulfide bonded proteins ready for the export 
to the cell surface, there must be cellular compartments where maturating proteins can be 
oxidized and processed. In prokaryotes the periplasm – the space between the inner and the outer 
membrane – contains such an oxidizing environment. In eukaryotes, the endoplasmic reticulum 
Figure 1.4 – The role of PDI during folding 
During oxidative folding in the ER, PDI oxidized the 
nascent reduced peptide donating its disulfide bond to the 
substrate. The now reduced PDI is then reoxidized by 
Ero1 which uses its FAD cofactor to transfer electrons 
onto molecular oxygen. 
As the oxidation of peptides is determined by the semi-
random proximity of cysteine residues at the time of 
oxidation, substrates containing more than two cysteines 
can end up with non-native disulfide bonds. Reduced PDI 
can attack substrate disulfide bonds, initiating a disulfide 
rearrangement in the substrate. 
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(ER) is the most important site for oxidative folding. Proteins destined for an oxidative 
environment, be it the cell surface, a mitochondrium or the ER itself, are translated by ribosomes 
directly bound to the ER membrane (rough ER) that separates the cytoplasm from the ER lumen 
[26]. In the ER, nascent proteins are often glycosylated cotranslationally and then oxidized by 
protein disulfide isomerase (PDI). PDI transfers an active site disulfide bond to a folding 
substrate and is in turn reoxidized by the actions of Ero1 [27], which generates disulfide bonds 
de novo, utilizing a FAD cofactor to directly transfer electrons onto molecular oxygen resulting 
in the generation of hydrogen peroxide (Fig. 1.4). In general, the oxidation of folding proteins 
and de novo disulfide bond generation are separated. PDI oxidizes substrates in both the plant 
[28] and animal kingdom and is subsequently reoxidized by ER oxidoreductases such as Ero1p 
in yeast [27], AERO1 in plants [29] or Ero1-Lα in mammals [30] that funnel the electrons to 
final acceptors such as molecular oxygen. In bacteria proteins are oxidized by DsbA[31], which 
in turn gets reoxidized by DsbB [32]. The hydrogen 
peroxide is further reduced to water by 
peroxiredoxins[33], which also can generate disulfide 
bonds and transfers them onto PDI [34, 35]. 
The redox potential is the chemical property that 
decides whether a compound placed in an environment 
with other redox active compounds is present in its 
oxidized or reduced form. For a given redox couple 
such as oxidized and reduced glutathione or cysteine 
and cystine (the disulfide linked form of two 
cysteines), the redox potential is determined 
experimentally by measuring the electrochemical 
potential towards the standard reaction 2H+ + 2e- -> H2 
at a pH of 7, which is assigned the redox potential of 0 
V. The experimentally measured redox potential for 
glutathione, if present in equal concentrations in its 
reduced and oxidized form, is -240 mV [36]. In 
general, electrons will flow from lower to higher 
Figure 1.5 - Standard redox 
potentials of selected cellular redox 
active proteins and compounds.  
Electrons are transferred along the 
gradient with molecular oxygen as 
terminal electron acceptor in aerobic 
organisms. 
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electron potentials. So, if for example the cellular reductant NADPH with a potential of -315 mV 
is added to glutathione, electrons will be transferred from NADPH to glutathione, oxidizing the 
former and reducing the latter. The larger the difference between the redox potentials the more 
complete will each partner become oxidized and reduced, respectively.  
In the cell, redox catalysts create a micro-environment by the arrangement of appropriate side 
chains in the vicinity of the active site, to modify the redox potential of the catalytic cysteines. 
Reductases such as TrxA are able to reduce their redox potential to values of -270 mV [37] while 
on the other hand oxidases such as DsbA increase their redox potential to -120 mV [38] in order 
to carry out their respective reaction more efficiently. PDI – being an isomerase in addition to its 
oxidase functionality – keeps its two active sites in a moderately oxidizing range at -175/190 mV 
[39] in order to be able to partly reduce target proteins at all during the initial step of the 
isomerization reaction. 
This work will focus on the redox biochemistry in the endoplasmic reticulum. Approximately 
one third of all proteins are destined for an oxidative environment and are synthesized by ER 
membrane associated ribosomes, which directly release the nascent polypeptide chain into the 
lumen of the ER [40]. In the ER a chain of redox partners funnels the electrons of the reduced 
nascent cysteines onto molecular oxygen, forming disulfide bonds in the protein undergoing 
folding during this process. The formation of disulfide bonds is a kinetic challenge, as their 
formation is orders of magnitude slower than the rapid folding processes [31, 41-43]. Yet the 
disulfide bonds due to their covalent nature provide a significant increase in protein stability 
enabling proteins to retain their functional conformation over wider ranges of  pH, ionic strength, 
solvent composition and redox environment. Thus, a network of enzymes has evolved to 
accelerate the oxidation of cysteines and to provide assistance in forming the correct disulfide 
linkages. 
 
1.3 Assistants in folding: The protein disulfide isomerase family 
In the lumen of the endoplasmic reticulum – a network of membranes attached to the nucleus – 
nascent proteins undergo folding in an oxidative environment. Compared to the formation of 
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secondary and tertiary structures which develop within 
milliseconds [41], the formation of covalent disulfide bonds 
in vitro is considerably slower with rates on the timescale of 
minutes or even hours [42, 43]. In comparison, the reported 
rate for the in vivo oxidation of proteins is generally faster, 
occurring within seconds [31]. The reason for the discrepancy 
between in vitro and in vivo oxidation rates is the presence of 
folding catalysts within the cell that assist in the oxidation and 
folding of maturing proteins. Those folding catalysts exhibit 
three major functions in order to accelerate oxidative 
refolding. For one, disulfide bonds need to be inserted into 
folding substrates. Oxidases – such as the Escherichia coli 
enzyme DsbA [31]– donate their active site disulfide bond to 
substrates. The now-reduced oxidases get in turn oxidized by specialized regenerating proteins – 
such as DsbB [32] – that are capable of generating disulfide bonds de novo, passing the electrons 
over intermediates onto molecular oxygen. With the combination of oxidases and an oxidizing 
environment in the periplasm (prokaryotes) or the endoplasmic reticulum (eukaryotes), 
respectively, proteins undergoing folding are oxidized upon translocation quickly and efficiently. 
As oxidases usually also catalyze the reverse reaction – the reduction of disulfide bonds given a 
reducing environment – they are also often called oxidoreductases. While rapid oxidation is all 
that is needed for small proteins to fold within a sensible timeframe, larger proteins are facing an 
additional challenge. As the number of possible disulfide bond combinations increases 
exponentially with the numbers of cysteines in a substrate (see Table 1.1), and many substrates 
follow distinct and complex oxidation patterns [44-46], proteins may form non-native disulfide 
bonds during folding. Therefore folding catalysts have to provide a second essential function. 
They attack non-native disulfides, creating a short-lived intermolecular disulfide bond. This 
results in a reduced cysteine in the folding protein, which can in turn attack other disulfide bonds 
in the vicinity starting an isomerization of bonds. This intramolecular rearrangement continues 
until the intermolecular disulfide is attacked, either by a cysteine of the rearranging substrate, or 
by the second active site cysteine of the isomerase. In order to be available for either oxidation or 
isomerization, misfolded proteins have to be present in a soluble form. Yet, most un- or 
Table 1.1: 
Increased number of 
cysteines exponentially 
increases the complexity of 
oxidative folding. 
Number of 
Cysteines 
Possible 
combinations 
2 1 
4 3 
6 15 
8 105 
10 945 
14 135135 
20 654729075 
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misfolded proteins tend to aggregate and precipitate out of solution, minimizing the surface area 
available for interactions with oxidases or isomerases. To overcome this, many folding catalysts 
also exhibit a chaperone function. This means they selectively bind non-natively folded proteins, 
sequestering them away from other misfolded proteins in to avoid aggregation. Periodically 
chaperones release their bound substrate in order to make it gradually available for processing by 
other folding catalysts. 
The very first protein found to accelerate the refolding of a denatured substrate was an enzyme 
later identified as PDI [47]. In refolding assays, the activity of the analyzed ribonuclease 
recovered significantly faster when PDI was added to the denatured protein undergoing 
refolding. PDI increased the rate of protein oxidation in a glutathione buffer, proving itself to be 
an oxidase. PDI also increased the rate of reactivation of scrambled ribonuclease, which is fully 
oxidized, but not functional as its cysteines are connected in a non-native way. In order to regain 
their functionality, such scrambled proteins need to isomerize their disulfide bonds, rearranging 
the way their cysteines are connected. Thus PDI was shown to also act as an isomerase. In later 
studies, PDI was also shown to act as a chaperone [48, 49], binding model substrates in a 
transient manner. Whether this is a byproduct of its substrate-binding capabilities or an 
independent function recently became a topic of discussion as anti-chaperone activity has been 
tied to PDI-protein interactions as well [48, 50]. Exhibiting three important functionalities PDI 
has become one of the most studied folding catalysts. In the course of this thesis, the focus will 
be on PDI’s role during oxidative folding. However, PDI also moonlights in other activities. The 
most prominent is its involvement in the assembly of the enzyme complexes prolyl-4-
hydroxylase [51] and microsomal triacylglycerol transfer protein (MTTP) [52]. In those cases 
PDI is an integral structural component, but is not involved in catalysis and does not require its 
active site. Several studies have reported that PDI is also located outside of the ER (for a review 
see [53]). Up to date, it is still unclear, how PDI is able to escape the ER retention mechanism 
and what role it plays outside of the ER. Yet it has been implied into medically relevant 
processes [54, 55] in those unusual locations and is currently under intense investigation. 
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1.3.1 The architecture of protein disulfide isomerase (PDIA1) 
Human PDI is a 57 kDa protein with a main chain comprised of 507 amino acids. Secondary 
structure predictions and protein characterization revealed early that the protein consists of four 
domains, each adopting the thioredoxin fold. The thioredoxin fold – named after the reductase 
thioredoxin A (TrxA) – is a common structural feature in many oxidoreductases. The core of the 
thioredoxin fold is characterized by a secondary structure sequence of β1-α1-β2-α2-β3-β4-α3 (see 
Fig. 1.6 and [56]) forming a central four stranded mixed β-sheet flanked by three α-helices. 
Often, the fold is expanded N-terminally by an additional β-strand and α-helix each to β0-α0-β1-
α1-β2-α2-β3-β4-α3 [57]. The active site consists of a CXXC motif which is located at the 
beginning of the first α-helix (α1). This allows the active site cysteines to form a disulfide as 
their thiols are placed in close spatial 
proximity. The two residues between 
the active site cysteines have been 
shown to greatly influence the redox 
potential [58]. Also the neighboring 
residues of the active site are highly 
conserved and thus form an extended 
active site motif of WCXXCK [59] 
most likely being involved in 
forming a suitable microenvironment 
for catalysis, for substrate binding or 
both. Further away in the sequence 
but in structural proximity is the so 
called cis-loop proline. This proline 
[60] and especially the N-terminally 
adjacent residue [61] have been 
shown to be important for the 
catalytic activity of the active site. 
Figure 1.6 – Schematic of the thioredoxin fold 
The canonical thioredoxin fold consists of four beta 
strands (blue arrows) forming a mixed beta sheet 
which is flanked by three alpha helices (red bars). The 
active site (marked in yellow) is located at the N-
terminus of the first alpha helix. The green pentagon 
denotes the location of the cis-proline, an important 
residue modifying the properties of the active site. 
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PDI, like many other related 
oxidoreductases, consists only of 
thioredoxin fold domains, though not 
all have an active site. Throughout 
the PDI family, there are three types 
of thioredoxin fold domains. The a 
domains contain a redox sensitive 
active site with active site cysteines. 
These domains are usually directly 
involved in the redox reaction 
performed by the enzyme. Domains 
devoid of an active site are referred 
to as b domains. These domains may 
or may not contain a rudimentary 
extended active site motif, but they 
never contain active site cysteines. 
Among the b domains, there is a 
subgroup called b’ domains. These 
domains share a structural feature of 
exposed hydrophobic residues or – if 
the structure is unknown – align with 
known b’ domains. Together, these residues form a cleft or groove of hydrophobic residues 
where unfolded substrate proteins have been shown to bind [62]. The thioredoxin domain 
architecture of PDI is a-b-b’-a. In addition to the thioredoxin domains, two more structural 
features could be detected in a secondary structure prediction of PDI. For one, the C terminus 
forms an additional helix – rich in acidic residues – not belonging to the thioredoxin motif. At 
the very end of this negatively charged helix, the canonical ER retention motif KDEL is located, 
but apart from ER retention, no functional role could be assigned up to this point to the C 
terninus. Despite being only a single helix, the C terminal extension is generally referred to as 
the c domain of PDI. The second structural feature is a very long linker between the b’ domain 
and the C terminal a domain. This extended linker region is often added to the domain 
Figure 1.7 – Crystal structure of yeast PDI 
Generated from structure 2B5E deposited at the 
RCSB. The four thioredoxin fold domains a 
(magenta), b (cyan), b’ (blue) and a’ (red) are 
arranged in the shape of a ‘U’ with the b domains 
forming the bottom and the a domains the sides. The 
active sites of the a domains are marked in yellow. 
The orange loop marks the x-linker, which has been 
suggested to regulate substrate binding. The highly 
charged and acidic c domain (green) contains the C-
terminal ER retention signal (KDEL), which is located 
beyond the residues visualized in the structure. 
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architecture as an ‘x’ due to its larger size. So the general architecture of PDI is often described 
as a-b-b’-x-a’-c, with the a’ domain being the a domain adjacent to the b’ domain. 
The first picture of a full length PDI molecule at atomic resolution came in 2006, when the X-ray 
crystal structure of yeast PDI (also referred to as PDI_A1) was solved [63]. In the crystal 
structure, the four domains are arranged in the shape of a twisted ‘U’ (see Fig 1.7). At the bottom 
of the ‘U’ the b and b’ domains form a base. The interface between those two domains is 
extensive and therefore there is little flexibility between the b and b’ domains. In contrast the two 
a domains are connected to their respective b domains through flexible linkers, allowing for 
larger movements of the active site domains in relation to the rigid base. In the originally 
published structure, both a-type domains are positioned to have their active sites facing each 
other. Yet, a second structure [64] (3BOA) showed the same molecule, but with its a’ domain in 
a completely different orientation facing outwards. This alternate conformation highlights the 
flexibility of the a-type domains in their orientation in relation to the b-b’ core.  
The crystal structure of yeast PDI not only provided a high resolution image of the domain 
arrangement, but also gave insights into features and possible functions of the domain types. The 
b-b’ domain core contains an unusual amount of 
solvent exposed hydrophobic residues. These 
residues are all facing towards the a domains, 
increasing the hydrophobicity on the base of the 
‘U’. In addition, the b’ domain contains a cleft 
which opens towards the a-type domains and 
which is very hydrophobic in nature (see Fig. 
1.8). This cleft is rather narrow not offering 
enough space for domains or even a single 
helix, but is suitable for the binding of 
unstructured peptide chains. Unfolded or 
misfolded proteins – the potential substrates of 
PDI and PDI family members – generally have 
a higher content of exposed hydrophobic 
surface, which usually leads to aggregation of 
Figure 1.8 – Surface hydrophobicity of PDI 
Surface representation of yeast PDI (green) 
with hydrophobic residues (Ala, Leu, Ile, 
Val, Pro, Met, Trp and Phe) colored in red. 
Active sites are marked in yellow. The 
hydrophobic cleft is clearly visible on the b’ 
domain between the active sites. 
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misfolded protein. Potential substrates also contain an above average amount of regions, where 
amino acids form neither α-helices nor β-sheets. These random coil or loop regions can fit into 
the hydrophobic cleft of the b’ domain. With its capability to bind unstructured and hydrophobic 
regions or other proteins, the hydrophobic base formed by the b-b’ domains appears to be an 
ideal candidate for substrate binding and recognition [65].  
The peptide binding capability was confirmed by a nuclear magnetic resonance (NMR) structure 
of the isolated b’ domain of human PDI and the associated ‘x’ linker region [66] that normally 
connects the b’ domain with the C-terminal a domain. In this structure, the hydrophobic region 
of the flexible linker binds into the hydrophobic pocket of  the b’ domain, suggesting a 
regulatory function of the ‘x’ linker and further supporting the hypothesis that the b’ domain – 
especially its hydrophobic cleft – represents the core of the substrate binding site. In the initial 
X-ray structure of full-length yeast PDI, another feature also pointed towards the substrate 
binding role of the b-b’ domain core; there were crystal contacts between two yeast PDI 
molecules from different asymmetric units, placing the b domain of one molecule between the 
active site domains of the other. The resulting model shows nicely, how domain-sized substrates 
might position themselves via the hydrophobic surface of the b-b’ core to interact with the active 
sites. 
The crystal structure also advanced our understanding of the active site domains. They are 
positioned with the active sites facing each other over the substrate binding site, hence 
suggesting a cooperative action. The active site domains of yeast PDI are very homologous to 
other active site domains of this family of oxidoreductases, with a highly conserved consensus 
motif. It also becomes clear, how key residues of the active site domains determine the redox 
potential of the active site. The most important factor are the residues between the active site 
cysteines. As shown in vitro by Wunderlich & Glockshuber [59] and in vivo by Quan et al.[58], 
mutations in this position can radically alter the redox potential, turning a reductase like TrxA 
into an oxidase able to replace DsbA in the periplasm of E. coli. There are also other key 
residues, supposed to modulate the redox potential such as the side chains of the cis-proline loop. 
This loop, located between helix two and strand three, comes into close proximity of the active 
site and was shown to be important for the modulation of the enzymatic activity. The full-length 
structure of PDI revealed the presence of a buried pair of charged and polar residues. Located 
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within the hydrophobic interior of the domain, these residues approach the active site from the 
back and are hypothesized to stabilize the reduced state and to assist in the deprotonation of an 
active site cysteine. In this way, the buried charged polar pair can simultaneously lower the 
redox potential and increase the reactivity of the reduced state. Unfortunately, the influence of 
this residue pair could not yet be conclusively proven. 
Despite all the information gained through the determination of the structure and a multitude of 
biochemical studies, many questions still remain regarding the function of PDI. The second 
crystal structure for example revealed large movements occurring within the molecule, which are 
necessary for the activity of the protein. Large scale conformational changes could also explain, 
how PDI might adapt to the enormous size range of potential substrates, and how the interaction 
with regenerating enzymes is regulated. Also PDI has evolved into a whole family in higher 
eukaryotes. While PDI1 is still regarded as the most important enzyme in the oxidative folding 
process in the ER, the role of most PDI family members still remains unknown.  
 
1.3.2. The PDI protein family 
PDI is ubiquitous throughout the eukaryotic realm. While PDI itself fulfills a critical part in the 
oxidative folding process and is lethal when knocked out, there is also a group of proteins with 
thioredoxin fold domains resident in the ER called the PDI protein family. In general there are 
more PDI like proteins expressed by an organism, the more complex the organism is. In humans 
there are six genes belonging to the PDI gene family (PDIA1 through PDIA6) encoding for the 
proteins PDI, PDIp, ERp57, ERp72, PDIr and P5. Their encoded proteins all have multiple 
thioredoxin fold domains, contain at least one b-type domain and at least one a-type domain with 
a CGHC as the active site motif. Besides this core group, ERp18, ERp27, ERp28, ERp44, ERp46 
and ERdj5 are usually also included into the PDI family. The members of the latter group are all 
ER resident proteins containing at least one thioredoxin fold domain, though they might lack 
either a-type domains or b-type domains or carry completely different active site motifs. 
Additionally a group of transmembrane oxidoreductases (TMX) are also usully included, 
extending the family to more than 15 related in higher eukaryotes [67]. These proteins are 
located in the ER membrane and contain at least one thioredoxin fold domain with an active site. 
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In this large – and still growing – group of proteins, the roles for most individual family 
members still remain unknown. Apart from PDI itself, the proteins ERp57, ERp27 and P5 were 
in the focus of this project.  
ERp57 is one of the most extensively studied PDI family members. It shares its domain 
composition (a-b-b’-a’-c) and more than 20% sequence identity with PDI as well as the overall 
‘twisted U’ architecture as seen in its crystal structure [68]. ERp57 catalyzes disulfide bond 
formation of a glycoprotein subset of substrates and requires the lectins calnexin and calreticulin 
to facilitate substrate-binding.  
Human P5 consists of two a-type and one b-type domain and is reported to have isomerase and 
chaperone activity, albeit with lower efficiency than PDI [69]. A second report also showed in 
vitro disulfide exchange activity [70], but its involvement in the ER folding process remains 
largely unexplored compared to the reports on its activities outside of the ER.  
ERp27 is only comprised of two b-type domains and completely devoid of an active site. It can 
bind unfolded peptides like ∆somatostatin as well as ERp57 [71] and might act as a mediator for 
ERp57 to interact with substrates not recognized by calnexin or calreticulin.  
Despite sharing structural features and belonging to the same protein family, these three proteins 
have been shown to behave completely different. The knowledge currently available about the 
roles and interactions of the PDI family members is very limited and to gain a comprehensive 
understanding of the folding machinery processing a wide variety of substrates in an efficient 
and timely manner, much remains to be done. The projects detailed within this thesis attempt to 
increase our knowledge about mechanistic aspects of the PDI family. 
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2. Materials & Methods 
2.1 Molecular Biology 
This section encompasses all methods used to:   a) analyze and manipulate DNA 
       b) transform E. coli cells with DNA and 
       c) cultivate E. coli cells. 
2.1.1 Separation of DNA molecules by size 
In order to analyze fragments of deoxyribonucleic acid (DNA), they were separated by size via 
electrophoresis in an agarose gel. To prepare a gel, agarose was boiled in TAE running buffer. 
The amount of agarose varied between 0.8% (w/v) and 1.4% (w/v) according to the size of the 
DNA fragments to be analyzed. After cooling down the gel 
slowly to temperatures below 60˚C without letting it solidify, 
ethidium bromide was added to a final concentration of 0.5 µg 
per ml. The liquid agarose solution was then poured into a gel 
scaffold, allowing it to solidify. One part of 6x concentrated 
DNA sample buffer was added to five parts of DNA solution and 
mixed before pipetting the sample into the wells of the agarose gel. The gel was immersed into 
TEA buffer and subjected to electrophoresis at 120 V for 45 min. To detect the fragment pattern 
of the separated DNA, the gel was subjected to UV light. The ethidium bromide within the gel 
intercalates into the DNA double helix and shows fluorescence if excited with light around 290 
nm wavelength. For documentations, the fluorescent image was recorded using the Biorad 
GelDoc documentation system 
 
2.1.2 Extraction of DNA from agarose gels 
To retrieve fragments from an agarose gel after analysis (see 2.1.1) the QIAquick gel extraction 
kit was used. First the bands of interest were excised using a fine scalpel under UV light from a 
TAE buffer 
4.84   g Tris 
1.14 ml Acetic Acid 
2.00 ml 0.5M EDTA 
add to 1L dd H2O 
adjust to pH 8.5 
Contents of TAE buffer 
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UV illuminator on the lowest setting. After each excision, the blade was carefully cleaned to 
avoid cross contamination. The target DNA was extracted from the agarose gel fragments using 
the NucleoSpin extract kit by Macherey-Nagel. In this protocol the gel is first dissolved using a 
urea buffer. Next, the DNA is bound to an anion exchange column, washed with ethanol and 
eluted using either TE buffer (10 mM Tris pH8.0, 1 mM EDTA) or ddH2O. The exact procedure 
is detailed in the kit protocol. 
 
2.1.3 Purification of plasmid DNA 
Plasmid DNA was extracted and purified from E. coli cell cultures using the Macherey-Nagel 
NucleoBond miniprep kit. Cells from a 5 mL overnight culture of E. coli were harvested by 
centrifugation (Eppendorf centrifuge 5417R, 25,000 x g, 3 minutes, 4 °C). The medium was 
discarded and the cells resuspended in 250 µL S1 resuspension buffer. Cells were subsequently 
subjected to alkaline lysis by the addition of 250 µL S2 lysis buffer containing sodium dodecyl 
sulfate and sodium hydroxide followed by a 5 minute incubation at room temperature. As soon 
as the solution cleared, 350 µl S3 neutralization buffer was added to move the pH to the neutral 
range and precipitate the SDS together with cell debris and membranes. In order to separate the 
precipitate from the solution, the samples were centrifuged (Eppendorf centrifuge 5417R, 25,000 
x g, 10 minutes, 4 °C) and the supernatant removed carefully to avoid contamination with 
precipitate. The supernatant was loaded on an anion exchange column provided with the kit, 
washed with ethanol and eluted using either TE buffer (10 mM Tris pH 8.0, 1 mM EDTA) or 
ddH2O. The exact procedure followed is detailed in the kit protocol. 
 
2.1.4 Digestion with restriction endonucleases  
Restriction endonucleases (also called restriction enzymes) are proteins that cleave the sugar-
phosphate-backbone of double stranded DNA molecules. These breaks are introduced only at 
target sites that are highly specific to each restriction enzyme. Due to their sequence specificity, 
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they are used to cut DNA-molecules in a predicted pattern, producing fragments that can be 
recombined later.  
A typical reaction with restriction enzymes contained: 
3.0 µl 10x reaction buffer*  
1.0 µl restriction endonuclease (10u/µl) 
x µl target DNA – 1µg of DNA in total 
Add to 30 µl autoclaved distilled water 
* - The buffer was specified and supplied by New England Biolabs together with the enzyme.  
 The reaction mix was incubated at the appropriate temperature as specified by the supplier for 1 
h. The reaction was stopped either by heat inactivation (if applicable), or by separation of the 
reagents and the DNA by agarose gel electrophoresis (see 2.1.1).  
 
2.1.5 Polymerase chain reaction and site directed mutagenesis  
The polymerase chain reaction (PCR) is a powerful tool to amplify DNA sequences with a 
known start and stop site. It is based on an in-vitro replication, where DNA-polymerase is 
provided with a template, a primer and activated nucleotides (dNTP). To duplicate a target 
sequence, it is first heated up to melt double stranded DNA, the temperature is then reduced, to 
enable the primer to bind. As soon as a primed single strand is available, the polymerase starts to 
duplicate the sequence following the primer, yielding two double stranded DNA molecules – one 
from each strand of the original. By iteration, the region between the two primers are nearly 
doubled on each cycled. Due to the exponential growth, even a very small amount of template 
DNA is sufficient to generate large quantities of the piece that is located between the two 
primers. 
As the primers get incorporated into the product, this method can also be used to introduce 
changes into a target DNA sequence. Primers used for site directed mutagenesis are designed to 
match with the sequence upstream and downstream of the mutation, but contain a mismatch at 
the site of mutagenesis. When the PCR is carried out, DNA molecules containing the sequence 
of the primer will vastly outnumber the ones containing the original sequence.  
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A typical PCR reaction contained: 
x µl template DNA – total of 200ng 
1.0 µl each Primer (concentration = 50µmol) 
1.0 µl dNTP (dATP, dCTP, dGTP, TTP – 10mM) 
10.0 µl 5x Pfu reaction buffer 
1.0 µl Pfu polymerase 
add to 50µl autoclaved and distilled water 
 
The reaction was then subjected to the following PCR protocol using an Eppendorf Mastercycler 
EPgradient S PCR cycler: 
Cycle name Temp. Duration Number of cycles 
Initial denaturation 95˚C 5 min 1 
Denaturation 95˚C 30 sec 25 
Primer annealing 55˚C 45 sec 
Elongation 65˚C 1 min/1kb* 
Final elongation 65˚C 7 min 1 
* - Elongation time depends on the length of the expected product. 
 
2.1.6 Sequencing of DNA 
Sequences of DNA were determined by the company SeqLab (Goettingen, Germany) from 
samples of plasmid DNA using dideoxy sequencing based on the method originally published by 
Sanger et al. [72]. 
 
2.1.7 Cultivation and storage of E. coli strains 
For general usage E. coli was grown in LB-medium (20 g/L LB powder in H2O) under 
permanent selection with one or more of the following antibiotics: 
Antibiotic Final concentration 
Ampicilin 200 µg/ml 
Tetracycline 200 µg/ml 
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Chloramphenicol  34 µg/ml 
Kanamycin 200 µg/ml 
A standard overnight culture contained 5 ml LB media supplemented with the appropriate 
antibiotic in a 15 mL test tube. It was inoculated by touching a pre-existing culture or plate with 
a sterile micropipette tip and inserting this tip briefly into the fresh culture medium. 
For protein expression, pre-cultures were grown in 200 mL of LB medium supplemented with 
the appropriate antibiotics in a 500 mL shaker flask. These cultures were inoculated from single 
colonies of freshly transformed E. coli. cells Main cultures of 2.5 L LB with the appropriate 
antibiotics in 5 L shaker flasks were inoculated by transferring 20 mL of pre-culture grown to an 
optical density at 600nm (OD600) of 1.5. 
For long-term storage of E. coli strains, 500 µl of a grown overnight culture were rapidly mixed 
with 1 ml of 20% (v/v) autoclaved glycerol and stored at –80˚C. 
 
2.1.8 Transformation of E. coli 
Preparation of competent cells 
The desired strain was streaked out and grown on an LB agar plate supplemented with antibiotics 
according to the strain resistances. 200 ml of LB medium were inoculated from a single colony 
of this LB plate and incubated shaking at 200 rpm and 37 °C. During the incubation, the optical 
density (OD600) was monitored. Cells were grown into the early log phase (OD600 = 0.3-0.5) and 
then harvested in sterile 50 mL falcon tubes by centrifugation (Eppendorf Centrifuge, 4000 x g, 
10 minutes, 4 °C). The supernatant was discarded and the pellet was kept on ice. All subsequent 
steps were carried out at 4 ˚C or on ice. The pellet was resuspended in 15 ml of ice cold sterile 
filtered TFB1 buffer (contents see table below) and incubated on ice for 90 minutes. The cells 
were then collected by another centrifugation step (Eppendorf Centrifuge, 2000 x g, 20 minutes, 
4 °C). After discarding the supernatant, the pellet was resuspended in 2 mL of ice cold sterile 
filtered TFB2 buffer (contents see table below) and aliquoted into 50 µl aliquots, which were 
flash frozen in liquid nitrogen and stored at –80 ˚C. 
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TFB1 buffer TFB2 buffer 
030 mM potassium acetate pH 5.0 10 mM MOPS pH 6.8 
100 mM RbCl 10 mM RbCl 
050 mM MnCl2 75 mM CaCl2 
010 mM CaCl2 15% glycerol 
15% glycerol  
 
Transformation of competent cells 
Plasmids were inserted into E. coli through heat shock transformation. For the transformation a 
50-100 µL aliquot of competent cells was removed from storage at -80°C and thawed on ice. 50 
µg of DNA were added to the thawed cells and the mixture was incubated on ice for 20 minutes. 
The cells were then transferred from the ice to a 42 °C heating block for one minute and then put 
back on ice. In order to increase the rate of transformation, 600 µL of LB medium devoid of 
antibiotics and for an incubation period for 20 minutes at 37°C could be added as an optional 
step. The transformed cells were spread on an LB agar plate containing appropriate antibiotics 
and incubated overnight at 37 °C. 
 
2.1.9 Large scale lysis of E. coli cells 
For protein purification purposes cultivated cells have to be harvested and lysed. Large scale 
lysis was performed with either an e615 cell disruptor (Constant Cell Disruption Systems LTD) 
or a M-110P mircofluidizer (Microfluidics). Both systems subject cells to an extreme pressure 
through application of Bernoulli’s principle. In both cases a cell suspension is pumped through a 
very small nozzle with high pressure. As the liquid passes the nozzle it is accelerated due to an 
decrease in diameter. The increase in velocity corresponds to an increase in kinetic energy which 
in turn has to result in a decrease of potential energy through a decrease in pressure in order to be 
in accordance with the principle of conservation of energy. Bernoulli’s principle relates the 
increase of velocity with a decrease in pressure. The very sudden change in pressure causes the 
cells to rupture and lyse. The procedure for each system was similar, with the exact handling as 
described in the manual. First the system was rinsed with the same buffer that was used to 
resuspend the cells. Then the cell suspension was passed twice through the system that was set to 
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a pump pressure of 1.5 kbar. After the second passage, the system was cleaned by rinsing with 
water and 20% ethanol (which was used to collapse and remove foam that formed during lysis), 
followed by rinsing with a solution of 0.5 M sodium hydroxide in water. In the end the system 
was rinsed multiple times with water to remove traces of sodium hydroxide to avoid corrosion. 
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2.2 Bioinformatics 
This section encompasses commonly used scientific programs, data bases and web bases tools. 
Office programs for writing, spread sheet calculus and the design of graphics and presentations 
are interchangeable and therefore not listed. 
 
2.2.1 UniProtKB Database 
This data base located at http://www.uniprot.org/ was used to gain information about amino acid 
sequences, post translational modifications, alternative names and DNA sequences (via links to 
the NCBI data base). PDI family members were searched using their common name (e.g. 
ERp57) and the organism Homo sapiens. The accession number from each entry was stored to 
use for other web tools such as the Expasy web tools. 
 
2.2.2 Expasy Tools and ProtParam 
Using the accession number gathered from UniProt, a wide array of tools could be applied. The 
most comprehensive collection of those programs are the ExpasyTools located at 
http:/expasy.org/ which use the amino acid sequence for prediction of protein properties. The 
program most commonly used within this thesis is ProtParam 
(http://web.expasy.org/protparam/). This tool was used to calculate the molar absorbtion 
coefficients, the theoretical PI and the molecular weight from the amino acid sequence. These 
parameters were then used to determine the concentration of each protein in solution. 
 
2.2.3 ClustalW 
ClustalW is an algorithm to align DNA and amino acid sequences and is employed by many web 
based alignment services and offline alignment tools. The most commonly used application of 
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ClustalW was the web service of genome.jp (http://www.genome.jp/tools/clustalw/) for 
alignment of amino acid sequences. 
 
2.2.4 GeneRunner 
GeneRunner is a freeware program for Windows based computers to edit, store and manage 
DNA sequences. It was used to plan the cloning of new expression vectors and to design primers 
from DNA sequences. Its DNA alignment feature was used to compare sequencing results to the 
source sequences in order to spot mutations. It was also used for in silicio restriction digests of 
sequences. 
 
2.2.5 Pymol 
Pymol is a powerful tool to visualize 3D-models generated from .coordinate files such as those 
deposited in the proteins database (PDB - www.rcsb.org). In these files the coordinates of all 
atoms are denoted, determined through either NMR or X-ray crystallography. Pymol was used 
under an academic license to create figures used for presentations, publications and this thesis. 
 
2.2.6 NCBI database and tools 
The National Center for Biotechnology Information (NCBI) houses the largest publicly available 
data bases on DNA sequences, ribonucleic acid (RNA) sequences and amino acid sequences. Its 
service PubMed contains an extensive literature database for the field of life science and related 
topics. In addition to data base searches, the NCBI hosts web servers for many alignment and 
database tools such as the various BLAST tools. All these services can be accessed free of 
charge (http://www.ncbi.nlm.nih.gov/).  
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2.2.7 Mosflm / XDS 
Mosflm (http://www.mrc-lmb.cam.ac.uk/harry/mosflm/) and XDS (http://homes.mpimf-
heidelberg.mpg.de/~kabsch/xds/) are programs used to process the image files obtained during 
an X-ray diffraction experiment. The experimental data is searched for patterns coinciding with 
the predicted patterns from known crystallographic space groups and each spot visible in the X-
ray diffraction data is indexed and its intensity is integrated. The processed data can then be 
utilized to solve the structure using for example the CCP4 suite. 
 
2.2.8 CCP4 program suite 
CCP4 is a compilation of a wide range of computational tools for structure determination of 
macromolecules by X-ray crystallography. It encompasses many scripts for the conversion of file 
types and the calculation of parameters used for structure determination. The programs most 
prominently used were Scala for the scaling of the intensity values, MolRep to solve the phase 
problem by molecular replacement, Phaser to solve the phase problem by single anomalous 
wavelength diffraction (SAD) and Buccaneer for automated model building. More information 
about this program suite can be obtained under http://www.ccp4.ac.uk/ 
 
2.2.9 Phenix program suite 
Phenix is a compilation of crystallography software similar to CCP4. Phenix offers programs to 
solve structures by molecular replacement as well as single (or multiple) wavelength anomalous 
dispersion (SAD or MAD respectively). The most prominently used tool from the Phenix suite as 
phenix.refine for the model refinement of ERp27. More information about this program suite can 
be obtained under http://www.phenix-online.org/ 
 
  
- 38 - 
 
2.2.10 HydroPro 
This freeware program was used to calculate the radii of gyration from a structure in the PDB 
format. Calculations were done based on an atomic level shell model (calculation mode 1) with 6 
passes and a radius sigma ranging from 1 Å to 2 Å. HydroPro is available at: 
http://leonardo.inf.um.es/macromol/programs/hydropro/hydropro.htm 
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2.3 Protein biochemistry 
This section encompasses the expression and purification of proteins as well as their use and 
handling in assays and crystallization. 
2.3.1 Determination of protein concentration 
The amount of purified protein in solution was measured by UV-spectroscopy using the PeqLab 
Nanodrop ND-1000 spectrophotometer. To calculate the protein concentration of a solution, an 
absorbance spectrum of the wavelength range 220-350 nm was recorded corrected for a blank 
against the solution devoid of protein. Absorbance and protein concentration are directly related 
via the extinction coefficient which was calculated from the amino acid sequence using the web-
based Expasy tool Protparam. 
 
2.3.2 Separation of proteins by SDS-polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique to 
separate proteins according to their molecular weight based on the protocol of Laemmli et al. 
[73]. Proteins move within an electric field according to their charge. As an excess of SDS is 
added to the sample, the negatively charged dodecyl sulfate anion binds to the protein covering it 
with negative charges. As the number of dodecyl sulfate ions is very large compared to the 
number of charged groups of a protein at a pH of 8.8, the inherent charge of the protein becomes 
insignificant. Thus, when subjected to an SDS-PAGE, all proteins migrate towards the anode of 
the electrophoresis chamber with their migration speed only determined by their size as they are 
slowed by the meshwork of polyacrylamide fibres.  
Polyacrylamide gels were prepared using the casting devices of the Mini Protean II system from 
BioRad. A front glass plate and a back glass plate were carefully cleaned and inserted into 
casting frames. The separating gel solution was prepared and filled into the glass frames. The 
acrylamide solution was overlaid with isopropanol to create a clear and level surface and then 
incubated for 45 minutes allowing the solution to polymerize and solidify. After polymerization, 
the isopropanol was decanted and stacking gel solution was poured on top of the solid separating 
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gel and a comb was inserted into the still liquid stacking gel. After another 45 minute incubation, 
the stacking gel was solidified and the gels with their glass frames were removed from the 
casting frames. For storage, the gels were wrapped in wet paper towels and stored at 4 °C. 
Reagent Stacking Gel Separating Gel (12%) Separating Gel (15%) 
30% Polyacrylamide* 17 mL 40 mL 50 mL 
1M Tris pH 6.8 12.5 mL none none 
1M Tris pH 8.8 none 25 mL 25 mL 
10% SDS in H2O 1 mL 1 mL 1 mL 
TEMED solution# 100 µL 40 µL 40 µL 
10% APS in H2O# 1 mL 1 mL 1 mL 
ddH2O Add to 100 mL Add to 100 mL Add to 100 mL 
*The used polyacrylamide solution had an acrylamide:bis-acrylamide ratio of 37.5:1 
#Marked items were added last and only shortly before casting the gels 
To prepare samples for an SDS-PAGE, proteins were fully reduced and denatured by heating 
them for 5 min at 95 ˚C in sample buffer. Precast gels (12 or 15%) were installed into the gel 
chamber and immersed into SDS running buffer. The boiled samples were then applied on the 
gel and subjected to electrophoresis at 180 V, 300 mA for 60-120 min until the dye buffer front 
had nearly traversed the gel completely. 
1x SDS running buffer  5x sample buffer 
14.4 g Glycine  5 g SDS  
2.0 g SDS  30.5 g Glycerol 
2.9 g Tris pH 8.8  15 ml 1M Tris/HCl pH 7.0 
add to 1L dd H2O  25 µl Bromphenol Blue 
 2.5 ml 1M DTT 
add to 50 ml dd H2O 
Contents of buffers used for SDS polyacrylamidd gel electrophoresis 
 
2.3.3 Coomassie staining of Polyacrylamide gels 
After running an SDS-PAGE, gels were removed from their glass frame and stained with 
Coomassie Brilliant Blue. For staining, gels were treated first with staining solution, then with 
destaining solution. In each solution, the gels were heated in a microwave oven for 1 min and 
then incubated for 20 min while slowly shaking (40 rpm). Gels were kept in destaining solution 
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for short term storage. For long term storage, gels were inserted into a drying frame between two 
sheets of cellophane and dried under hot air for 2 h. 
Staining and destaining solutions: 
Reagent Staining Destaining 
Acetic Acid (glacial) 100 ml 50 ml 
Ethanol 200 ml 100 ml 
Coomassie Brilliant Blue R-250 2000 mg  
dd H2O add to 1 l add to 1 l 
 
 
2.3.4. Protein Purification Protocols 
Within this project three different protocols were employed to purify all proteins. All PDI family 
member proteins were purified from E. coli using either a His-Tag or an Intein-Tag system. 
Riboflavin binding protein (RfbP) was purified without tag directly from chicken eggs. 
 
Purification of PDI family proteins using the intein expression system 
This purification protocol was modified from Tian et al. [63] and used for every protein 
expressed with the intein purification system. An E. coli expression strain (BL21DE3 or 
BL21DE3/RIL codon augmented) was transformed with a pYTB12 expression construct 
carrying the protein of interest as a fusion protein with the intein tag. E. coli cells were grown on 
an LB plate supplemented with the antibiotics ampicilin (resistance conferred by the pYTB12 
vector) and in case of BL21DE3/RIL cells with chloramphenicol. After incubation at 37 °C 
overnight, single colonies were picked and transferred into a starter culture of 200 mL LB 
medium (500 mL shaker flask, supplemented with antibiotics). This starter culture was incubated 
overnight while shaking at 200 rpm for 14-18 h at 37 °C. The starter culture should reach an 
OD600 ≥ 2.0 in order to be used for inoculation of the main culture. 25 mL of starter culture were 
added to 2.5 L of LB medium (5 L shaker flask, supplemented with antibiotics) and incubated 
while shaking at 200 rpm and 37 °C. The OD600 of the main culture was monitored and upon 
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reaching a value of 0.6 (usually after 3.5 h), protein production was induced by the addition of 
IPTG to a final concentration of 1 mM. The induced culture was then incubated while shaking at 
200 rpm and 15 °C for 16-20 h. During this incubation step the main culture should reach at least 
an OD600 ≥ 1.3. Cells were harvested by centrifugation (Beckman J-X26P centrifuge with a 
JLA8.100 rotor, 10,000 x g, 8 minutes, 4 °C) and weighted after removal of the LB medium. The 
cells were  resuspended in 5 mL of lysis buffer (500 mM NaCl, 20 mM Tris, pH 8.5) per g of cell 
pellet by pipetting the cell suspension up and down. Next the cells were subjected to lysis with 
one of the cell disruption systems ‘French Press’, ‘CellDisruptor’ or ‘MicroFluidizer’. The lysate 
was cleared of cellular debris by centrifugation (Beckmann J-X26P centrifuge, JLA16.250 rotor, 
35,000 x g, ≥40 minutes, 4 °C). Usually during this centrifugation step, the chitin beads were 
prepared. Per gram of cell pellet, 2 mL of Biorad Chitin Beads (equal to 4 mL of slurry) were 
loaded into an empty column resulting in a column volume of 60-90 mL. The storage solution 
was drained and the column equilibrated with 5-10 column volumes (CV) of low salt buffer (100 
mM NaCl, 20 mM Tris, pH 8.5). The low salt buffer was drained from the column and the 
cleared lysate was added to the column and incubated for at least two hours at room temperature 
(while rocking or slowly rotating) with the chitin beads. After incubation the column was washed 
with at least 5 CV of low salt buffer. The column was put into high salt buffer (1 M NaCl, 20 
mM Tris, pH 8.5) and washed with 20 CV of high salt buffer. After re-equilibration with at least 
5 CV of low salt buffer, the column was drained of buffer, filled with low salt buffer containing 
50 mM of fresh and reduced dithiotreitol (DTT) and incubated rocking overnight (at least 16 h) 
at room temperature for redox-induced intein cleavage. 
After cleavage, the protein was eluted from the column by draining the cleavage buffer and the 
addition of 1-2 CV low salt buffer. The eluate was loaded onto a MonoQ 10/100 GL anion 
exchange column (GE Healthcare) using an ÅktaPurifier FPLC system (GE Healthcare) and the 
column was eluted using filtrated and degassed low salt buffer and high salt buffer as buffer A 
and B, respectively.  
For the elution the following profile was used: 
Step 1 2 3 4 5 
Elution volume in CV 0→5 5→10 10→25 25→30 30→35 
Buffer composition in % B 0→0 0→20 20→40 040→100 100→100 
Fractionation size in mL 0 12 4 8 12 
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During the elution, the absorbance at 280 nm and 260 nm was monitored and PDI family 
members eluted around 25-35% of buffer B in step 3 usually with multiple peaks corresponding 
most likely to different conformations exposing a different amount of charged residues at the 
protein surface. During the first purification of a protein, fractions with a mean absorbance of 
more than 200 mAU were checked for protein content and purity via SDS-PAGE. Fractions 
containing reasonably pure (>80%) protein of the expected size were pooled and concentrated to  
a final volume of 5 mL (with a maximum concentration of 50 mg/mL) using Centricon 
concentrators with an appropriate MWCO depending on the molecular weight of the protein (see 
Table). The pooled and concentrated sample was loaded onto a Superdex 200 26/60 HiLoad size 
exchange chromatography column (GE Healthcare) pre-equilibrated with 1.2 CV of sample 
buffer (250 mM NaCl, 20 mM Tris pH 8.5) and eluted with 1.2 CV of sample buffer using an 
ÅktaPurifier FPLC system while monitoring the absorbance at 280 nm and 260 nm. Starting at 
an elution volume of 120 mL, the elution was sampled into 4 mL fractions. PDI family members 
usually eluted in one or two peaks at an elution volume that is earlier than expected for a protein 
of their size. Fractions with a mean absorbance over 250 mAU were checked for purity and all 
fractions with a purity >95% were pooled and concentrated 
using a Centricon concentrator (MWCO: see table). The 
concentrated protein was either used directly for experiments 
or divided into 200 µL aliquots. These aliquots were flash 
frozen in liquid nitrogen and stored at -80 °C. 
 
Purification of PDI family proteins using a His-tag for purification. 
This purification protocol was used for all proteins expressed from the modified pET23 vector 
kindly provided by Lloyd Ruddock from the University of Oulu, Finland. The codon augmented 
E. coli expression strain BL21DE3/RIL was transformed with a pYTB12 expression construct 
carrying the protein of interest. E. coli cells were grown on an LB plate supplemented with the 
antibiotics ampicilin (resistance conferred by the pYTB12 vector) and chloramphenicol 
(resistance inherent to the RIL expression strain). After incubation at 37 °C overnight, single 
colonies were picked and transferred into a starter culture of 200 mL LB medium (500 mL 
MW of sample MWCO 
4 kD – 15 kD 3 kD 
15 kD – 45 kD 10 kD 
45 kD or more 30 kD 
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shaker flask, supplemented with antibiotics). This starter culture was incubated overnight while 
shaking at 200 rpm for 14-18 h at 37°C. The starter culture should reach an OD600 ≥ 2.0 in order 
to be used for inoculation of the main culture. 25 mL of starter culture were added to 2.5 L of LB 
medium (5 L shaker flask, supplemented with antibiotics) and incubated while shaking at 200 
rpm and 37 °C. The OD600 of the main culture was monitored and upon reaching a value of 0.6 
(usually after 3.5 h), protein production was induced by the addition of IPTG to a final 
concentration of 0.5 mM. The induced culture was incubated at 15°C for 16-20h while shaking at 
200 rpm. During this incubation step the main culture should reach at least an OD600 ≥ 1.3. Cells 
were harvested by centrifugation (Beckman J-X26P with a JLA8.100 rotor, 10,000 x g, 8 
minutes, 4 °C) and weighed after removal of the LB medium. The cells were resuspended in 5 
mL of Buffer A (1 M NaCl, 20 mM Tris, 10 mM Imidazol, pH 8.5) per g of cell pellet by 
pipetting the cells up and down. Next the cells were subjected to lysis with one of the cell 
disruption systems ‘French Press’, ‘CellDisruptor’ or ‘MicroFluidizer’. The lysate was cleared of 
cellular debris by centrifugation (Beckmann J-X26P centrigue with a JLA16.250 rotor, 35,000 x 
g, ≥40 minutes, 4°C). The cleared lysate was supplemented with PMSF (~1 mg per 20 mL of 
lysate) and loaded onto a HisTrap column (Novagen) using a peristaltic pump. The loaded 
column was attached to an an ÅktaPurifier FPLC system and washed extensively with buffer A 
at a flowrate of 4 mL/min until the monitored absorbance at 280 nm became stable (<1 mAU 
absorbance change per mL). The protein was then eluted with 40% of buffer B (1 M NaCl, 20 
mM Tris, 300 mM Imidazol, pH 8.5) at a reduced flow rate of 0.8 mL/min. Fractionation was 
started as soon as the monitored absorbance at 280 nm exceeded 500 mAU and the following 10 
mL were directly loaded onto a Superdex 200 26/60 HiLoad size exchange chromatography 
column pre-equilibrated with 1.2 CV of sample buffer (250 mM NaCl, 20 mM Tris pH 8.5). The 
column was eluted with 1.2 CV of sample buffer using an ÅktaPurifier FPLC system while 
monitoring the absorbance at 280 nm and 260 nm. Starting at an elution volume of 120 mL, the 
elution was sampled into 4 mL fractions. PDI family members usually eluted in one or two peaks 
at an elution volume that is earlier than expected for a protein of their size. Fractions with a mean 
absorbance over 250 mAU were subjected to SDS-PAGE and all fractions with a purity >95% 
and the correct size were pooled and concentrated using a Centricon concentrator. The 
concentrated protein was either used directly for experiments or divided into 200 µL aliquots. 
These aliquots were flash frozen in liquid nitrogen and stored at -80 °C. 
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Purification of riboflavin binding protein (RfbP) from chicken eggs 
In order to obtain correctly disulfide linked and glycosylated protein, riboflavin binding protein 
(RfbP) was purified directly from chicken eggs. Approximately 35 eggs purchased at a local 
grocery store were opened and separated to obtain one liter of egg white, discarding the yolk. 
The egg white was diluted using an equal volume of 100 mM sodium acetate buffer, pH 4.3. 
After centrifugation (Beckmann J-X26P with a JLA8.100 rotor, 10,000 x g, 15 minutes, 4 °C) 
the supernatant was loaded onto a XK16/60 column packed with FastFlow DEAE Sepharose 
(GE Healthcare) anion exchange chromatography material pre-equilibrated with buffer A (100 
mM sodium acetate, pH 4.3). After loading the sample, the column was attached to an 
ÅktaPurifier FPLC system and was washed and eluted using a linear gradient of buffer A and 
buffer B (150 mM NaCl, 100 mM sodium acetate, pH 4.3) with the following profile:  
Step 1 2 
Elution volume in CV 0→5 5→25 
Buffer composition in %B 0→0 0→100 
Fractionation size in mL 0 5 
 
The absorbance of the bound riboflavin at 445 nm was monitored to pool all RfbP-containing 
fractions. For the first  purification, all protein containing fractions were checked by SDS-PAGE 
and the pure (>98%) fractions were concentrated and subjected to size exclusion 
chromatography. For the size exclusion chromatography, the sample was loaded onto a Superdex 
200 26/60 HiLoad size exchange chromatography column pre-equilibrated with 1.2 CV of 
sample buffer (250 mM NaCl, 20 mM Tris, pH 8.5). The column was eluted with 1.2 CV of 
sample buffer using an ÅktaPurifier FPLC system while monitoring the absorbance at 280 nm, 
260 nm and 445 nm. Starting at an elution volume of 120 mL, the elution was sampled into 4 mL 
fractions and fractions with an absorbance at 445 nm of more than 50 mAU were checked on a 
SDS-PAGE for size and purity. As all the protein bound to the DEAE sepharose column was 
RfbP with a very high purity (>98%), the size exclusion chromatography was omitted in all 
following purifications. The RfbP was dialyzed twice against 50 mM ammonium formate buffer 
(pH 8) and lyophilized for storage at -80 °C. 
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2.3.5 Reduced carboxymethylation of model substrates 
In order to permanently unfold model substrate proteins such as RfbP or RNAse A for ITC 
binding experiments, all cysteine residues were modified with iodoacetic acid (IAA) to prevent 
any refolding reaction. For the modification, the usually lyophilized substrate protein was 
reconstituted in modification buffer (100 mM Tris, pH 8.5). Solid guadinium chloride as well as 
a solution of 1 M DTT in modification buffer were added to the reconstituted protein to a final 
concentration of 50 mM DTT and 6 M guadinium chloride. The protein was incubated under 
these denaturing conditions at 55 °C for 40 minutes. After the denaturation period, the protein 
solution was allowed to cool to room temperature, before 1 M IAA (dissolved in 1 M NaOH) 
was added to a final concentration of 150 mM and the reaction was incubated at room 
temperature for 45 minutes in the dark. The carboxymethylation reaction was quenched by the 
addition of an excess of DTT (1 M DTT in modification buffer to a final concentration of 200 
mM). The modified protein was subsequently dialyzed against 5 L of ITC buffer (250 mM NaCl, 
2 mM EDTA, 20 mM Tris, pH 8.5) overnight at 4 °C with a 3 kD MWCO. 
 
2.3.6 Preparation of apo-riboflavin binding protein 
In its native conformation RfbP binds riboflavin with high affinity (KD=1nM) [74]. As the 
absorbance of bound riboflavin interferes with the absorbance of the 2-nitro-5-thiobenzoate 
(NTB2-) chromophore used in Ellman’s assay, the riboflavin has to be removed before native 
RfbP can be used in this assay. Also the apo-RfbP can be used for a titration curve of riboflavin 
fluorescence as apo-RfbP stoichiometrically removes riboflavin from the solution while 
quenching its fluorescence. To generate apo-RfbP, RfbP was reconstituted in ITC buffer (250 
mM NaCl, 2 mM EDTA, 20 mM Tris, pH 8.5) and was dialyzed thrice for at least 2 h each 
against 2 L of 6 M urea in ITC buffer at 4°C with a 3 kD MWCO dialysis membrane. After 
removal of riboflavin, the urea was removed by dialyzing twice for at least 2 h against 5 L of 
ITC buffer at 4°C with a 3 kD MWCO membrane. 
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2.3.7 Preparation of di-eosine-gluthatione (Di-E-GSSG) 
Oxidized gluthathione (GSSG) was modified with the eosine fluophore to generate the substrate 
used in the fluorescence self-quenching assay (FSQ assay), according to a procedure which was 
based on the protocol published by Raturi et al. [75] with modfications. For this purpose GSSG 
was dissolved in conjugation buffer (100 mM potassium phosphate buffer, pH 8.5, 2 mM EDTA) 
to a final concentration of 1 mM. To this solution solid eosinisothiocyanate was added to a final 
concentration of 10 mM and incubated in the dark at room temperature overnight (at least 8 h). A 
SephadexG25 size exclusion chromatography column (Biorad Econo, 5 mL) pre-equilibrated in 
FSQ reaction buffer (100 mM sodium citrate, pH 7.0, 2 mM EDTA) was used in order to remove 
both excess eosinisothiocyanate and incompletely conjugated GSSG. The size exclusion 
chromatography column was loaded with the overnight reaction and run by gravity flow with 
FSQ reaction buffer. The eluate was divided into 0.5 mL fractions and fractions were tested for 
an increase in fluorescence before and after reduction with 10 mM DTT. Fluorescence readings 
were taken with a Fluoromax-4 (excitation at 525 nm, emission at 545 nm, bandpass of 2 nm, 10 
measurements of 0.5 seconds each). All di-E-GSSG fractions that showed fluorescencereduced to 
fluorescenceoxidized ratio of equal to or greater than 
10 were pooled. The concentration of di-E-GSSG 
was determined by the absorbance of E-GSH at 525 
nm with a molar extinction coefficient of ε=88,000 
M-1cm-1. If needed, di-E-GSSG can be concentrated 
by dialysis against solid PEG 5,000 at 4 °C in the 
dark with a 500 dalton MWCO membrane. 
 
2.3.8 Fluorescence self-quenching 
(FSQ) assay 
The FSQ assay based on the publication by Raturi 
et al. [75] was employed in an attempt to 
characterize the oxidoreductase function of PDI 
Figure 2.1 – Di-Eosin-Glutathione 
Hyphothetical structure of oxidized 
glutathione modified with Eosin 
groups. In the oxidized form the two 
eosin moieties (triple ring structures 
visible in the top half) are kept in 
proximity. 
- 48 - 
 
family members. This assay is based upon the fluorescence properties of di-E-GSSG. In its 
oxidized form, the two eosine moieties of the molecule are kept in close proximity (see Figure 
2.1.) by the disulfide bond of the oxidized glutathione, thus quenching the fluorescence signal of 
each other. Upon reduction the spatial restriction and thus the quenching is removed and the 
fluorescence signal increases. In the original publication, the assay was performed in a phosphate 
assay buffer (100 mM potassium phosphate buffer, pH 7.0, 2 mM EDTA) with DTT as reductant 
in the reaction. As it is very hard to exactly reproduce DTT concentrations and DTT is unstable 
in aqueous solution and prone to air oxidation, it was replaced by TCEP as a reductant. This 
allowed for a large batch of aliquoted stock solution to be prepared in advance which could then 
be frozen for storage. As TCEP is unstable in phosphate buffer the buffer substance was replaced 
creating a new FSQ assay buffer (100 mM sodium citrate, pH 7.0, 2 mM EDTA). For a standard 
curve FSQ substrate was measured at different concentrations in the oxidized and reduced form 
using the Fluoromax-4 flurimeter with the excitation wavelength set to 525 nm (bandwidth = 1 
nm) and emission at 545 nm (bandwidth = 1 nm). After establishing a standard curve of a FSQ 
substrate batch, kinetic experiments were set up using the following composition: 
Parameter Setting  Parameter Setting 
Temperature 25 °C  Integration time 50 ms 
Interval time 50 ms  Total time 10 seconds 
Excitation wavelength 520 nm  Emission wavelength 540 nm 
Excitation bandpass 1 nm  Emission bandpass 1 nm 
 
The experiment was started by the addition of TCEP and the fluorescence signal was recorded 
using the kinetic record mode (measurement frequency = 5 Hz). The data of the first 10 seconds 
of the measurement were fitted to a linear equation. The slope of the straight line was plotted 
against the concentration of the FSQ substrate and this plot was fitted against the Michaelis-
Menten equation. 
 
2.3.9 Riboflaving quenching assay 
This refolding assay was published first by Rancy&Thrope [76] and uses the fluorescence 
properties of riboflavin to monitor refolding. Riboflavin binding protein (RfbP) is used to store 
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riboflavin (vitamin B2) in high quantities for example in the eggs of birds. The protein binds 
riboflavin with high affinity (KD of 1 nM) in a one to one stoichiometry. Free riboflavin in 
solution fluoresces at an excitation of 450 nm, yielding an emission at 530 nm. Upon binding of 
riboflavin by apo-RfbP, this fluorescence is quenched. Thus, the fluorescence can be used to 
observe the refolding of denatured RfbP, as only the correctly folded protein is able to bind 
riboflavin and to quench its fluorescence. RfbP has 18 cysteines forming nine disulfide bonds 
and is therefore an excellent model substrate for oxidative folding. 
The experiment was set up by recording a baseline of a sample containing only riboflavin and 
refolding buffer (50 mM potassium phosphate buffer pH 7.0, 2 mM EDTA, 1 mM GSSG, 0.5 
mM GSH). The experiment was then started by the addition of reduced and denatured RfbP 
devoid of riboflavin. The fluorescence was recorded in regular intervals using a Fluoromax-4 
fluorescence spectrometer with the following settings: 
Parameter Setting  Parameter Setting 
Temperature 25 °C  Integration time 300 ms 
Interval time 10 seconds  Total time 54000 seconds 
Excitation wavelength 450 nm  Emission wavelength 525 nm 
Excitation bandpass 2 nm  Emission bandpass 3 nm 
 
 
2.3.10 Isothermal titration calorimetry (ITC) 
In preparation for ITC experiments the proteins to be analyzed – usually a member of the PDI 
family and substrate – were dialyzed against 5 L of ITC buffer (250 mM NaCl, 2 mM EDTA, 20 
mM Tris, pH 8.5) overnight at 4 °C with a 3 kD MWCO dialysis tubing. A 500 mL sample was 
taken from the 5 L of buffer used in the dialysis, filtered and degassed using a Whatman 
Membrane filter (pore size = 0.2 µm). The dialyzed proteins were centrifuged (Eppendorf 
centrifuge 5417R, 25,000 x g, 4 °C, 30 minutes) to remove aggregates and precipitated protein. 
After centrifugation the concentration of the proteins was calculated by measuring the 
absorbance at 280 nm with a Nanodrop spectrophotometer blanked against the filtered dialysis 
buffer using the extinction coefficients calculated by the web-based Expasy tool Protparam and 
the amino acid sequence of the protein. The proteins were diluted to the correct concentrations 
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(standard concentrations: 1 mM for each PDI family member in the syringe and 50 µM for the 
substrate in the cell) with the filtered sample buffer. Aliquots of the proteins sufficient for one 
experiment (450-500 µL for the syringe, 1.8-2.0 mL for the cell) as well as 2 mL of filtered 
dialysis buffer were then thermally equilibrated and degassed for at least 10 minutes, using the 
Microcal Vacuum station set to a temperature 1 °C below the temperature planned for the ITC 
experiment. During this time period, the Microcal VP-ITC used in this project was prepared for 
the experiment. Each of the syringes, the sample cell and the reference cell were extensively 
rinsed using at least three times their volume capacity of ddH2O followed by at least three times 
their volume capacity of filtered dialysis buffer. The degassed and equilibrated proteins were 
filled into the syringe (300 µL – air bubble free) and the reference cell (1.65 mL), respectively, 
and the degassed and equilibrated buffer was filled into the reference cell (1.65 mL). The 
standard settings for ITC experiments measuring the interactions between PDI family members 
and model substrates were: 
Parameter Setting  Parameter Setting 
Temperature 25 °C  Injection volume 10 µL 
Reference Power 15 µcal/sec  Injection speed 300 µL/min 
Syringe concentration 1 mM  Injection spacing 6 minutes 
Cell concentration 50 µM  Injection delay 3 minutes 
Number of injections 30  Initial injection 5 µL 
 
Deviations from those conditions are noted in the Results section of this thesis. 
 
2.3.11 Circular dichroism spectroscopy (CD spectroscopy) 
In order to verify the unfolding of reduced carboxymethylated substrate proteins, or to exclude 
the influence of reduction or mutation on the folding status of PDI family members, CD 
spectroscopy was performed. All buffer substances and denaturants interfering with CD 
spectroscopy were removed by dialysis against CD buffer (50 mM potassium phosphate buffer, 
pH 8.0). In case of Tris buffer, it is also possible to minimize its interference with this technique 
by dilution of the buffer below 3 mM. The protein sample was diluted to an Abs280nm of 1.0 with 
either CD buffer (for dialyzed samples) or ddH2O (for non-dialyzed samples). The JASCO J-810 
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spectropolarimeter was purged with nitrogen and the sample cell set to a temperature of 20°C. 
The sample was filled into the sample cuvette and inserted into the sample cell. For test scans, 
the following parameters were used: 
Parameter Setting  Parameter Setting 
Scan type Continuous Scan  Scan Speed 100 nm/minute 
Scan range 185-260 nm  Bandwidth 2 nm 
Number of scans 1   
 
The test runs were terminated as soon as the voltage needed for a sufficient signal exceeded 600 
V. The sample was continuously diluted between runs until either the voltage never exceeded 
600 V, or until the maximum absolute value of the circular dichroism signal fell below 20 
mdeg/cm. With the protein concentration thus adjusted the measurement data scans were taken 
with the following parameters: 
Parameter Setting  Parameter Setting 
Scan type Continous Scan  Scan Speed 30 nm/minute 
Scan range 185*-260 nm  Bandwidth 2 nm 
Number of scans 10   
*value chosen as low as possible with the voltage during a scan not exceeding 600 V 
For final data evaluation the signal was normalized against the protein concentration used in the 
final scan. 
 
2.3.12 Dynamic Light Scattering (DLS) 
Dynamic light scattering, also known as photon correlation spectroscopy, is a spectroscopic 
method to determine the volume distribution of particles in solution. A monochromatic beam of 
light is directed at a solution of particles. The wavelength of the scattered light differs from the 
input light due to the Doppler shift as it interacts with particles moving in solution due to 
Brownian motion. The magnitude of the shift is related to the speed of the Brownian motion 
which in turn is related to the diffusion constant and the size of the particle. A detector registers 
the wavelengths of scattered light perpendicular to the incident laser light. From the distribution 
of wavelength deviations, the program calculates a distribution profile of volumes in solution 
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under the assumption that each particle has a spherical shape. Additionally, molecular weights 
are calculated based on the determined volumes. 
For the experiment, the sample solution is adjusted to an approximate protein concentration of 
0.5 mg/ml. A quartz cuvette is filled with 80 µl of sample and inserted into a DynaPro Titan DLS 
photometer (Wyatt Technology). A single experiment consists of a series of measurements with 
the following parameters: 
Parameter Setting  Parameter Setting 
Acquisition time 10 sec  Solvent Model PBS 
Number of Acquisitions 20  Refraction Index* 1.333 
Laser Power 100%  Viscosity* 1.019 cp 
Temperature 10 °C  Cauchy Coefficient* 3119 nm2 
* These values are given by the solvent model ‘PBS’ 
The data is automatically evaluated by the Dynamics V6 software supplied with the equipment 
and presented as a distribution of molecular radii and molecular weights. 
 
2.3.13 Crystallization of proteins 
In order to determine the three dimensional structure of a protein at atomic resolution through X-
ray crystallography, single crystals of the investigated proteins are needed. As up to this date 
there is no known method to determine crystallization conditions of a protein ab initio, proteins 
are screened in many test setups for suitable crystallization conditions. Once promising 
conditions are identified, they are verified in the fine-screening process and then – should they 
yield reproducible crystals – optimized. Crystallization is a special form of precipitation and 
therefore a protein solution is slowly brought to the solubility limit. As the protein becomes 
supersaturated, the protein begins to form ordered protein-protein-contacts to reduce solvent 
exposure and thus the need for solvation. While being inside a supersaturated solution, these 
nuclei of precipitation will extend and can – if forming slowly enough – form the regular lattices 
of a protein crystal. 
Within the scope of this project, the predominant crystallization technique was the vapor 
diffusion crystallization. Here protein and precipitant are mixed at lower concentrations and 
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placed in a closed system together with a precipitant solution of higher concentration and several 
orders of magnitude greater volume. Due to its greater volume, this reservoir precipitant solution 
will determine the vapor pressure and the sample drop will lose solvent until its osmolarity is 
equal to the osmolarity of the reservoir solution. This loss in solvent slowly increases the 
concentration of both protein and precipitant in the sample drop, potentially leading to 
supersaturation and crystallization of the sample. 
The initial screening was done using sitting drop vapor diffusion crystallization. Here the sample 
drop sits on a shelf above the reservoir solution in a sealed chamber. This was the method of 
choice as it can be automatized using the Honeybee 963 Cartesian dispensing system, which uses 
only very small amounts of protein solution (0.3 µL/drop) to create a large number of 
crystallization experiments. The first step in crystallization screening was to test the protein in 
standardized screens on 96-well crystallization plates. The crystallization plates were 
subsequently examined in 24 h intervals for the formation of crystals or crystalline precipitation. 
Promising conditions were varied in fine screens using the hanging drop vapor diffusion 
crystallization technique, where the sample drop is suspended from a cover slide over the 
reservoir solution, increasing the drop surface. This method is set up by hand and uses larger 
amounts of protein to yield larger crystals. 
 
2.3.13 Diffraction experiments 
Protein crystals obtained from the crystallization process outlined above were removed from the 
sample drop using a mounted CryoLoop (Hampton Research). In order to preserve the protein 
crystals, they are kept in liquid nitrogen for storage and are cooled to -180 °C with cold nitrogen 
gas during the experiment. As the formation of ice crystals within the solvent channels of the 
crystal can damage or destroy the crystal lattice during the freezing process, the crystals were 
first transferred into a suitable cryo-solution. This cryo-solution usually consists of the so-called 
‘mother liquor’ – the precipitant solution present in the sample drop – supplemented with cryo-
protectants. Commonly used cryo-protectants are glycerol, ethylene glycol, PEG 400, 
methoxypolyethylene glycol 350 (MPG), sugars or oil. The crystals were allowed to equilibrate 
in the cryo solution for 2-5 minutes before being flash frozen in ice-free liquid nitrogen. 
- 54 - 
 
For the initial diffraction experiments, crystals were mounted on the goniometer of the in-house 
X-ray system. X-rays generated by a MicroMax-007HF X-ray generator (Rigaku) were targeted 
onto the crystal and the diffraction pattern was recorded using an R-AXIS HTC imaging plate 
detector. For the initial estimation of crystal quality, the following settings were used to save 
beam time: 
Parameter Setting 
Detector distance 200 mm 
Number of Images 2 
Φ angle 0.5° 
Interval angle 90° 
Exposure time 10 minutes 
 
Crystals diffracting to a resolution of 3 Å were then used to record a complete data set using 
either the home source or synchrotron beam lines. All data sets which were used to solve the 
structure of ERp27 were taken at the BESSY synchrotron with the following settings: 
Parameter Setting (native ERp27) Setting (SeMet ERp27) 
Detector distance 222.41 mm  249.42 mm 
Number of Images 500 720 
Φ angle 1.0° 0.5° 
Interval angle 1.0°  0.5° 
Exposure time 5 sec 2 sec 
Wavelength 0.91841 Å 0.97977 Å 
 
2.3.14 Data Processing 
A diffraction experiment generates data in the form of diffraction images. Each image 
corresponds to the X-ray scattering of the crystal at a particular orientation. Each image contains 
a significant number (usually more than 50) of observed reflections and the data sets used to 
solve and refine the structure contained 500 and 720 images respectively. In order to gain the 
structure factor amplitudes used for structure determination, the data needs to be processed. Data 
processing was done with the programs Mosflm or XDS consisting of four steps in each case. 
First the images are indexed. Based on a small subset of the data, the agreement of the observed 
reflections with one of the 14 Bravais lattices is calculated. The objective of this step is to 
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suggest possible space groups, to determine initial unit cell parameters of the crystal and to 
assign the Miller indices to each reflection. After a preliminary space group has been assigned, 
the intensity of each reflection is calculated in the integration step. The program measures the 
intensity of each observed reflection and corrects for the local background. Due to space group 
symmetry, the very good signal-to-noise ratio of strong reflections can be used to correctly 
identify and integrate weak reflections. After the intensity of all reflections has been measured, 
the intensities are scaled and merged. A single structure factor can give rise to multiple observed 
reflections due to symmetry and data set redundancy. During the course of an experiment at a 
synchrotron, the beam intensity typically declines. This leads to weaker measured intensities in 
later images. To counteract this decline in signal, reflection intensities are scaled before all 
intensities belonging to one structure factor are averaged. As a result of scaling and merging, a 
single averaged intensity is calculated for each structure factor. After this step, Rsym is calculated 
from the agreement between the separate observations of a reflection and its symmetry mates. 
Using this parameter the quality of the data set can be judged with good data sets resulting in 
Rsym below 5% while bad data sets exceed an Rsym of 10%. The final step of the data processing 
is the calculation of the structure factor amplitudes from the scaled and merged intensities. The 
calculated structure factor amplitudes can then be used to solve the structure. 
2.3.15 Structure solution 
During a diffraction experiment, only the position and intensity of the scattered X-rays are 
recorded. These measurements give rise to the structure factor amplitudes. The information 
contained in the phase of the scattered X-rays cannot be recorded by current detectors and is 
therefore lost. This lost information is at the core of the phase problem of crystallography. A 
phase has to be assigned to each structure factor in addition to its amplitude in order to be able to 
calculate an electron density map. Multiple methods have been developed in order to obtain the 
lost information. Within this project, the single wavelength anomalous dispersion (SAD) and 
molecular replacement methods have been used.  
For the SAD approach a data set is collected from a crystal containing an anomalous scatterer. 
Selenium is often employed, as seleno-methionine can be incorporated into proteins during 
expression and thus modified proteins often from crystals which are identical to the native 
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protein. All chemical elements, when excited at their element specific absorption edge, give rise 
to anomalous scattering. Due to the absorption of radiation, the phase of the scattered X-rays 
shifts uniquely. This leads to differing intensities in reflections related by Friedel’s Law, which 
should have equal intensities in the absence of anomalous scatterers. This difference contains the 
phase information. Through comparison of the Friedel pairs I(h,k,l) and I(-h,-l,-k), an initial 
phase can be assigned to the structure factor if sufficient anomalous signal is available to 
accurately determine the phases. An electron density map can be calculated using the determined 
phases and amplitudes of the structure factors. 
For molecular replacement, phase information from already existing structures is used to solve 
the phase problem. The pre-existing template structure should have high structural homology 
with the structure to be solved. The Patterson function is calculated from both the template and 
the experimentally determined structure factor amplitudes. The resulting Patterson maps are then 
matched first by rotation of the search template in three dimensions, followed by translation in 
three dimensions. After the most suitable position and orientation of the template has been found, 
an electron density map is calculated using the experimentally determined structure factor 
amplitudes and the phases of the template. 
An electron density map gives the distribution of electrons – and thereby the position of each 
atom – in the three dimensions. Using the initial electron density map, a model is built in 
accordance with the electron densities as well as with the pre-existing knowledge about the 
molecule such as amino acid sequence and stereochemical parameters such as bond lengths and 
bond angles. This initial model building is often automated using software tools from the CCP4 
or Phenix program suites. Within this project Buccaneer from the CCP4 suite was used for the 
initial model building. With the initial model the refinement process can be started. During 
refinement, the model parameters (i.e. coordinates, B-factors) are used to improve the accuracy 
of the determined phases and therefore the electron density map. The improved electron density 
map allows for a more detailed model which in turn will lead to an even more accurate electron 
density map. This model improvement is usually done manually in Coot using the pre-existing 
knowledge about a protein. During refinement, the R-factor is calculated to judge the agreement 
of the model with the experimental data. The R-factor gives the deviation of the calculated 
structure factor amplitudes from the experimentally observed structure factor amplitudes. Thus 
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lower R-factors indicate a higher model quality. As the model quality increases, it is important 
that the number of model parameters should not exceed the number of observed reflections in 
order to avoid model bias. For validation of the model, the free R-factor (Rfree) is calculated [77]. 
During each refinement cycle, the same random fraction of data (usually 5-10%) is not refined 
and the Rfree is calculated from this unrefined data. If for a new model only the R-factor 
decreases while the Rfree does not improve, the model could be over fitted and the refinement 
step should be reevaluated. After multiple steps of successful refinement, the final model should 
yield an R-factor below 25% and an Rfree below 30%. 
The quality of the final model is validated by comparing model parameters like bond lengths and 
angles with the ideal values from literature [78]. As these parameters are often constrained to the 
ideal values during refinement, the orientation of amino acids is used as independent criterion of 
model accuracy. In a Ramachandran plot, the Φ and Ψ angles of each amino acid are plotted. For 
each amino acid there are favorable regions on the plot, unfavorable but allowed regions and 
disallowed regions defined in the literature [79]. In the Ramachandran statistics the vast majority 
(>95 %) of amino acids should fall into the favored region with only a small portion in 
unfavorable or disallowed regions. It is possible for amino acids to attain conformations from the 
disallowed regions of the plot, but those amino acids should have well defined electron density 
and an environment that can explain the unusual conformation. 
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2.4 Materials 
2.4.1 List of primers 
# Name Sequence 5` to 3` Usage 
1 CGHC->SGHS a` 
for 
GTACTATGCCCCATGGTCTGGTCACTC
TAAGAGATTGGCCCCAAC Mutagenesis of yeast PDI 
2 CGHC->SGHS a` 
rev 
GTTGGGGCCAATCTCTTAGAGTGACC
AGACCATGGGGCATAGTAC Mutagenesis of yeast PDI 
3 Q87K for CATTACCTTGGCCAAGATCGACTGTAC Mutagenesis of yeast PDI 
4 Q87K rev GTACAGTCGATCTTGGCCAAGGTAATG Mutagenesis of yeast PDI 
5 L400E for GGACGTTCTTGTTGAGTACTATGCCCC  Mutagenesis of yeast PDI 
6 L400E rev GGGGCATAGTACTCAACAAGAACGTCC Mutagenesis of yeast PDI 
7 Seq -20/6490 for GTTTTTGCTTGGATCCCAGG Sequencing of yeast PDI 
8 seq 575/7085 for CCCTCCGCCATGGACGAGCC Sequencing of yeast PDI 
9 seq 555/7065 rev GGCTCGTCCATGGCGGAGGG Sequencing of yeast PDI 
10 seq 1038/7548 for CCTCCCCAATCGTGAAGTCC Sequencing of yeast PDI 
11 seq 1018/7528 rev GGACTTCACGATTGGGGAGG Sequencing of yeast PDI 
12 seq 1433/8043 rev CAGCCGGATCCCCTTCCTGC Sequencing of yeast PDI 
13 yPDI GLY242 for GCATGCCATATGGGTGAAATCGACGGTTCCG Mutagenesis of yeast PDI 
14 yPDI GLY242 rev CAGAATTCAACCAAAGTAGGGCAAGGCTTCC Mutagenesis of yeast PDI 
15 yPDI GLN140 for GCATGCCATATGCAACCGGCTGTCGCCG Mutagenesis of yeast PDI 
16 yPDI GLN140 rev GTGAATTCATTGGCTTTGCTTGATCATGAATTGG Mutagenesis of yeast PDI 
17 yPDI VAL365 for GCATGCCATATGGTGAAGTCCCAAGAGATCTTCG Mutagenesis of yeast PDI 
18 yPDI VAL365 rev GCATGAATTCACACGATTGGGGAGGCATCAC Mutagenesis of yeast PDI 
19 yPDI start for GCTGGTCATATGCAACAAGAGG PCR amplification 
20 yPDI term rev CGAGTCAGAATTACAATTCATCGTGAATGG PCR amplification 
21 yeast htm1 5' GCATACTAGTGTTTGCTGCTTATGGGTGCTTCTAG PCR amplification 
22 yeast htm1 3' GCATCTCGAGTCATCATACAATAAATAAGTTGATGATGG PCR amplification 
23 yeast htm1 c term 
min 5' 
GCATCATATGAACAACTCTGTCTACTC
GTCGCACTTGG PCR amplification 
24 yeast htm1 c term CGATCTCGAGTCATCATGGGATCAGG PCR amplification 
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min 3' CACGTGCTAAATTGC 
25 human calreticulin 
5' 
CGATCATATGGAGCCTGCCGTCTACTT
CAAGGAGC PCR amplification 
26 human calreticulin 
3' 
CGATCTCGAGTCACTACAGCTCGTCCT
TGG PCR amplification 
27 human calnexin 5' GCATCATATGCATGATGGACATGATGATGATGTG PCR amplification 
28 human calnexin 3' CGATCTCGAGTCATCACTCTCTTCGTGGCTTTCTG PCR amplification 
29 human ERp57 5' CGATCCATGGCCGACGTGCTAGAACTCACGG PCR amplification 
30 human ERp57 3' GCATCTCGAGTCATTAGAGATCCTCCTGTGCC PCR amplification 
31 yeast htm1 639for  See Constantin Braun's Diploma Thesis Sequencing of yeast htm1 
32 yeast htm1 1032for See Constantin Braun's Diploma Thesis Sequencing of yeast htm1 
33 hPDI cluster 1 for GACGTGGCTTTTGATGCGGCAGCAAACGTCTTTGTGGAG 
Entropy reduction 
mutagenesis 
34 hPDI cluster 1 rev CTCCACAAAGACGTTTGCTGCCGCATCAAAAGCCACGTC 
Entropy reduction 
mutagenesis 
35 hPDI cluster 2 for GAGTTCTTTGGCCTGGCGGCGGCAGCGTGCCCGGCCGTGCGCC 
Entropy reduction 
mutagenesis 
36 hPDI cluster 2 rev GGCGCACGGCCGGGCACGCTGCCGCCGCCAGGCCAAAGAACTC 
Entropy reduction 
mutagenesis 
37 hPDI cluster 3 for CGCCTCATCACCCTGGCGGCGGCGATGACCAAGTACAAG 
Entropy reduction 
mutagenesis 
38 hPDI cluster 3 rev CTTGTACTTGGTCATCGCCGCCGCCAGGGTGATGAGGCG 
Entropy reduction 
mutagenesis 
39 hPDI cluster 4 for CAAGTACAAGCCCGAAGCGGCAGCGCTGACGGCAGAGAGG 
Entropy reduction 
mutagenesis 
40 hPDI cluster 4 rev CCTCTCTGCCGTCAGCGCTGCCGCTTCGGGCTTGTACTTG 
Entropy reduction 
mutagenesis 
41 yPDI cluster 1 for TACGAAGAAGCCCAGGCAGCAGCTGCTGCGGCAGCCGATGCTGACGCTG 
Entropy reduction 
mutagenesis 
42 yPDI cluster 1 rev CAGCGTCAGCATCGGCTGCCGCAGCAGCTGCTGCCTGGGCTTCTTCGTA 
Entropy reduction 
mutagenesis 
43 yPDI cluster 2 for TTATACCCAGGTGGTGCGGCCGCCGCATCTGTTGTGTACCAA 
Entropy reduction 
mutagenesis 
44 yPDI cluster 2 rev TTGGTACACAACAGATGCGGCGGCCGCACCACCTGGGTATAA 
Entropy reduction 
mutagenesis 
45 yPDI cluster 3 for GGCAACTTGAACATGGCGGCAGCATTCCCTCTATTTGCC 
Entropy reduction 
mutagenesis 
46 yPDI cluster 3 rev GGCAAATAGAGGGAATGCTGCCGCCATGTTCAAGTTGCC 
Entropy reduction 
mutagenesis 
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47 
a forw CACCACCATATGGACGCCCCCGAGGAGGAGGACC human PDI truncations 
48 
a rev 
GAATTCGGATCCTTACGGGCCCGTGC
GCTTCTTCAGC human PDI truncations 
49 
a' forw CACCACCATATGAAGCAGCCTGTCAAGGTGCTTG human PDI truncations 
50 b forw CACCACCATATGGCTGCCACCACCCTGCCTGACG human PDI truncations 
51 b rev GAATTCGGATCCTTACAGCTGGTTGTGTTTGATAAAGTCC human PDI truncations 
52 b' forw CACCACCATATGCCCCTTGTCATCGAGTTCACCG human PDI truncations 
53 b' rev GAATTCGGATCCTTACTTGATTTTGCCCTCCAGGAACG human PDI truncations 
54 
c rev 
GAATTCGGATCCTTACAGTTCATCTTT
CACAGC human PDI truncations 
55 pET23 mod forw TAAGGATCCGAATTCACTAG Sequencing of plasmids provided by L. Ruddock 
56 pET23 mod rev CATATGGTGGTGATGGTG Sequencing of plasmids provided by L. Ruddock 
 
The suffix ‘for’ or ‘forw’ denominates the primer binding 5’ to the sequence to be amplified, 
mutated or sequenced. The suffix ‘rev’ denominates the primer binding 3’ to the target sequence. 
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2.4.2 List of expression vectors 
# Vector Antibiotic Insert Origin Tag Position Linker 
1 pTYB12 Amp yeast PDI1 G.Tian CBD N-term Intein 
3 pTYB12 Amp yeast PDI1 SSSS XK1 CBD N-term Intein 
5 pTYB12 Amp human PDI G.Tian CBD N-term Intein 
7 pTYB12 Amp chicken ERp57 G.Tian CBD N-term Intein 
9 pTYB12 Amp yeast PDI SSCC XK1 CBD N-term Intein 
11 pTYB12 Amp yeast PDI CCSS XK1 CBD N-term Intein 
13 pTYB12 Amp yeast PDI 18AA C-trunc #3 G.Tian CBD N-term Intein 
14 pTYB12 Amp yeast PDI 28AA C-trunc #4 G.Tian CBD N-term Intein 
15 pTYB12 Amp yeast PDI abb'a' c-del #5 G.Tian CBD N-term Intein 
16 pTYB12 Amp yeast PDI b'a'c #6 G.Tian CBD N-term Intein 
17 pTYB12 Amp yeast PDI bb'a'c #7 G.Tian CBD N-term Intein 
18 pTYB12 Amp yeast PDI abb' #8 G.Tian CBD N-term Intein 
19 pTYB12 Amp yeast PDI ab #9 G.Tian CBD N-term Intein 
20 pTYB12 Amp yeast PDI abb'c #10 G.Tian CBD N-term Intein 
21 pTYB12 Amp yeast PDI C64A #11 G.Tian CBD N-term Intein 
22 pTYB12 Amp yeast PDI C409A #12 G.Tian CBD N-term Intein 
23 pTYB12 Amp yeast PDI P106A #13 G.Tian CBD N-term Intein 
24 pTYB12 Amp yeast PDI P451A #14 G.Tian CBD N-term Intein 
25 pTYB12 Amp yeast PDI P106A + P451A #15 G.Tian CBD N-term Intein 
26 pTYB12 Amp yeast PDI C64S + C409S #18 G.Tian CBD N-term Intein 
27 pTYB12 Amp yeast PDI C64A + C409A #19 G.Tian CBD N-term Intein 
28 pET23_X Amp human ERp27 L. Ruddock His (x6) N-term none 
29 pET23_X Amp human ERp46 L. Ruddock His (x6) N-term none 
30 pET23_X Amp human ERp18 L. Ruddock His (x6) N-term none 
31 pET23_X Amp human ERp44 L. Ruddock His (x6) N-term none 
32 pET23_X Amp human PDIp L. Ruddock His (x6) N-term none 
33 pET23_X Amp human PDIr L. Ruddock His (x6) N-term none 
34 pET23_X Amp human P5 L. Ruddock His (x6) N-term none 
35 pET23_X Amp human ERp57 L. Ruddock His (x6) N-term none 
 
All vectors carried the Lac promoter which is induced by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration as indicated in the Methods section. 
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2.4.3 Equipment 
Type Model Supplier 
Autoclave  Systec V-150 Systec 
Balance 0.5-500 g XS 6002S Dual Range Mettler Toledo 
Balance 0-1 g XS 105 Dual Range Mettler Toledo 
CD-Spectropolarimeter  J-810 Jasco 
Cell disruptor 
M-110P Microfluidics 
E615 Constant Cell Disruption Systems LTD 
Centrifuge 0-1000 mL Avanti J-26 XP Beckmann Coulter 
Centrifuge 0-2 mL 5417 R Eppendorf 
Centrifuge 0-5 0mL: 5810 R Eppendorf 
Column body (FPLC) XK 16 GE Healthcare 
Column body (gravity flow) Econo-Column 1,5 x 15 cm Biorad 
Column body (gravity flow) Econo-Column 2,5 x 20 cm  Biorad 
Crystal mounting CryoLoop Hampton Research 
Crystallization robot HoneyBee 963  Zinsser Analytik 
Dish washer Professional G7883 CD Miele 
Dynamic Light Scattering 
Spectrophotometer DynaPro Titan Wyatt Technology 
Fluorescencespectrometer Flouromax4  Horiba Jobin Yvon 
FPLC system  Äkta purifier GE Healthcare 
FPLC: Anion exchange column MonoQ 10/100 GL GE Healthcare 
FPLC: Size exclusion 
chromatrography column 
HiLoad 26/60 Superdex 200 prep 
grade GE Healthcare 
FPLC: Nickel affinity column Ni-MAC Cartridge 5 mL Merck (Novagen) 
Gelelectophoresis chamber Mini-Protean 3-cell Biorad 
Ice machine Eismaschine 94774 Ziegra Eismaschinen 
Illumination table P265.1 Roth 
Incubator Type B15 Thermo Electron Corp. 
Liquid culture incubator ISF-1-W Kühner 
Liquid handling robot Lissy  Zinsser Analytik 
Magnetic stirrer  MR 3002 Heidolph 
Microscope SteREO Discovery.V12 Zeiss 
Microscope: Camera AxioCam MRC Zeiss 
Microscope: Light source  KL 2500 LCD Zeiss 
PCR Cycler Mastercylcer EPgradient S Eppendorf 
pH-electrode BlueLine 14pH Schott 
Pipettes pipet lite Rainin 
Pippetboy pipetus Hirschmann Laborgeraete 
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Power supply PowerPac Basic Biorad 
Spectrophotometer Bio-Photometer Eppendorf 
Spectrophotometer Nanodrop ND 1000  Peqlab 
Spectrophotometer UV-Vis Agilent 
Thermoblock  Rotilabo-Block Heater 250 Roth 
Thermomixer comfort Eppendorf 
X-ray detector R-AXIS HTC Rigaku 
X-ray generator MicroMax-007HF Rigaku 
X-ray optics VariMax HF Osmic Inc. 
 
2.4.4 Consumables 
Type Model Supplier 
24-well plate SuperClear Crystalgen 
96-well plate ClearPlate Halfarea MB Greiner 
Chitin Beads S6651L New England Biolabs 
Concentrator 10 mL Vivaspin 6 Sartorius stedim Biotech 
Concentrator 30 mL Vivaspin 20 Sartorius stedim Biotech 
Disposable cuvettes UVette Eppendorf 
DEAE Sepharose DFF100 Sigma-Aldrich 
Dialysis cassettes Slide-A-Lyzer Pierce Biotechnology 
Dialysis tubing Spectra/Por SpectrumLabs.Com 
Micro reaction tubes Safe-Lock 1.5 mL / 2 mL Eppendorf 
Pipette tips  10 µl, 200 µl, 1000 µl Rainin 
Reaction tubes Greiner tube 15 ml / 50 ml Greiner 
 
3.4.5 Chemicals and Solvents 
Chemical Catalogue ID Supplier 
2-Propanol (Isopropanol) 6752.4 Roth 
Acetic acid (glacial) 7332.2 Roth 
Acetonitrile AE70.2 Roth 
Ammonia CP17.1 Roth 
Ammonium carbonate 09832 Fluka 
Ammonium peroxodisulfate 09913 Fluka 
Ammonium sulfate 9318.1 Roth 
Ampicillin (sodium salt) K029.2 Roth 
Barium Chloride 11760 Fluka 
Chloramphenicol 3886.3 Roth 
Chymotrypsin C4129 Sigma-Aldrich 
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Coomassie Brilliant Blue R25 3862.2 Roth 
Dithiothreitol 6908.4 Roth 
Ethanol (absolute) 9065.2 Roth 
Ethanol (denatured) K928.4 Roth 
Formic acid 399388 Sigma-Aldrich 
Glycerol A3552 AppliChem 
Guanidinium chloride 0037.1 Roth 
Hydrochloric acid 4623.2 Roth 
Hydrogen peroxide 8070.4 Roth 
Imidazole 3899.4 Roth 
Iodo acetic acid I6806 Sigma-Aldrich 
L-Glutathione (oxidized) G4376 Sigma-Aldrich 
L-Glutathione (reduced) A2084 AppliChem 
Magnesium chloride HN03.3 Roth 
MES 69892 Sigma-Aldrich 
Methanol 4627.5 Roth 
Nickel sulfate T111.1 Roth 
Papain 8933.1 Roth 
Phenylmethylsulfonyl fluoride 6367.2 Roth 
Poly ethylene glycol 10,000 81280 Fluka 
Poly ethylene glycol 3,000 81227 Fluka 
Poly ethylene glycol 400 81350 Fluka 
Poly ethylene glycol 5,000 monomethyl ether 81323 Sigma-Aldrich 
Potassium chloride HN02.3 Roth 
Potassium hexacyano ferrate (III) 60300 Fluka 
Potassium hydroxide 6751 Roth 
Potassium phosphate dibasic P749.3 Roth 
Potassium phosphate monobasic P9791 Sigma-Aldrich 
Potassium phosphate tribasic 60494 Fluka 
Riboflavin R7649 Sigma-Aldrich 
Sodium acetate 3580.1 Roth 
Sodium azide K305.1 Roth 
Sodium chloride 3957.2 Roth 
Sodium dodecylsulfate 2326.2 Roth 
Sodium hydroxide 6771.1 Roth 
Trichloroacetic acid 91228 Fluka 
Trifluoroacetic acid 302031 Sigma-Aldrich 
TRIS (2-Amino-2-hydroxymethyl-propane-1,3-diol) 4855.3 Roth 
Tris(2-carboxyethyl)phosphine HN95.2 Roth 
Trypsin T1426 Sigma-Aldrich 
Urea 2317.2 Roth 
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3. Results & Discussion 
3.1 The multistate-equilibrium of yeast PDI 
One of the first tasks of this project was to purify recombinant yeast PDI for biochemical 
experiments and crystallization attempts. For purification the E. coli XK2 strain was used 
together with a pTYB12-PDI vector allowing for the inducible expression of an intein-PDI-
fusion protein. The purification was carried out as described in the Methods section of this 
document utilizing a three-step purification strategy consisting of an affinity chromatography 
with chitin beads, an anion exchange chromatography using a MonoQ column and a final size 
exclusion chromatography using a Superdex200 column. During the purification process protein 
heterogeneity could be detected on the the anion exchange column. As can be seen from the 
elution profile monitoring the absorbance at 280 nm (Figure 3.1), protein eluted from the column 
at concentrations of 260 mM, 290 mM, 310 mM and 335 mM of sodium chloride with a possible 
additional species eluting at 295 mM sodium chloride forming a shoulder of the second peak. 
When samples from each absorbance peak were subjected to SDS-PAGE analysis (Figure 3.2. 
A), the peaks 2-5 contained only a single pure protein band running at a height of 57 kD while 
the first peak contained a possible degradation product. So the anion exchange chromatography 
revealed the existence of multiple isoforms of yeast PDI, apparently differing in its surface 
charge. This indicates either multiple different conformations that expose a different amount of 
charged residues to the solvent, or the existence of multiple oligomeric forms of PDI that bury 
different amounts of charged residues in the interface, or a combination of both. All peaks 
containing pure yeast PDI were subsequently pooled and concentrated. The absorbance profile of 
a size exclusion chromatography of the pure yeast PDI sample clearly shows two distinct peaks 
each (Figure 3.3). When characterized with SDS-PAGE both peaks contained one pure protein 
running at the same height indicating equal size (Figure 3.2. B). The elution volume during size 
exclusion chromatography is determined by the molecular weight, the oligomeric state and the 
molecular shape of the sample. The expected elution volume for a globular 54 kD protein on a 
Superdex 200 XK26/60 column is 220 mL. With elution volumes of 154 mL and 182 mL for the 
two species, the smaller species is already eluting considerably earlier than expected for its size. 
For the remainder of this thesis, the earlier eluting species will be referred to as the dimer while 
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(Top) Figure 3.1 – Anion exchange chromatography during the purification of yeast PDI 
Multiple protein species elute over a range of 250-400 mM salt. A sample was taken from 
each peak as indicated. The last peak eluting around 450mL was ignored as its absorbance at 
260 nm was greater than the absorbance at 280 nm. 
 
(Below) Figure 3.2 – SDS gel electrophoresis of protein samples from the PDI purification 
Left panel: Fractions taken from the anion exchange chromatography (Fig. 3.1) 
Middle panel: Pre-stained protein ladder (taken from www.invitrogen.com) 
Right panel: Fractions taken from the size exclusion chromatography (Fig. 3.3) 
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the species eluting later will be referred to as a monomer since a monomer/dimer equilibrium 
would explain the elution behavior with two peaks. 
In order to study the monomer-dimer equilibrium, samples were taken from both the monomer 
and the dimer species (as indicated in Fig. 3.3). After an 18 h incubation at 4°C both samples 
were subjected to analytical size exclusion chromatography on a Superdex200 10/100 GL. Apart 
from the protein amount, both samples eluted in an identical fashion (Fig. 3.4) indicating that 
after 18 h both samples had re-equilibrated to the same state. Interestingly, the monomer-dimer-
equilibrium is the same despite the concentration difference. So as a follow-up, a dilution series 
with a dilution factor of three was created from the monomer sample. After 18 h of equilibration, 
each sample was separated by analytical size exclusion chromatography. Each absorbance profile 
at 280 nm was analyzed using the UNICORN software to automatically detect peaks and 
calculate the corresponding peak areas. As can be seen from both the elution profiles and the 
integrated peak areas (Fig. 3.5), the ratio of monomer to dimer was more or less constant with an 
average factor of 1.96±0.18. Only the highest concentration differed significantly, most likely 
due to the higher overlapping area between the two peaks (factor changes to 2.03±0.12 when the 
highest concentration is excluded). These results show that the equilibrium between both 
molecular species is independent of the protein concentration. To further characterize the 
dynamics of the monomer-dimer-equilibrium, a time course experiment was performed. Pooled 
fractions of yeast PDI were separated once again and a sample taken from a dimer fraction was 
injected onto the analytical size exclusion column at different time points after elution (Figure 
3.6). Over time the monomer was formed from the dimer and after three hours the equilibration 
between both forms was nearly complete. To investigate the physiological relevance of the size 
exclusion experiments, a glutathione redox buffer was added to a sample and, as can be observed 
on the chromatogram of the size exclusion chromatography run, the glutathione buffer greatly 
accelerated re-equilibration (Fig. 3.6).  
Since the glutathione buffer accelerated the re-equilibration and PDI being a redox-active 
enzyme, the influence of the redox status on the monomer/dimer distribution was investigated. 
Samples of both PDI species were kept under oxidizing conditions through the addition of the 
inorganic oxidant potassium ferricyanide at a concentration of 10 mM immediately after the 
separation. After incubation for 18 h at 4°C both species were analyzed by analytical size 
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(Top) Figure 3.3 – Size exclusion chromatography of the pooled fractions 2-5 from Fig. 3.1 
Despite uniformity in the SDS PAGE analysis (Fig. 3.2A), at least two molecular species 
could be observed when the sample was loaded onto a preparative Superdex200 HiLoad 
SD26/60 column. The absorbance at 280 nm yielded maxima at 154.7 mL and 177.2 mL, 
corresponding to apparent molecular weights of 188.8 kD and 95.5 kD, respectively. 
(Below) Figure 3.4 – Analytical Size Exclusion Chromatography 
Fractions corresponding to both peaks from the previous size exclusion chromatography step 
were incubated at 4°C overnight and injected onto a Superdex200 10/100 GL column. Again, 
the absorbance profile shows two major peaks (11.9 mL and 13.4 mL) for both fractions. For 
further experiments, fractions were taken from the ‘D2’ run as indicated. 
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(Top) Figure 3.5 – Equilibrium formation at different concentrations 
A sample taken from the 177 mL peak (Figure 3.3 – fraction D2) was diluted with sample 
buffer as indicated and incubated overnight at 4°C. The undiluted sample had a concentration of 
270 µM. The dilution samples were analyzed on a Superdex200 10/100GL column injecting 
increasing volumes in order to keep the absorbance in a reasonable range for analysis resulting 
in volumes of: 50 µL (undiluted & 1:3); 100 µL (1:9 & 1:27); 200 µL (1:81 & 1:243) 
 
(Below) Figure 3.6 – Time course of the equilibrium formation 
A sample eluting earlier on the analytical size exclusion chromatography (Figure 3.4 – 11.2-
11.7 mL) was incubated for the indicated time at 4°C. ‘Redox’ indicated the addition of 
oxidized and reduced glutathione to a final concentration of 1 mM and 250 µM, respectively, 
prior to incubation. 
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exclusion chromatography. Despite the long incubation period, the dimeric species still eluted 
predominantly as a dimer (>95%) while the monomeric species eluted primarily as a monomer 
(>95%) as can be seen in Figure 3.7. In contrast, when the two PDI species were incubated with 
the reductant DTT (10 mM, 18 h, 4°C), both samples eluted as a monomer when subjected to 
size exclusion chromatography (Fig. 3.8). So while the addition of an oxidant prevents re-
equilibration and locks each species in its current state, the addition of a reductant forces both 
species into the monomeric form.  
As the initial anion exchange chromatography had shown the existence of differently charged 
groups, a charged-based separation of the PDI species was attempted. Purified yeast PDI was 
transferred into a sample buffer supplemented with 0.1% hydrogen peroxide and containing only 
100 mM sodium chloride. This sample was then loaded onto a small (2 mL) Resource Q  anion 
exchange column equilibrated with buffer A (20 mM Tris pH 8.5, 100 mM NaCl, 0.1% hydrogen 
peroxide). After washing with five column volumes of buffer A, the sample was eluted using a 
linear gradient over 60 column volumes to 100% of buffer B (20 mM Tris, 1 M NaCl, 0.1% 
hydrogen peroxide). As oxidants will damage the column matrix over time, the column was 
washed extensively immediately after the elution. PDI eluted in two major peaks corresponding 
at 250 mM and 350 mM of salt, respectively (Figure 3.9). Each of those peaks was pooled and 
concentrated separately and then subjected to size exclusion chromatography. As can be seen in 
Figure 3.10 the species eluting at 250 mM salt from the anion exchange column corresponds to 
the monomeric form, while the species eluting at 350 mM salt corresponds to the dimeric form. 
Thus it could be demonstrated that yeast PDI can be present in at least two distinct states. One 
state is either dimeric or very elongated and exposes more negatively charged residues on the 
surface. The other state is either monomeric or less elongated and possesses a surface with a 
reduced number of negatively charged residues. 
In the literature, there have been many older studies mentioning and investigating the dual state 
behavior of PDI when subjected to size exclusion chromatography. Depending on the study, the 
two states have been interpreted to be full-length PDI and a truncated form [80], a monomer and 
a dimer [81] or a dimer and a tetramer [82]. A more recent publication attributed the occurrence 
of a monomer-dimer-equilibrium to the presence of Zn2+ cations [83]. The zinc is supposed to 
coordinate the cysteine thiols present in the b’domain of two different protein disulfide 
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(Top) Figure 3.7 – Arresting the equilibration under oxidizing conditions 
Using fractions taken from the analytical separation of the two PDI species (see Fig. 3.4), 
samples were supplemented with the inorganic and thiol-free oxidant potassium ferricyanide 
(K3[Fe(CN)6]) to a final concentration of 20 mM. Under this oxidizing condition, the samples 
were incubated at 4°C overnight and then analyzed on a Superdex200 10/100GL analytical size 
exclusion column.  
 
(Below) Figure 3.8 – Effects of reductant on the equilibrium 
Using fractions taken from the analytical separation of the two PDI species (see Fig. 3.4), 
samples were supplemented with the reductant dithiothreitol (DTT) to a final concentration of 
20 mM. Under this reducing condition, the samples were incubated at 4°C overnight and then 
analyzed on a Superdex200 10/100GL analytical size exclusion column. 
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(Top) Figure 3.9 – Separation of PDI species by surface charge 
Yeast PDI was loaded on a Resource Q 2mL anion exchange chromatography column and 
eluted using a linear gradient of salt (Buffer A: 100 mM NaCl, 20 mM Tris pH 8.5; Buffer B: 
500 mM NaCl, 20 mM Tris pH 8.5) and a slow flow rate of 0.5 mL/min. Two distinct species 
eluted at approximately 250 mM NaCl and 350 mM NaCl, respectively. Fractions were taken 
from the absorbance peaks, concentrated using a Microcon concentration device (MWCO: 
10 kD) and analyzed by size exclusion chromatography. 
 
(Below) Figure 3.10 – Size exclusion analysis of charge-separated samples 
As describes above, samples eluting at different salt concentrations during the anion exchange 
chromatography were injected onto a Superdex200 10/100GL after a concentration step. The 
two species differed significantly in their elution profile. 
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isomerase molecules to create a non-covalently linked dimer. So while the existence of multiple 
states has been described, the relevance of this observation remains contested. The existence of a 
truncation can also be excluded as both observed forms can interconvert into each other. When 
the elution volumes of both PDI species were compared to a calibration curve of globular 
proteins of known molecular weight, the two species revealed apparent molecular weights of 
95.5 kD and 188.8 kD respectively. A dimer of yeast PDI has a calculated molecular weight of 
114 kD and thus the observed apparent weight of the smaller species is too small for a dimer, 
even if the dimer of PDI would assume a perfectly globular shape. As there are no reports of an 
interaction of PDI with size exclusion chromatography materials, it makes the hypothesis of a 
dimer-tetramer-equilibrium highly unlikely. The currently favored hypothesis of a zinc 
dependent dimerization can be excluded, as it has been shown to rely on a pair of cysteine 
residues located in the b’ domain of PDI. These two cysteines, while not involved in catalysis, 
were suggested to coordinate a Zn2+ ion with the cysteines of a reduced active site of another 
PDI molecule [83]. However, protein disulfide isomerase from S. cerevisiae used in these 
experiments does not contain this crucial pair of amino acids. The only cysteine residues apart 
from the active site are found in the a domain where they form a structural disulfide bond as 
could be seen in the crystal structure and by Ellman’s assay [63]. The same crystal structure was 
solved as a tetramer, but with very small protein-protein-contacts so that the tetrameric state was 
concluded to be a crystallization artifact. However, the second crystal structure of yeast PDI was 
solved as a dimer (Fig 3.10) and in this case the two PDI molecules shared approximately 2700 
Å of interface surface. The interface of this dimer occludes both the hydrophobic cleft of the b’ 
domain and involves the surface around the active site of the a’ domain. Therefore, it was 
suggested that the dimeric state represents an inactive or storage form [64].  
The monomer-dimer-equilibrium is therefore the favored hypothesis, as both the dimer and the 
monomer have been shown to exist in vivo and in vitro. The apparent weight derived from the 
size exclusion chromatography is not in disagreement with a monomer and a dimer, as the 
protein deviates from a spherical form and becomes elongated and thus yields an increased 
apparent molecular mass. This is in line with results obtained by sedimentation velocity 
experiments in the literature [84] that determined an axial ratio of 5.7 for a monomer of rat PDI. 
As it has been shown, the formation of the monomer-dimer-equilibrium is dependent on the 
redox environment of the proteins. With two redox active cysteine pairs present in PDI, the 
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redox dependency suggests a disulfide linked dimer. It has been shown [85], that the redox 
potential of the a domain active site (-188 mV) differs from the redox potential of the a’ domain 
active site (-152 mV). Also the crystal structure of yeast PDI shows the a’ domain in a reduced 
state while the active site of the a domain is mainly in the oxidized state with only 20% being 
reduced [63]. This is the redox equilibrium PDI reaches after reduction in the absence of further 
reductants. Thus, when two PDI molecules engage each other, the reduced active site of the a’ 
domain can attack the disulfide bond of the a domain of the second molecule forming an 
intermolecular disulfide bond. The most likely candidate for such a nucleophilic attack is the N 
terminal cysteine of the active site as it has been shown [86-88] that the pKA of this residue is 
reduced, and it is therforee more likely to form the reactive thiolate. Under the experimental 
condition we see rather slow interconversion taking several hours to reach equilibrium. Yet, 
under physiological conditions this should be a short lived link, as it leaves two reduced 
Figure 3.11 – Structure of a yeast PDI dimer 
Crystals grown at 22°C diffracted in a different space group (C2221 compared to the I4 of the 
earlier structure). In this structure PDI forms a dimer with an interface of 2700Å. Most of this 
surface is split evenly between the b, b’ and a’ domain. While the active site of both a domains 
are still solvent exposed and therefore potentially functional, the active site of the a’ domains 
are buried into the outward surface of the b domain of the respective partner molecule. In 
addition to the removal of the a’ domain active site from the solvent, the access to the 
hydrophobic cleft of the b’ domain is also occluded by the interaction. 
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cysteines in close proximity ready to attack the intermolecular bond for another rearrangement. 
This would trigger an attack by the C terminal cysteine of the active site in the same fashion as it 
disengages PDI from an isomerization substrate. This is in line with the results of the 
equilibration in the presence of a redox buffer where additional free thiols result in a greater 
chance of a nucleophilic attack on the intermolecular disulfide. Under reducing conditions, no 
disulfide can form and thus the complete protein population is present in the monomeric state. In 
contrast, oxidation would not shift the population to the dimeric state. With all active sites in the 
oxidized form, there is no reduced cysteine present to initiate a disulfide exchange between 
molecules and thus all the monomers will stay monomers. Likewise, dimers will remain in the 
dimeric state as the two free cysteines which would otherwise attack the intermolecular disulfide 
are in close proximity and thus are likely to form an additional disulfide. With no free thiols 
present in the solution, no interconversion can take place just as observed experimentally. The 
only problem with the monomer-dimer-hypothesis is the static monomer dimer ratio over a large 
range of PDI concentration. In standard monomer dimer dynamics as well as in the outlined 
model, an increase in concentration should result in an increase in chance encounters of two PDI 
molecules in solution and thus to an increase in the dimer over the monomer. Respectively a 
decrease in PDI concentration should result in an increase of the monomer over the dimer. This 
dimer would also have to adopt a radically different conformation as the one solved by X-ray 
crystallography (Fig. 3.11 – taken from [64]) as it needs a direct contact of the active sites of two 
different molecules. 
It is also possible to explain the results through two different protein conformations. The 
different species on the size exclusion chromatography could be the result of different shapes 
instead of different sizes. The difference in surface charge that enables the separation through 
anion exchange chromatography could be a result of different intramolecular interfaces between 
the domains of PDI exposing and burying different charged residues in their two conformations. 
In prior publications, PDI has already been shown to be a flexible protein prone to large 
movements of its domains [64], and, recently, conformational changes of a single domain have 
been documented [89] which extend to the x-linker and the b’ domain. Different conformations 
of a monomer would explain the similar ratios of both species over a wide concentration range as 
the distribution of two conformations would not necessarily be concentration-dependent. The 
active site of the thioredoxin fold is located at the beginning of an α-helix and the active site 
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disulfide bridges the helix and the preceding loop. Thus, it is possible that a change in redox 
status of the active site results in a conformational change of the corresponding active site 
domain. Such a conformational change of a single domain could be translated via the domain 
interfaces to the whole protein, resulting in an altered shape and thus the apparent molecular 
weight on a size exclusion chromatography differs. It has been shown that the redox status 
actually changes the conformation of the a’ domain of human PDI [89], thereby controlling its 
activity as a chaperone. Attributing the different apparent size to conformational changes has the 
great advantage that it explains why the ratio of the two species stays constant over a large 
concentration range. Conformational changes within a single molecule are not influenced by its 
Figure 3.12 – Suggested model for the monomer-dimer-equilibrium. 
Middle panel: The active sites of two different domains (blue and red, respectively) can 
interact with each other due to their different redox states. A cysteine in the thiolate form 
performs a nucleophilic attack on the disulfide bonded cysteine of the a domain. Likewise, 
the dimer can be disbanded by another nucleophilic attack, thus restoring both active sites to 
their monomeric form. 
Right panel: Under reducing conditions, all active sites are present in the reduced state and 
therefore no linkage between two active site domains can occur. 
Left panel: Under oxidatizing conditions, there are no free thiols present which could initiate 
a disulfide exchange reaction. Therefore the separated form stays separated (top), while the 
disuflide-bonded species stays linked (bottom). 
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concentration (excluding dimerization). Yet there are also inherent problems with this 
hypothesis. First of all a monomer running at nearly four times the apparent molecular weight 
has so far not been described in the literature. The elution volume in a size exchange 
chromatography has been shown to correlate with the radius of gyration of a molecule [90]. This 
property depends on both the size and the shape of a given sample. In order to estimate the 
potential range of the radii of gyration for a given molecular weight, I compared the globular 
carbonic anhydrase (29kD) with a stretch of collagen triple helix. While the radius of gyration 
for the carbonic anhydrase has been reported at 2.08 ± 0.03 nm [91], the radius of a 30 kD stretch 
of collagen triple helix was calculated to be 9.7 nm. The calculation was done with HydroPro 
and based on the available structure 1CAG, of which four were fused head to tail to yield a 
30 kD fragment. Thus while it is possible for monomers to run at more than four times their 
actual weight in a size exclusion chromatography, it would require an extremely stretched 
conformation. Also the observed rate of equilibration is very slow, hinting at the formation or 
breaking of covalent bonds. Finally, a change in redox state should shift PDI from one form to 
the other. While this is the case for a treatment with reductant, an oxidization of the protein does 
not shift every protein to the second state but only inhibits the formation of the equilibrium. 
It might be possible for the two active sites of one protein to interact with each other via the 
same mechanism described for the monomer-dimer-hypothesis. In this case the behavior under 
different redox conditions can be explained by the disulfide exchange between the active sites. 
Also the constant ratio of both species at varying concentrations is not in disagreement, as the 
two species would indeed be two different conformations of the protein. It would also explain the 
extreme shifts in the apparent weight as the disulfide bonded state forces PDI to adopt a compact 
ring-like arrangement with its four domains, while the non-bonded state could be much more 
elongated. This compact arrangement would be similar in shape to the existing crystal structure 
of yeast PDI where both active sites are facing each other. For the first structure of yeast PDI 
(2B5E), the radius of gyration was calculated to be 3.04 nm, which is larger than the radius of 
the 66 kD bovine serum albumin (BSA - 2.99 nm [91]). Thus, even the ring-like arrangement 
would most likely run at the observed molecular weight. However, it is unclear, if the protein is 
flexible enough to allow both active site domains to interact without sterical hindrance and 
conformational strain. A mechanism excluding intermolecular interactions would also be 
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required as otherwise an increase in concentration would increase the chance of active sites 
interacting with each other, again resulting in a shift in the ratio of both species. 
In conclusion, the two different species are both PDI and are most likely a result of a disulfide 
exchange between its active sites. With its dependency on the redox environment it is likely that 
the equilibrium between both species has a regulatory role to either control the activity of PDI, or 
to change the substrate selectivity. However, further experiments are required to determine the 
mechanisms underlying this dynamic. With the separation of both species by charge and under 
oxidizing conditions it should be possible to isolate and lock both species and subject them to 
mass spectrometry for a determination of the molecular mass. Unfortunately, it will be extremely 
difficult to assess the catalytic activities of each species as the isolation requires a strongly 
oxidizing environment which would interfere with the redox activity assays. The chaperone 
activity, however, could still be tested using appropriate assays like the refolding assay utilizing 
glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH) [92]. 
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3.2 Crystallization of PDI family members 
At the time this thesis was written, only two structures of PDI family had been solved without 
the truncation of domains. The first structure published was protein disulfide isomerase from S. 
cerevisiae [63]. It was previously known from secondary structure prediction and structural 
studies of single domains that this protein consists of four thioredoxin fold domains two of which 
contain an active site. While PDI had been suggested to be linear [83], the crystal structure 
showed the arrangement of these four domains in the shape of a twisted ‘U’, with the two active 
sites facing each other over the hydrophobic surface of the b’ domain. This non-linear shape was 
maintained, despite large-scale domain movements, in a second structure of the yeast enzyme 
[64]. The second protein solved in full-length is ERp57. This protein could be crystallized in 
complex with tapasin and showed a similar ‘U’ shape as the first PDI structure, even in complex 
with a substrate [68]. As it is still unclear, how PDI family member differ from each other, new 
structures are greatly anticipated. 
As there are two different structures of yeast PDI, each showing a different conformation 
although the crystals were grown with the same precipitant, yeast PDI was crystallized to screen 
for additional conformations. The published crystallization conditions for full-length yeast PDI 
were reported to be 28-30% PEG 2000 MME, 200-500 mM magnesium chloride and 100 mM 
sodium cacodylate buffer (pH=6.5) using hanging drop vapor diffusion with 1 µL of protein (30 
mg/mL) and 1 µL of precipitant [63]. Thus, hanging drop crystallization experiments were set up 
with the precipitant concentration extended from 26 to 32% PEG 2000 MME, 100-600 mM 
magnesium chloride at 4°C and 20°C. While most conditions yielded a clear solution or a 
separation into two liquid phases, several setups resulted in protein crystals. Unfortunately, the 
resulting crystals were not very large and most were not uniform (Figure 3.12 A-C). In testing at 
the in-house X-ray generator the crystals diffracted only weakly. When diffraction experiments 
were carried out at the BESSY synchrotron in Berlin, the crystals only diffracted up to a 
resolution of 6 Å. In an effort to increase crystal size and uniformity, a second screen was 
performed with a smaller range of precipitant conditions and selected additives as instructed by 
Dr. Geng Tian. Indeed the crystal size increased markedly, especially with barium chloride as an 
additive (Figure 3.12 D). Although the crystals were still not uniform, they had uniform parts 
that could be selectively exposed at the synchrotron. Despite the increase in crystal quality, these 
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Figure 3.13 – Protein crystals of PDI from S. cerevisiae 
A+B: Crystals grown from 30% PEG 2000; 300 mM MgCl2; 30 mg/mL protein; 1 µL 
protein + 1 µL precipitant after five weeks at 22°C. 
 
C:  A mostly single crystals grown from 30% PEG 2000; 200 mM MgCl2; 30 mg/mL 
protein; 1µL protein + 1µL precipitant after five weeks at 22°C. 
 
D:  Larger crystals with clean ends appeared after three months at 22°C from 28% PEG 
2000; 300 mM MgCl2; 10 mM BaCl2; 30 mg/mL protein; 1 µL protein + 1 µL 
precipitant.  
A B C 
D 
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crystals only diffracted up to 4.8 Å. Due to the extremely long growth period of more than three 
months, the crystallization of yeast PDI was abandoned in favor of other not yet crystallized 
family members. 
Together with yeast PDI, PDI from H. sapiens and ERp57 from Gallus gallus were set up for 
crystallization. Due to the similarity of both proteins to yeast PDI, the screening was performed 
with the honeybee pipetting robot in a sitting drop setup at a similar protein concentration of 500 
µM. Unfortunately, the initial screening including the Index screen, the Wizard Screens 1-5, the 
Crystal Clear screen and the Nextal PEG screen yielded no lead conditions. With the 
optimization of the purification of human PDI, larger quantities of protein became available and 
the crystallization attempts were resumed. A rule of thumb for the correct protein concentration 
in crystallization is a ratio of approximately 50% precipitation in the Index crystallization screen 
conditions after 24 h. When the Index screen was performed at a concentration of 40 mg/mL 
human PDI (700 µM), only 22% (21 out of 96) conditions yielded a precipitate. The 
concentration of protein was therefore increased to 85 mg/mL (1.5 mM), but still only 38% (37 
out of 96) of the tested conditions yielded precipitation. At a concentration of 300 mg/mL  (5.25 
mM) the Centricon concentration device was unable to further concentrate the protein solution, 
yet human PDI still remained in solution. When the Index screen was performed at this 
concentration, the 50% rule was met with 52% of the conditions (50 out of 96) yielding 
precipitates, however, no protein crystals were observed. Therefore, additional crystallization 
screens were performed in a sitting drop setup with the honeybee crystallization robot: Optimix 
1/2/3/5/PEG, Protein Complex screen and Nextal PEG. After four weeks of observation, a single 
condition with potential microcrystals could be observed in the Optimix 5 screen (Figure 3.13 
A). Starting from this condition, a hanging drop fine screen was set up to find suitable conditions 
for optimization. In the initial crystallization range (100 mM MES pH5.5-6.5; 12-18% PEG 5000 
MME; 50-300 mM CaCl2) several crystalline objects were observed (Figure 3.13 B+C). 
Unfortunately, these crystals could not be tested, as the PEG precipitant itself falls out of 
solution and forms a thick rubbery layer in which the crystals are embedded. Additional fine 
screens were performed around this condition with no improvement, even when set up as sitting 
drop vapor diffusion crystallization or microcapillary diffusion crystallization. Also the Additive 
screen from Hampton Research yielded no improved results.  
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Figure 3.14 – Crystallization of human 
protein disulfide isomerase 
A:  Initial condition with crystalline 
objects 
 
Optimix 5 – E9 
100 mM  MES pH 5.5 
150 mM CaCl2 
15%   PEG 5000 MME 
 
Protein concentration: 300 mg/mL 
0.3 µL protein + 0.3 µL precipitant 
Four weeks of growth 
 
B: Crystals in fine screen 1 
Fine screen – A1 
100 mM  MES pH 5.5 
50 mM  CaCl2 
12%   PEG 5000 MME 
 
Protein concentration: 300 mg/mL 
1 µL protein + 1 µL precipitant 
Three weeks of growth 
 
 
 
 
 
C: Crystals in fine screen 2 
Fine screen 2 – A5 
100 mM  MES pH 5.5 
250 mM CaCl2 
12%   PEG 5000 MME 
 
Protein concentration: 300 mg/mL 
2 µL protein + 2 µL precipitant 
Six weeks of growth 
 
A 
 
B 
 
C 
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With all further efforts leading into dead ends, protein modification was considered. Protein-
protein-interfaces are a necessity for the formation of proteins crystals. In an ordered crystal, the 
protein molecules form a regular lattice as they are oriented in the same way by crystal contacts, 
which usually involve surface contacts between protein molecules. It has been shown that the 
large and charged side chains of glutamate and lysine are both predominantly present on the 
surface [93], yet at the same time they are disfavored in protein-protein-interfaces [94]. 
Therefore replacing these charged and flexible residues with alanine – which has a small and 
low-entropy side chain but does not introduce an increase in main chain flexibility like glycine – 
can establish surface areas suitable for crystal contacts [95]. Indeed this mutational approach 
could be shown to increase the likelihood of crystallization and the quality of the structural data 
obtained [96]. A surface entropy reduction analysis was performed with the sequence of human 
PDI and the folding model of yeast PDI as known from the crystal structure. With this input, the 
web-based service SERp (Surface Entropy Reduction prediction located at 
http://services.mbi.ucla.edu/SER/) suggested several regions for mutation (Fig. 3.14). This type 
of surface mutation remains an option for further crystallization attempts, but due to time 
constraints the crystallization of human PDI within the scope of this project was discontinued. 
 
Figure 3.15 – Proposed mutations for surface entropy reduction 
With the sequence of human PDI as input, the algorithm proposed several regions for 
mutation. Displayed above are the two top results with a final score of 7.0 or greater. These 
residues are calculated to increase the surface entropy of human PDI and are not very 
conserved. In an alignment with the sequence of yeast PDI, the side chains of the 
corresponding residues were located at the protein surface. 
 
A 
 
B 
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Figure 3.16 – ERp27 crystallization 
A: Crystal Clear screen G2 
100 mM MES pH=6.5; 200 mM ammonium sulfate; 30% PEG 5000 MME 
 
B: Optimix 1screen E7 
100 mM Tris pH=8.5; 100 mM MgCl2; 25% PEG3350 
 
C: Fine screen 1 B5 (see next page) 
100 mM Tris pH=8.5; 50 mM MgCl2; 25% PEG 3350  
 
D: Fine screen 2 with micro seeding 
100 mM Tris pH=8.5; 150 mM MgCl2; 22.5% PEG 3350 
 
C 
 
D 
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Within the context of this project, large protein amounts of other human PDI family members 
were generated. The initial crystallization screens Index, Wizard 1+2, the Crystal Clear screen 
and the Optimix screens 1-3 were performed with PDIp, ERp46, ERp27, ERp18 and PDIr as 
sitting drop vapor diffusion setups at 20°C with typical protein concentrations of slightly above 1 
mM. Out of all those crystallization attempts, only ERp27 produced crystals during the screening 
process. ERp27, a protein predicted to consist of two thioredoxin fold domains but devoid of 
active site cysteines, crystallized initially in three conditions (Fig 3.15 A+B). All conditions were 
at near neutral pH (6.5 and 8.5) with polyethylene glycol (PEG 3350 and PEG 5000 MME) as 
precipitant. Fine screens were designed around both the Optimix1 E7 condition (0-200 mM 
MgCl2, 20-30% PEG 3350, 100 mM Tris pH 8.5) and the Crystal Clear G2 condition (100-400 
mM ammonium sulfate, 25-35% PEG5000 MME, 100 mM MES pH 6.5). Each fine screen was 
set up as hanging drop vapor diffusion experiments with 1 µL of 1.2 mM ERp27 and 1 µL of 
precipitant and kept at 20°C. While no crystallization could be observed for conditions derived 
from the Crystal Clear G2 condition, the Optimix1 E7 condition translated well into the hanging 
drop method with many conditions yielding crystals. Under these conditions, ERp27 formed 
many yet rather thin needles which were mostly grown together or were twinned (Fig. 3.15 C). A 
finer second screen which varied protein concentrations and drop size gave only slight 
improvements. The crystals were extracted from the crystallization tray with a nylon loop and 
incubated in mother liquor supplemented with 15% glycerol, MPD or PEG 400 as cryo 
protectants for three to five minutes before flash cooling them in liquid nitrogen. Unfortunately, 
only about 20% of the extracted crystals yielded observable diffraction when tested (as outlined 
in 2.3.13). As all of the diffracting crystals had been soaked in cryo solution containing glycerol, 
the other two cryo protectants were disregarded in further trials with ERp27. While the crystals 
showed diffraction in accordance with crystalline protein, the resolution at the in-house X-ray 
generator was limited to 8.5 Å. In addition, no clear spots could be detected, instead the crystal 
diffracted with elongated smeared signals that overlapped each other (Fig. 3.16 A). When the 
crystals were tested at the ESRF synchrotron in Grenoble, a slightly better resolution could be 
achieved, but the problem with the smeared spots remained (Fig. 3.16 B). The screening process 
was extended to the additive screen, but the crystal quality only improved marginally with a 
higher fraction of the crystals giving diffraction and a slightly improved resolution. 
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As ERp27 showed promising initial results, crystallization was continued together with the intern 
Wolfgang Koelmel. To further optimize the crystallization conditions protein stability was tested 
in different buffers. Yet neither a change in pH nor different salt concentrations could improve 
ERp27 stability as tested with a Thermofluor assay. ERp27 also did not show a preference for 
any specific cations or anions. Crystallization at different temperatures (4°C and 37°C) did not 
improve the crystal quality over crystallization at 20°C. However, seeding using the crystals 
obtained in previous crystallization trials resulted in improved crystals. For seeding, 4-8 large 
crystals were extracted – preferably selecting needles that were not grown together with 
neighboring crystals. The crystals were transferred into a 200 µL PCR tube containing 20 µL of 
mother liquor. Next the tube was placed into a sonication bath and the crystals were subjected to 
sonication for 60 seconds. This solution was used for seeding in hanging drop crystallization 
setups, by touching the liquid with a pipette tip and subsequently touching the crystallization 
drop, transferring shards of ERp27 crystals as seed.  
A 
 
Figure 3.17 – Initial diffraction experiments with ERp27 crystals 
A: Test diffraction at the in-house X-ray generator (see 2.3.13 for details) 
B: Test diffraction at the ESRF synchrotron facility 
 Exposure time: 1 sec; Phi angle: 0.5°; Detector distance: 200 mm; Wavelength 1 Å 
B 
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Using this technique, the crystal number per crystallization drop decreased while simultaneously 
the crystal size and quality increased (Fig. 3.15 D). Unfortunately, the diffraction did not 
improve with the seeding and no data set could be collected. As the crystal needles were often 
fanning out after reaching a medium size and even the rare single crystals displayed frayed ends 
and growth defects, it seemed likely that flexible parts of ERp27 were disrupting the formation 
of a uniform crystal. To test this hypothesis, we performed limited proteolysis to trim disordered 
regions. ERp27, at a final concentration of 500 mM, was incubated with varying amounts of 
three proteases, trypsin, chymotrypsin and papain, for 20 minutes at room temperature. The 
digests were analyzed by SDS PAGE (Figure 3.17). Both papain and chymotrypsin heavily 
degraded ERp27, leaving only a 10 kD fragment which possibly corresponds to one of the tightly 
folded thioredoxin domains. In contrast, a digest with trypsin initially removes only small parts 
of approximately 3 kD in size from the protein. At higher concentrations and over time, this 
stable fragment of approximately 24kD was further degraded yielding the same 10 kD fragment 
Figure 3.18 – Limited proteolysis of ERp27 
ERp27 at a final concentration of 500 µM was incubated for 20 minutes with the indicated 
proteases at three different concentrations. The left most lane shows undigested ERp27 as a 
control. While both chymotrypsin and papain rapidly degraded the protein, trypsin at lower 
concentrations only trimmed approximately 3 kD from ERp27. 
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as papain. The stable 24 kD fragment had a large enough size to encompass both thioredoxin 
domains. The digestion time was therefore optimized with trypsin at a concentration which only 
yields this fragment (see Fig. 3.18). After a large scale digest of ERp27 the tryptic fragment was 
purified using preparative size exclusion chromatography (HiLoad 26/60 Superdex 200 prep 
grade; GE Healthcare). As expected, the digested fragment eluted slightly later (∆Ve=5 mL) than 
undigested ERp27 (see Fig 3.19) with no observable impurities. Using this fragment, the fine 
screen established for ERp27 was set up. The fragment crystallized in the same conditions but 
yielded larger crystals of a higher quality (Fig 3.20 A). These crystals diffracted to a resolution 
of 3.5 Å when tested at the in-house X-ray generator (Fig 3.20 B) and a complete data set 
(Exposure time: 10 minutes per frame; Phi-angle: 0.5°; 360 images) was collected. Initial 
indexing suggested the monoclinic space group C2, however, the data could not be scaled in this 
space group and hence the crystal were assigned to the triclinic space group P1. Unfortunately, it 
became apparent during data analysis, that the seemingly single crystal contained more than one 
Figure 3.19 – Time course of ERp27 proteolysis by trypsin 
ERp27 at a final concentration of 500 mM was incubated with 50 µg/mL trypsin for the 
indicated times at room temperature. At this low concentration, the digestion time is of little 
consequence as the stable fragment is very resistant to further digestion. For the final 
digestion protocol the incubation time was set to 20 minutes. 
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lattice which all diffracted simultaneously. After several cycles of reproduction and testing, 
uniform crystals were found that in testing showed only signs of a single crystal lattice. These 
crystals were sent to the BESSY synchrotron facility in Berlin, where they diffracted to a 
resolution of 2.6-2.8 Å. Two complete data sets were recorded (Exposure time: 1 second per 
frame; Phi-angle: 0.5°; 720 images). The images were indexed with iMOSFLM in the space 
group P1 and scaled with SCALA from the CCP4 program suite. During indexing and scaling it 
became obvious, that each dataset contained data from multiple slightly misaligned crystal 
lattices. Using MOLREP and Phaser (as implemented in the CCP4 package) it was attempted to 
solve the phase problem by molecular replacement. Numerous models were tested in molecular 
replacement calculations: the existing NMR structure of the N-terminal thioredoxin fold domain 
Figure 3.20 – Purification of the tryptic fragment by size exclusion chromatography  
Comparison of the elution profile of full length (black, left Y axis) ERp27 and the same 
protein partially digested with 50 µg/mL of trypsin (red, right Y axis). The fragment 
generated by proteolytic digestion elutes 5 mL later than the full-length protein and appears as 
a single species. As only one third of the full-length protein was subjected to proteolysis, each 
curve was scaled to its own axis to allow for a better comparison. 
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of ERp27 and the bb’ domain fragments of yeast PDI, human PDI and human ERp57. Yet 
despite this multitude of molecular replacement templates, no suitable matches could be made. 
Unable to solve the structure by molecular replacement it was attempted to soak ERp27 crystals 
with heavy metal atoms to solve the phase problem by multiple isomorphous replacement. 
However, when ERp27 crystals were placed in mother liquor containing heavy metal salts, they 
shattered and dissolved within a minute. Therefore seleno-methionine substituted ERp27 was 
expressed using M9 minimal medium supplemented at induction with seleno-methionine. The 
purification of seleno-methionine ERp27 was analogous to the purification of regular ERp27, as 
was the protocol for the tryptic digestion. The seleno-methionine protein crystallized under the 
same conditions as regular ERp27, although the resulting crystals diffracted X-rays only poorly. 
The crystallization conditions were optimized by Wolfgang Koelmel by screening for different 
cations. By replacing magnesium chloride with sodium chloride, he was able to create selenium-
containing crystals that diffracted up to a resolution of 2.8 Å at the BESSY synchrotron in 
Berlin. Multiple data sets were recorded at a wavelength of 1 Å, which is very close to the 
Figure 3.21 – Crystallization of a tryptic fragment of ERp27 
A: Shortened ERp27 crystallizes under similar conditions as the full-length variant, but 
yields larger and more uniform crystals. Yet there are still growth defects visible as a 
single needle apparently consists of multiple smaller parallel needles. 
B: Test diffraction taken at the in-house X-ray generator (Exposure time: 20 minutes; Phi 
angle 0.5°; Detector distance: 240mm)  
A 
 
B 
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 Native dataset 
Spacegroup P1 
Unit cell dimensions (Å, °) a = 57.83 b = 68.36 c = 86.78 
α = 70.45 β = 88.16 γ = 64.96 
Unique reflections 54,973 
Resolution limits (Å) 57.8–2.2 
Completeness (highest shell) 96.2 (95.4) 
Multiplicity 5.4 (5.4) 
Rsym / Rpim (highest shell) 0.113 (0.836) / 0.063 (0.394) 
Mean <I/σI> (highest shell) 11.5 (2.0) 
 
 
 SeMet dataset 
Spacegroup P1 
Unit cell dimensions (Å, °) a = 61.04 b = 63.94 c = 105.07 
α = 90.59 β = 106.81 γ = 118.65 
Unique reflections 31,863 
Resolution limits (Å) 44.9-2.8 
Completeness (highest shell) 98.5 (98.5) 
Multiplicity 3.9 (3.9) 
Rsym / Rpim (highest shell) 0.176 (0.700) / 0.103 (0.408) 
Mean <I/σI> (highest shell) 7.5 (2.0) 
  
Phasing statistics  
Number of sites 24 
Figure of merit 0.371 
  
Refinement  
Resolution limits (Å) 41.7-2.2 
Number of working/test reflections 53,561/1,371 
Number of protein/solvent atoms 8,770/738 
Wilson B-factor (Å2) 30.1 
Overall average B-factor (Å2) 42.5 
Average B-factor individual domains (Å2) b domains: 43.7±1.8 | b’ domains: 41.4±4.8 
R factor (R free) 0.170 (0.217) 
Coordinate error (Å) 0.29 
RMS deviations from ideal values in  
Bond lengths (Å) 0.007 
Bond angles (°) 1.070 
Dihedral angles (°) 15.639 
Planar groups (Å) 0.005 
Ramachandran statistics 97.61/2.11/0.28 
 
Table 3.1 – Crystallographic statistics for the structure of ERp27 
 
Modification of a table generated by Wolfgang Kölmel. 
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absorption edge of selenium at 0.9795 Å. As before each data set contained the diffraction 
patterns of multiple crystal lattices. Using selected images, Dr. Jochen Kuper was able to index 
and subsequently process the intensities arising from the major crystal lattice. With the program 
XDS the images were processed and scaled. The ShelxC/D/E platform allowed solving the heavy 
atom substructure, resulting in the identification of 24 Se sites out of a total of 30 sites. The 
resulting sites were input into PhaserEP to solve the phase problem using single wavelength 
anomalous dispersion (SAD) resulting in a figure of merit (FOM) of 0.371. The resulting 
electron density map was promising, showing the positions of helices and a few β-strands. In 
order to improve the accuracy of the determined phases the density modification program Parrot 
was used for solvent flattening with a solvent content of 45 % and NCS averaging improving the 
figure of merit to 0.611. The resulting electron density map was detailed enough to place four 
copies of the NMR structure of the N-terminal domain into the electron densities. This allowed 
for automated model building using Buccaner. The resulting model, as expected, contained five 
chains of ERp27 in the asymmetric unit, which were nearly complete with chain lengths varying 
between 217 and 220 amino acids. This model was used for further refinement with Phenix and 
was manually modified by Wolfgang Koelmel with Coot in further rounds of refinement, 
resulting in the final model as shown in Figure 3.21 with an R factor of 17% (Rfree = 21.7). The 
final crystallographic statistics of the model are given in Table 3.1.  
The final model contains five molecules (designated A through E) of ERp27 in the asymmetric 
unit (Fig. 3.21). The protein molecules form stacks where one molecule is rotated by 72° in 
comparison to its neighbors. There are a total of five possible orientations that are iterated 
throughout the crystal in the same order (C→A→B→D→E→C). Crystal contacts within a stack 
are extensive, with interfaces of approximately 1050 Å2 shared by neighboring molecules of the 
same stack. The hydrophobic cleft – the suggested substrate binding site – is part of this intra-
stack interface (Fig. 3.21 A – green PEG molecules). In contrast, the interfaces between 
molecules of different stacks are much smaller, ranging from 60 Å2 to 320 Å2 with each 
molecule being in 7-9 interactions with a total interface area of ~550 Å2 on average. Aside from 
their orientation, the five chains found in the asymmetric unit are very similar. When 
superimposed onto each other (Fig. 3.22) low pairwise root mean square (rms) deviations 
varying between 0.337 Å and 0.684 Å (mean: 0.504 Å) were observed, however, it should be 
pointed out that ncs restrains with target values of 0.5 Å were incorporated during refinement. 
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A 
 
90° 
Figure 3.22 – Structure of ERp27- Crystal content 
(A) Five molecules make up the asymmetric unit of the ERp27 crystals. The crystal lattice is 
comprised of five ERp27 molecules (ribbon models colored in blue, cyan, yellow, red and 
green for the A/B/C/D/E chains respectively) stacked upon each other with a clockwise 
rotation of 72° between each molecule. Two chains have bound parts of a polyethyleneglycol 
molecule (green stick model) in their hydrophobic pocket. For better orientation, the N-
termini are colored in magenta and the C-termini are colored in orange. (B) Asymmetric unit 
containing two partial stacks (same coloring). While the crystal contacts within a stack are 
extensive (~1000 Å2), the contact area between stacks is rather limited (<320 Å2). This 
explains the needle shaped morphology of ERp27 crystals along with their tendency to split 
into parallel needles, causing multiple similar lattices to be present in one crystal.  
B 
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B 
 
A 
 
Figure 3.23 – Superposition of the five molecules in the asymmetric unit 
Five molecules make up the asymmetric unit of the ERp27 crystals. (A) Superposition of the 
peptide backbone. All five molecules were superimposed with the secondary-structure-
matching (SSM) function of Coot. The backbone atoms of all chains match except for one 
deviation in the C chain (green, bottom right), where a crystal contact forces a loop inward. 
(B) The same superposition with a representation of the side chains reveals a very good match 
for the majority of residues. Only selected amino acids exhibit different conformations, 
mostly at the surface due to crystal contacts. 
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Only molecule C showed a single deviation in the C-α-backbone, where a crystal contact causes 
a minor deformation of a loop. The side chains are also positioned in a very similar fashion with 
only minor deviations for surface residues most likely involved in crystal contacts. Each chain in 
the model is significantly shorter (217 to 220 residues) than the 248 amino acids for full-length 
human ERp27 after removal of the signal sequence as expected due to the proteolysis with 
trypsin. Taking into account the cleavage sites of trypsin after Lys and Arg residues, only the 
first eight amino acids presumably present in the digestion product are not resolved in the 
structure (Fig 3.23), while the C-terminus terminates with a lysine which apparently constitutes 
the C-terminal cleavage site. The amino acids at the N-terminus are most likely disordered. 
As expected from previous secondary structure analysis in the literature [71], each single ERp27 
molecule consists of two domains. Each domain is folded into the canonical thioredoxin fold 
with the secondary structure sequence of β1-α1-β2-α2-β3-β4-α3 (Fig 3.24). The N-terminal domain 
extends this fold with a single alpha helix before and after this motif (α0-β1-α1-β2-α2-β3-β4-α3-α4). 
The C-terminal domain also possesses an α0 helix but lacks the α4 helix. As seen from the 
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       250        260        270  
SVEHVQNFCD GFLSGKLLKE NRESEGKTPK VEL  
 
Figure 3.24 – Sequence of ERp27 
The open reading frame of ERp27 translates into 273 amino acids (Uni-Prot accession 
number: Q96DN0). The first 25 amino acids (shaded grey) respresent the signal sequence for 
the import into the ER and were not contained within the expression construct used. After 
purification, ERp27 was subjected to limited proteolysis with trypsin, yielding a fragment 
approximately 3 kD smaller. Analysis of potential trypsin cleavage sites (red letters) shows 
that Ser 30 as well as Lys 256 have to be included in the digestion product. The structure 
(shaded in green) accounts for 219 of the 227 amino acids of the crystallized fragment.  
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sequence, ERp27 lacks the active site motif (CXXC) of the thioredoxin family. The structure 
shows that the the sole two cysteine residues present are positioned in such a way that their side 
chains face into the interior of the protein without any surface accessibility. This further confirms 
a lack of redox activity which is consistent with the alignment of ERp27’s domains with the bb’ 
domains of other PDI family members. 
Within this project it has been shown (see 3.4) that ERp27 can bind proteins that are permanently 
unfolded through reductive carboxymethylation. It is also known from crosslinking experiments, 
that ERp27 can bind the unstructured peptide ∆-somatostatin [71]. Based on the ∆-somatostatin 
binding and an alignment of ERp27 with the bb’ domain it has been hypothesized that the C-
terminal domain of ERp27 – like PDI’s b’ domain – contains a hydrophobic cleft for substrate 
Figure 3.25 – Structure of ERp27 – Single molecule 
Model of the D chain (red molecule Figure 3.21). Each molecule consists of two domains 
(cyan and green). Both domains fold in accordance with the canonical thioredoxin fold motif 
(β1-α1-β2-α2-β3-β4-α3) with additional helices (α0 and α4) flanking the central fold. The N-
terminal domain contains a putative glycosylation site (purple – stick model). The C-terminal 
domain of the D chain has a PEG molecule (yellow – stick model) bound to its hydrophobic 
cleft (colored limon) and contains the ERp57 interaction site (turquoise – stick model). 
A 
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Figure 3.26 – The hydrophobic cleft of ERp27 
(A) Surface representation of the ERp27 D molecule with a bound PEG. The surface of the 
protein is represented as a mesh with oxygen atoms in red, nitrogen atoms in blue and carbon 
atoms in green. The hydrophobic cleft is shown in the solid surface representation (coloring as 
mesh). A PEG molecule from the crystallization mother liquor is bound to this grove, which is 
lined mainly by hydrophobic, apolar residues. This structural feature can be found in many 
PDI family members and has been shown to facilitate substrate binding. In ERp27 tyrosine 
147 extends its hydroxyl group into the floor of the cleft, disrupting the hydrophobic 
character. In the overlay of all five chains, the orientation in this tyrosine is flexible. The 
deviant A chain also has a molecule of PEG bound and its tyrosine is rotated into a 
conformation that no longer intrudes the 
hydrophobic cleft. (B) Close-up overlay of the 
hydrophobic cleft between the A chain (cyan) 
and the D chain (green). The PEG molecule of 
both models has been removed. The crucial 
tyrosine 147 – represented as stick model – 
rotates its hydroxyl group away from the surface 
extending the hydrophobic cleft from 9.5 Å to 
almost 14 Å. 
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interaction. This hypothesis is further supported by the results of isothermal titration calorimetry 
analysis (see 3.4). In these experiments ERp27 interacts with unfolded proteins in the same way 
as the corresponding fragment of human PDI.  The structure confirms the presence of a 
hydrophobic cleft in the C-terminal domain of ERp27. The helices α0 and α2 together with the β3-
β4-loop form a grove in the surface of the C-terminal domain (Fig. 3.25). The bottom of this 
grove is lined with hydrophobic side chains originating from the central β-sheet. In two of the 
five chains of the structure, this grove is filled with a fragment of the much longer 
polyethyleneglycol (PEG) molecule used as precipitant. This binding illustrates how unfolded 
linear polypeptide chains may bind to this site. In the D chain displayed in Figure 3.23, the 
flexible PEG molecule gets distorted by a ridge that runs through the bottom of the hydrophobic 
cleft, limiting its length to 9.5 Å. This ridge is formed by the hydroxyl group of Tyr 147, which 
is the most prominent polar group at the bottom of this otherwise apolar cleft. In the 
superposition of all five chains, however, the side chain of Tyr 147 in the A chain deviates from 
the consensus position (Fig. 3.25 B). The A chain is the second chain that has a PEG molecule 
bound and in this case the side chain of Tyr 147 has rotated to an angle where the hydroxyl 
group is no longer interrupting the hydrophobic cleft to the same extend. This could be a sign of 
induced fit upon substrate-binding, where the interaction of the unfolded polypeptide induces a 
conformational change to open up the hydrophobic cleft to a larger degree. Yet, judging from the 
superposition, the conformational flexibility of Tyr 147 seems to be independent of the general 
conformation of the surrounding residues. Thus, the hydroxyl group could initially be in place to 
act as a hydrogen bond donor or acceptor, but could easily be displaced in case of very 
hydrophobic substrate to make room for additional hydrophobic residues. So with the Tyr 147 
hydroxyl in the raised position, ERp27 binds two to three hydrophobic side chains followed by a 
contact with the peptide backbone. In contrast, with the tyrosine rotated out of the way, the 
hydrophobic cleft extends to a length of approximately 16 Å, which would be enough to 
accommodate two additional hydrophobic side chains. Thus, the flexibility of Tyr 147 appears to 
be a mechanism to offer an energetically more favorable binding site to a broader substrate 
population. A co-crystal structure with a peptide substrate like ∆-somatostatin would provide 
additional insights as to which ERp27 residues make contact with features of the substrate and 
what groups in the substrate are bound specifically.  
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The role of the N-terminal domain is not readily discernable from the structure. This domain is 
homologous to the b-domain in the four-domain-members of the PDI family with sequence 
identity levels ranging from 9.2% (ERp44) to 23.3% (PDI_A1). So far only a structural role has 
been suggested for these domains [97]. Usually the b domain together with the substrate-binding 
b’ domain forms a rigid base. The catalytically active thioredoxin domains (a domains) are 
flexibly linked to this two-domain core. The b domain has been suggested to correctly space the 
catalytic domains N- and C-terminal from the bb’ core as well as to ensure the correct orientation 
of N-terminal active sites in relation to the substrate-binding site located in the b’ domain. 
Figure 3.27 – Planar regression analysis of the domain orientation in the PDI family 
In order to analyze the relative orientation of the b and b’ domains with respect to each other, 
the planes defined by the central β-sheets of each domain from multiple PDI family members 
were calculated, using the coordinates of the main chain atoms as basis for a planar regression 
analysis. From each residue participating in the central β-sheet, the coordinates of the Cα 
atom as well as the carbon and nitrogen of the peptide bond were included into the data set. 
The resulting parameters defining each plane (see table below) were then used to calculate 
reference points for each plane which were included into the structure of the respective 
thioredoxin domain. (A) Ribbon model of ERp27 (green) with the reference planes for the N-
terminal b domain (red dots) and for the C-terminal b’ domain (green dots). Both planes 
intersect at a shallow angle of 25.7°. (B) Ribbon model of the bb’a fragment of human PDI 
(pdb: 3UEM) with the reference planes for the b domain (red dots) and the b’ domain (green 
dots). The angle between the two planes is much larger with 55° in the case of human PDI. In 
each case, the calculated planes fit very well with the central β-sheet, when superimposed. 
 
Protein Parameters – b domain Parameters – b’ domain Interplanar angle 
ERp27  z0= -67.1; a= 0.46 ; b= 1.19 z0= -41.8; a= -0.13; b= 0.77 25.71° 
PDI (3UEM) z0= -23.8; a= 0.84; b= -1.26 z0= -3.91; a= -0.57; b= -0.70 55.00° 
PDI (2B5E) z0= -25.0; a= -0.10; b= 0.38 z0= -51.1; a= 0.88; b= -0.28 56.32° 
ERp57 (2H8L) z0= 77.8; a= -0.19; b= 0.07 z0= 134; a= -2.10; b= 0.85 54.85° 
ERp72 (3EC3) z0= 16.3; a= 0.38; b= 0.05 z0= 33.1; a= -0.37; b= -0.80 54.94° 
 
A 
 
B 
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 In an overlay of structures of human PDI, yeast PDI, ERp57 and ERp72, the orientation of the b 
domain to the b’ domain appears to be highly conserved [97]. Even in the three domain protein 
ERp44 only minor deviations could be observed. In contrast, the N and C terminal domains of 
ERp27 appear to adopt a very different orientation towards each other. As an overlay provides 
only qualitative information about similarity, I quantified the orientation of the two thioredoxin 
domains using the central β-sheet of each domain as a reference. Using a planar regression 
analysis of the coordinates of all backbone atoms that are part of the central β-sheet, a reference 
plane was assigned to each domain (Fig. 3.26 A). As can be seen, both planes intersect each 
other at a shallow angle of 25.7°. When the same regression analysis was performed for PDI 
(human and yeast), ERp57 and ERp72, the orientation of the two domains is clearly different 
(Fig 3.26 B) with the regression planes encompassing angles between 54.9° and 56.3°. These 
results clearly show a common orientation among the larger PDI family members in their bb’ 
core, while ERp27 deviates significantly from this arrangement. This could be due to a novel 
function inherent in the N-terminal domain, but no such function could be deduced from either 
structure or function of the protein. It thus stands to reason, that the lack of catalytically active 
domains removed the orientation constraint from the domain interface allowing it to change 
during the course of evolution. The function of the N-terminal domain in ERp27 is most likely 
one of keeping the C-terminal domain in solution. This is supported by the results from the group 
of Lloyd Ruddock [71], showing a sharp decrease in protein solubility, when the N-terminal 
domain has been removed. All PDI family members show extremely high solubility in-vitro. 
This is only sensible as the primary folding catalysts of the cells have to keep hydrophobic 
substrates in solution during their interaction while acting in a highly crowded cellular 
compartment with extremely high total protein concentrations. Thus, the N terminal domain of 
ERp27 keeps the functionally critical C terminal domain soluble, enabling the protein as a whole 
to fulfill its role. It seems likely that the evolutionary pressure for high solubility has also 
modified the domain interface resulting in the observed change in orientation. 
Another interesting feature surrounding the substrate binding activity of ERp27 is the interaction 
between ERp27 and the PDI family member ERp57. ERp27, like the known ERp57-interaction-
partners calnexin and calreticulin, contains the EWD motif that is recognized by ERp57. This 
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motif is located in the β3-β4-loop which closes of the hydrophobic cleft. Initial MNR-studies on 
the ERp27-ERp57 interaction [71] reported a distinct movement of the involved tryptophan 
during interactions of ERp27 with both ∆-somatostatin and ERp57. Thus, the interaction with 
ERp57 initiates a conformational change in the β3-β4-loop which is involved in substrate-
binding. It is unclear, if the conformational change has an influence on the affinity of ERp27 
towards an unfolded substrate. ITC experiments with ERp27, ERp57 and ∆-somatostatin could 
provide insights into a potential modulation of substrate recognition of ERp27 through ERp57 
interaction. Taking the properties of both PDI family members into account, such a modulation 
would make sense. ERp57 is a very potent redox catalyst, but lacks a general substrate binding 
activity as shown in the literature [98] as well as within this project (see 3.4). It has been shown 
that ERp57’s activity in protein refolding is critically dependent on the interaction with calnexin 
and calreticulin [98, 99]. These two interaction partners belong to the protein family of lectins 
that selectively bind substrates carrying N-glycans, thereby limiting the refolding activity of 
ERp57 to glycoproteins. ERp27 on the other hand only contains a substrate binding site and is 
devoid of catalytic activity on its own. ERp27 could be shown to bind both glycosylated and 
non-glycosylated proteins and could therefore be an adaptor protein to enable ERp57 to act on 
non-glycosylated substrates. This could be a way to cope with a high substrate load or with an 
accumulation of misfolded proteins during stress situations. A potential upregulation of ERp27 
during chemically-induced ER stress is currently investigated by quantitative real-time PCR in 
cooperation with the group of Heike Hermanns. The results will hopefully further our 
understanding of the actions of ERp27 and its interactions with the PDI family during the 
unfolded protein response (UPR) of a cell. 
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3.3 Fluorescence-based assays for activity measurements of PDI 
family proteins 
In order to understand the web of functions that – as a whole – results in the oxidative folding of 
proteins in the endoplasmic reticulum it is very useful to compare the activity of different PDI 
family members to each other. However, due to the presence of multiple activities in a singular 
molecule – such as oxidase, isomerase and chaperone activity in the case of PDI – it is very 
difficult to measure the kinetic parameters of a single activity. Yet the knowledge of those 
kinetic parameters would enable a direct comparison of proteins within the PDI family in regard 
to other family members, thus possibly suggesting specific roles for each. With the exact 
determination of kinetic parameters such as rate and binding constants one could also 
characterize mutations and structural features more exactly. Over the decades of research done 
on PDI and related proteins many assays have been used to estimate the activity. RNase 
refolding assays observe the refolding of either reduced and unfolded or scrambled (randomly 
oxidized) RNase [63, 100-102]. The non-native RNase refolds in the presence of a redox buffer 
and, at various time points, samples of the refolding RNase are assayed for activity. This widely 
used assay has several drawbacks. For one it does not measure the activity of PDI directly, thus 
greatly decreasing the accuracy. The assay only registers completely refolded molecules and 
does not distinguish between folding intermediates at different stages of maturation. It also does 
not account for the difference in oxidation versus isomerization. While this is appropriate for an 
approximation of the overall activity of an enzyme, the assay cannot be used to determine kinetic 
parameters for selected activities. Another often applied assay is based on the precipitation of 
redox sensitive insulin [103]. Here, insulin is reduced in the presence and absence of a disulfide 
exchange catalyst by directly observing the progress of the reduction through the turbidity – and 
thus the absorbance – of the solution. While this assay can be used to determine the kinetic 
parameters of the reduction reaction, the assay is rather insensitive and has difficulties to 
measure low activities. For the chaperone activity, multiple assays have been established. 
Unfortunately, different assays cast a conflicting picture on the chaperone activity of PDI. While 
the refolding of the disulfide free protein GAPDH (D-Glyceraldehyde-3-phosphate 
dehydrogenase) [92] is assisted by the addition of PDI, the binding of unfolded cholera toxin 
[48] suggest an anti-chaperone or chaperone activity depending on the redox state.  
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For the in depth characterization of PDI activity, a combination of three assays were tested. The 
first assay was initially established by Raturi et al. [75] to measure the catalysis of redox 
reactions. It is based on the fluorescent properties of a molecule of oxidized glutathione (GSSG) 
labeled by a conjugation of eosin to its two N-termini. In the oxidized state, the eosin moieties 
are in close proximity and thus mutually quench their fluorescence. Upon reduction of 
glutathione, two independent molecules are created and the quenching is abolished. The resulting 
rise in fluorescence can be monitored in real time and even allows for detection of nanomolar 
concentrations of PDI [104], which is a far more sensitive and accurate quantification of the 
reduction compared to the insulin turbidity assay. As the substrate for reduction is a low 
molecular weight molecule, the reaction rate observed in this fluorescence self-quenching assay 
(FSQ assay) is most likely uninfluenced by additional substrate binding and recognition sites and 
only dependent on the active site. The information gained from the FSQ assay allows for a better 
analysis of the reduction of macromolecules.  
A second suitable assay was proposed by Stefan Lorenz (University of Bayreuth) using a domain 
with a redox sensitive fold [105]. The inserted flap (IF) domain of the phage protein BGX3 is 
domain inserted into a loop in another protein. The fold of the domain is dependent on the close 
spatial proximity of its termini and thus the isolated IF domain is unfolded. When cysteine 
residues are introduced at both the N- and C-terminus, the folding of the IF domain becomes 
dependent on its redox status. The folding of this domain is a rapid process that can be monitored 
through the single tryptophan residue which changes its fluorescence as it gets sequestered on the 
inside of the domain away from the solvent. With the help of this substrate it is possible to 
observe the catalysis of both the oxidation and the reduction by an enzyme. As the substrate is a 
macromolecule, the reaction rate is influenced by both the rate of catalysis and the substrate 
binding of an enzyme. Using the IF domain in an assay would allow to compare oxidase and 
reductase capabilities to test the hypothesis that they are closely linked. Together with the data 
from the FSQ assay it could also be used to determine the substrate binding properties of PDI 
family members.  
- 104 - 
 
The third and final assay is a protein refolding assay that can be used to investigate the isomerase 
activity of PDI family members. As described above, there are several drawbacks using the 
refolding of RNase. Also RNase contains only eight cysteine residues which allow for 105 
different SS-bond combinations. This means that even in randomly oxidatized RNase there is a 
residual activity of ~1%[47]. All those problems can be sidestepped by the use of riboflavin 
binding Protein (RfbP) to assay refolding as described by Rancy & Thorpe [76]. Riboflavin is 
bound with a very high affinity (KD=1 nM) by native apo-RfbP [74] and upon binding, the 
fluorescence of riboflavin is abolished. During refolding reactions, this allows for a direct 
measure of the number of completely refolded substrates as this is directly linked to a reduction 
in fluorescence. With 18 cysteines present in RfbP, if provides an isomerization challenge of far 
greater complexity as it results in more than 34 million potential combinations of disulfide 
bonds. Just like the RNase refolding, RfbP can be used both as a reduced and a scrambled 
substrate and is therefore suited to characterize the isomerase function of a protein especially in 
Figure 3.28 – Fluorescence measurements during di-E-GSSG purification 
The eluate from the Sephadex 25G chromatography was fractionated and samples drawn from 
each fraction. After incubation with either buffer (black squares) or 10 mM DTT (red circles) 
the fluorescence was measured. As the Fluoromax-4 was not yet purchased at the time of the 
experiment, the measurements were made using a BioRad Fluorostar with an excitation filter 
of 520 nm (5 nm bandpass) and an emission filter of 555 nm (10 nm bandpass). 
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combination with the other two assays, thus providing information about substrate binding and 
oxidation or reduction respectively. 
The di-eosin-glutathione (di-E-GSSG) substrate used in the FSQ assay was prepared as described 
in the methods section (see 2.3.7). The final step in the substrate preparation is to separate the 
conjugated di-E-GSSG from the non-conjugated educts glutathione and eosin isothiocyanate as 
well as from the glutathione molecules with only a single eosin moiety. This was done using a 
column packed with Sephadex 25G as chromatography material which is usually used for size 
exclusion chromatography. For the initial purification, a column with a volume of 5 mL was 
packed using a peristaltic pump. The reaction mix containing the di-E-GSSG was layered onto 
the surface of the column. After the substrate had entered the column overlaid with FSQ reaction 
buffer (see 2.3.7) the eluate was collected in 0.5 mL fractions, but only fractions 11 and onwards 
Figure 3.29 – Fluorescence standard curve of di-E-GSSG 
Samples of di-E-GSSG at concentrations of 125 µM to 6 mM were reduced with 10 mM DTT 
for 60 minutes at room temperature. After incubation, the samples were examined for 
fluorescence using a BioRad Fluostar with an excitation filter of 520 nm (5 nm bandpass) and 
an emission filter of 555 nm (10 nm bandpass). Each data point is the average of three 
independently prepared samples. The first four data points were fitted to a linear equation to 
gain the conversion factor between fluorescence signal and the concentration of fluorescent 
product. A concentration of E-GSH of 2 µM yields a fluorescece signal of 23400 units.  
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showed signs of color. From each fraction two samples of 10 µL were drawn and incubated with 
either reaction buffer or reaction buffer containing 10 mM DTT. After an incubation period of 60 
minutes at room temperature in the dark, the samples were tested for fluorescence. As suggested 
by the coloring, fluorescence could only be observed for fractions 11 and later (Fig. 3.3.1). This 
suggests that there is an interaction between the Sephadex 25G material and the di-E-GSSG, 
because in a normal size exclusion chromatography every component of the loaded sample 
should be eluted after one column volume. Yet the first fraction containing any eosin eluted after 
1.1 column volumes. As visible in the fluorescence plot, the fluorescence of the reduced eluate 
peaks at fraction 17. In contrast the fluorescence of the non-reduced fluorescence increases 
steadily over the monitored range. While di-E-GSSG fluoresces at the examined range, it does so 
with a very poor efficiency compared to free eosin or the reduced mono-eosin glutathione (E-
GSH) [75]. Therefore the fluorescence observed from the non-reduced samples most likely 
corresponds to single conjugated glutathione carrying only one eosin moiety and is therefore not 
subject to quenching. When comparing the ratio of the signals given by the reduced and oxidized 
Figure 3.30 – Reduction of di-E-GSSG by DTT 
The fluorescence of di-E-GSSG in concentrations ranging from 15 nM to 1 µM was measured 
simultaneously in a Fluostar plate reader. For the first 120 seconds only the base fluorescence 
of the di-E-GSSG in its oxidized form was recorded. At the 120 second mark, DTT was added 
to a final concentration of 15 µM. The raw data (left panel) shows a variable base line 
depending on the di-E-GSSG concentration. For better comparison, the signal of the first 60 
seconds of each sample was averaged and then subtracted from each data point of this sample 
to exclude the background fluorescence (right panel). After the addition of DTT the 
fluorescence increases with the rate of the increase dependent on the substrate concentration.  
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samples from each fraction, the maximum ratio of reduced to oxidized signals (signalRED to 
signalOX) was 14.71 for fraction 15. This was much lower than the ratio of 70 given in the 
literature. When pooling the fractions with a fluorescence ratio of greater than 10, the final 
concentration of di-E-GSSG as determined by the absorbance at 525 nm was 150 nM. Following 
optimization of the di-E-GSSG purification to include a larger Sephadex column (120x10 mm) 
the purity of the substrate could be improved to yield fluorescence ratios of up to 60.  
Using a dialysis tube with a molecular weight cut off of 500 Da, the substrate could be 
concentrated by dialysis against PEG 5000 to a concentration of up to 8 µM di-E-GSSG. Using 
this substrate a standard curve was generated to relate the fluorescence intensity to the quantity 
of the product E-GSH. When samples in a concentration range between 125 nM and 6 µM were 
Figure 3.31 – Reduction of di-E-GSSG catalyzed by yeast PDI 
The fluorescence of di-E-GSSG at concentrations ranging from 0 nM to 525 nM was 
measured simultaneously in a Fluostar plate reader. For the first 120 seconds only the base 
fluorescence of the di-E-GSSG in its oxidized form was recorded. At the 120 second mark, 
DTT was added to a final concentration of 15 µM. At the same time yeast PDI in FSQ assay 
buffer was added to a final concentration of 50 nM through a different injector. The baseline 
corrected signal (left panel) increases over time with the rate depending on the di-E-GSSG 
concentration. To determine the reaction rate, the data points of the first 20 seconds after the 
addition of DTT and PDI were fitted to a linear equation, the slope was plotted against the 
substrate concentration (right panel) and converted from the change in signal (∆FU/sec) to the 
quantity of formed E-GSH (pM/sec) after subtracting the background reduction in the absence 
of enzyme. The data points were fitted by linear regression with weighted errors and a fixed 
intercept at y=0 yielding a slope of 2.5×10-5 sec-1 with an R2 of 0.999. 
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reduced by the addition of 10 mM DTT, the increase in fluorescence was dependent on the 
concentration of di-E-GSSG in a linear fashion up to 1 µM (Fig. 3.3.2). At higher concentrations, 
the fluorescence increased at a slower rate, most likely due to inner and outer filter effects.  
With these results the FSQ assay had to be restricted to a substrate concentration of 1 mM or 
lower. The first kinetic experiment was the reduction of substrate by 15 µM of DTT. Samples of 
di-E-GSSG in sample buffer were prepared with a final concentration between 20 nM and 1 µM. 
Using the BioRad Fluostar, a fluorescence plate reader, the fluorescence was recorded for 2 
minutes, then DTT was injected into the well. As expected, the fluorescence increases upon 
addition of the reductant (Fig. 3.3.3). As each sample gave a different base line signal prior to the 
addition of DTT, the data were normalized to exclude the background signal. The normalized 
data showed an increase in fluorescence after DTT addition, which is dependent on the 
concentration of the substrate present. Interestingly, the signal of the two samples with the lowest 
concentration of di-E-GSSG showed a slightly different behavior than the other six signals. 
Instead of an asymptotic growth seen for higher concentrations, the signal suddenly increases 
upon DTT addition for the 15 nM and 30 nM samples. After this initial surge, the signal stays 
constant (30 nM) or even decreases in a linear fashion (15 nM). The decrease can be attributed to 
minor bleaching of the fluorophor, which in case of the 30 nM sample gets presumably 
compensated by fluorescence of the newly generated E-GSH. The reasons for the jump in the 
signal, however, remain unclear, especially as it restricted to only two samples. The six samples 
with higher substrate concentration do not show this jump, but instead an initially linear increase 
in signal. However, both the bleaching effect as well as the signal anomaly is small (less than 30 
units) compared to the increase in fluorescence upon reduction (120-1150 units for 30-1000 nM 
respectively).  
Using this background reduction rate as a blank, experiments were performed with yeast PDI as 
reduction catalyst. In this setup, after a baseline measurement both DTT and enzyme were added 
to the reaction. The reductant and the enzyme were not pre-incubated together but added 
separately. In comparison to the rate of reduction by 15 µM DTT alone, the rate was greatly 
increased in the presence of 50 nM yeast PDI (wild type). At 250 nM di-E-GSSG, a 
concentration of 15 µM DTT in the absence of enzyme increased the fluorescence signal of 250 
nM di-E-GSSG by 121.5 fluorescent units, corresponding to an increase in E-GSH concentration 
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by 10.3 pM. In the presence of 20 nM yeast PDI, the same condition results in a fluorescence 
increase of 3295 fluorescent units corresponding to an increase in E-GSH concentration by 563 
pM (Fig. 3.3.4 – left side). In order to characterize the catalysis of the reduction by PDI, the rate 
of reduction was determined from a linear fit of the initial 20 seconds of the reaction. As the 
concentration of di-E-GSSG during the initial seconds of the reaction is close to the known 
initial concentration, the reaction rate can be set in relation to the substrate concentration. 
However, for the samples with a di-E-GSSG concentration of 375 nM and higher the increase in 
the fluorescence signal had already started to leave the linear initial phase, leading to a worse fit 
and therefore an increased error in the slope (Fig 3.3.4 – right panel). This is the result of the 
restrictions of the initially used Fluostar fluorescent plate reader that only enables measurements 
at intervals of 4 seconds or more. Reducing the period for the linear range would therefore lead 
to an even greater uncertainty as less than five data points would be fitted. Despite this 
shortcoming of the initially used fluorometer, it is apparent that there is a linear relationship 
between the reaction rate and the substrate concentration. This would be in line with a pseudo-
first order reaction as the concentration of DTT greatly exceeds the concentration of the substrate 
and can therefore be approximated to remain constant throughout the reaction. However, the 
number of thiol groups available for reduction is not significantly changed by the addition of 50 
nM PDI to 15 µM DTT. Therefore a pseudo-first order model cannot explain the increase in 
reaction velocity.  
The other possible explanation is that we are observing the low concentration range of 
Michaelis-Menten-like kinetics. When the concentration of the substrate is significantly lower 
than the KD of the enzyme, the change in the reaction rate is dependent on the change of the 
substrate concentration in a linear fashion. Further exploration of the Michaelis-Menten model 
enables at least estimates of the kinetic parameter KM and vmax. The Michaelis-Menten equation 
(eq.3.3.1) describes the catalysis of a reaction in relation to the concentration of the substrate [S] 
and the properties KM and vmax of the enzyme. Plotting the rate of the reaction against the 
concentration of the substrate yields the Michaelis-Menten plot (Fig. 3.3.5), a hyperbolic curve 
that asymptotically approaches a maximum reaction rate vmax as its upper boundary and that 
reaches v=vmax/2 at a concentration that is called the Michaelis-Menten constant KM which is 
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specific for an enzyme in a given reaction environment. We can see that for concentrations that 
are very small compared to KM there is a linear relation between the concentration of the 
substrate and the reaction rate (eq.3.3.2) which are connected by the linearity factor α. 
Rearranging eq.3.3.2 for the reaction rate we can now substitute the reaction rate v in the 
Michaelis-Menten equation (eq.3.3.1) for eq.3.3.2, which can be transformed to yield a relation 
between α and the kinetic parameters [S], KM and vmax (eq.3.3.3). As this relation only holds true 
for the linear part of the Michaelis-Menten model, when KM greatly exceeds [S] or [S] 
approaches zero, we can approximate eq.3.3.3 by removing the [S] term. This yields eq.3.3.4, a 
direct relation between the slope of the near-linear part of the Michaelis-Menten equation and the 
two enzyme specific parameters KM and vmax. Applying this to our data for wild type yeast PDI 
we can estimate the ratio vmax/KM to 2.5x10-5 sec-1. This in itself is not useful without an estimate 
of either KM or vmax. Yet we can also give a range for our Michelis-Menten constant. For that we 
have to look at the deviation of our data from the linear plot. At the highest concentration used in 
this experiment series, the error from our linear fit amounts to 5%. So we can say that the 
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difference between a linear fit (eq.3.3.5) and the Michaelis-Menten-model (eq.3.3.1) is limited to 
5% at a concentration of 525 nM. When rearranging the equations for the linear model and the 
Michaelis-Menten kinetic to yield the difference between those two in relation to the value of the 
Michaelis-Menten model we arrive at a very simple relationship (eq.3.3.6). The deviation of the 
Michaelis-Menten model from its initial linear slope is equal to the ratio of the substrate 
concentration and the Michaelis-Menten constant. The maximum deviation derived from our 
data of 5.2% at a substrate concentration of 525 nM would put the Michaelis-Menten constant at 
a value of 10 µM or higher. This in turn means that the maximum reaction speed is in the range 
of 250 pM/sec or higher. 
 
In order to use the FSQ assay for comparison of different redox catalysts it has to be ascertained 
that the increase in reduction rate is caused by the catalytic activity of the active sites. Therefore 
wild type PDI and a mutant with all four active site cysteines replaced by serine (yPDI SSSS) 
were directly compared. In addition, another mutant of reduced activity – yeast PDI 18E1 – was 
tested. The yeast PDI 18E1 contains four additional cysteines that were engineered to form two 
disulfide bonds linking the a domain with the b domain and the a’ domain with the b’ domain, 
respectively. As could be shown [64] the disulfides form as intended and restrict the mobility of 
the a domains with respect to the bb’ domain core. When those three variants of PDI were tested, 
only the wild type accelerated the reduction of di-E-GSSG (Fig. 3.3.5). The addition of PDI 
SSSS actually retarded the reduction by DTT. This could be caused by an interaction of the 
substrate with the hydrophobic cleft, removing part of the substrate from the solution and 
Figure 3.32 – Comparison of the wild-type, 
SSSS and 18E1 variants of yeast PDI 
The reduction of Di-E-GSSG was 
monitored at a concentration of 100 nM in 
a Fluostar plate reader. The experimental 
procedures are as described for Fig 3.3.4 
and the baseline corrected graphs are 
shown at the right. While the wild type 
accelerates the reduction, the 18E1 mutant 
has no effect and the SSSS variant even 
retards the reaction. 
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quenching the residual fluorescence of both di-E-GSSG and E-GSH impurities. This is also 
supported by the fact that the fluorescence signal drops below the baseline which was recorded 
prior to the addition of enzyme and DTT. In contrast, the 18E1 mutant of PDI does not influence 
the reduction significantly. The lack of activity in either direction points towards both active sites 
being locked in a conformation where they are inaccessible for the substrate. In addition, the 
hydrophobic surface that might interact with the substrate in case of the SSSS mutant is covered, 
rendering the PDI 18E1 completely inactive. Only PDI shown to be catalytically active in other 
assays accelerates the reduction of di-E-GSSG, while the inactive mutants either do not influence 
or even impair the reduction.  
As a next step, a comparison between human PDI, yeast PDI and ERp57 (from Gallus gallus) 
was started, but was paused due to the introduction of a new fluorimeter. The data collection on 
the Biorad Fluostar is restricted by multiple limitations of the plate reader itself such as the 
minimum interval between measurements and the lack of a monochromator to generate or read 
the exact excitation or emission wavelengths, respectively. The Fluoromax4 fluorimeter allows 
for steadier and more exact measurements and was therefore used as soon as it was available. 
After generating standard curves, for the new system the comparison between the two PDI 
variants and chicken ERp57 was resumed in a concentration range of 100 nM to 2 µM. As 
expected both variants of PDI were very similar in their signal. In contrast the addition of ERp57 
resulting in a very large increase of the reaction speed (Fig 3.3.6). When fitting the initial 
reaction rate, the reaction velocity was non-linear even for the first 10 seconds. A further 
reduction of the time frame used for a linear fit would reduce the number data points used in a fit 
to a level where the noise inherent in single data points has a great effect on the result of the fit. 
Despite those problems, the initial reaction velocity was determined by linear fit using a 
minimum of ten data points. Plotting the reaction velocity against the substrate concentration, the 
data for chicken ERp57 followed the Michaelis-Menten model rather well (Fig 3.3.7). In 
contrast, the data of both human and yeast PDI were not following Michaelis-Menten kinetic and 
could not be fitted well with a hyperbola. Both proteins showed a sigmoidal plot of reaction 
velocity versus substrate concentration as described by the Hill equation for cooperative ligand 
binding [106].  
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As both Hill coefficients fitted to the data for human and yeast PDI are close to two, the number 
of active sites per PDI molecule, this might suggest a cooperative mode of substrate binding 
between both active sites. As both active sites face each other over the hydrophobic cleft (see 
Introduction for a model of PDI), they might indeed bind substrate together. On the other hand, 
cooperativity is usually moderated through conformational changes upon substrate binding of 
one active site, which are relayed through the protein to another active site. It has been shown, 
that redox changes in the a’ domain result in conformational changes that are not limited to the a’ 
domain, but are relayed through the flexible linker to at least the bb’ core of PDI [89].  
Also, the reduced reaction speed in the low concentration range might be explained by 
adsorption effects of the substrate, or the protein on the surface of the cuvette. These changes 
would lead to a more pronounced reduction of the reaction speed at low concentrations as the 
fixed amount of substrate that would be removed from solution would represent a greater 
fraction of the total.  
Figure 3.33 – Comparison of human and yeast PDI with chicken ERp57 
The reduction of di-E-GSSG was observed either in the absence of enzyme or in the presence 
of human PDI (hPDI), yeast PDI (yPDI) or chicken ERp57 (cERp57) (left panel – 400 nM 
substrate). While the activity of the two PDI variants was very similar, the addition of chicken 
ERp57 caused a vastly accelerated reduction of the substrate. This led to the problem that the 
linear phase of the reduction is so short, that it cannot be properly resolved by the Fluoromax4 
fluorimeter without a stopped-flow system. This is illustrated by the residuals of the linear fit 
for ERp57. Where the residuals of the fits for human and yeast PDI were randomly distributed 
around the base line, the residuals for ERp57 indicate a misfit (right panel). Yet a further 
reduction of the number of data points would greatly increase the influence of random noise. 
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Figure 3.34 – Fits of the reduction of di-E-GSSG catalyzed by PDI or ERp57 
The initial reaction rates were fitted to the di-E-GSSG reduction data (Fig 3.3.6) and plotted 
against the substrate concentration used. When the reaction rates of reactions catalyzed by 
yeast PDI were fitted using the Michaelis-Menten equation, the deviation of the data from the 
fit was rather large (R2 value of 0.964, panel A). The Hill equation, which is an extension of 
the Michaelis-Menten kinetic used for cooperative enzymes, gave a much better fit of the 
same data (R2 value of 0.998, panel B). The Hill equation also proved significantly better to 
fit the data from human PDI (panel C – Hill fit) whereas it made barely a difference for 
chicken ERp57 (panel D – Michaelis-Menten-equation). Although the Hill fit consistently 
gives a better R2 value, this is mathematically to be expected due to the greater number of 
parameters. 
A 
 
B 
 
C 
 
D 
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Figure 3.35 – Standard curve of 
riboflavin fluorescence at 450/525 nm. 
The fluorescence of a solution 
containing 1 µM of riboflavin was 
assayed for fluorescence with the 
settings as described in the Methods 
section (2.3.8). Apo-RfbP was then 
added, while keeping the total riboflavin 
concentration at 1 µM. The fluorescence 
decreases in a linear manner (red line 
indicates fit) up to a concentration of 
900 nM RfbP. The data points marked in 
red have been excluded from the fit. 
 
Figure 3.36 - Refolding of reduced RfbP 
Reduced RfbP in 0.6 M guadinium hydrochloride was diluted to a final concentration of 1 µM 
(6 mM guanidinium hydrochloride) into refolding buffer containing 1 µM riboflavin. The 
fluorescence of riboflavin was monitored at an excitation wavelength of 450 nm and an 
emission wavelength of 525 nm over 9 hours. After an initial surge, the fluorescence 
decreased in a linear fashion (left panel). As the fluorescence decreases significantly faster 
than the control without RfbP, the reduction can only in part be attributed to the bleaching of 
the riboflavin and can only be explained by the formation of native RfbP. The addition of PDI 
to the reaction increased the rate of folding in a concentration dependent manner. When the 
linear part was fitted and the rate was plotted against the concentration of the enzyme (after 
subtracting the ‘no PDI rate’), a linear relationship could be discerned between the 
concentration of the folding catalyst and the apparent folding rate (right panel). This enables a 
comparison of the folding activity of each enzyme by comparing the slope of the linear plot. 
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At higher concentrations, filter effects could come into play as suggested by the reduction of di-
E-GSSG by DTT alone. The reaction velocity values for DTT at substrate concentrations above 
1 µM are lower than expected for the linear relationship between substrate concentration and 
reaction speed of a pseudo-first-order reaction. Such filter effects would further distort a 
hyperbolic into a sigmoidal curve, especially as the sigmoidal shape is more pronounced the 
lower the reaction speed as indicated by the Hill coefficients. Thus, while the reliability of the 
determined kinetic is questionable, the qualitative difference between ERp57 and PDI in their 
acceleration of the reduction is obvious. Yet this result is rather surprising, as ERp57 had been 
less active than PDI itself in classic assays such as RNAse refolding [107] or insulin turbidity 
assays [108].  
To put the surprising reductive capabilities of ERp57 in perspective, all three proteins were also 
tested in the refolding of riboflavin binding protein (RfbP). As described in the beginning of this 
chapter, this assay provides information about the combination of oxidase, isomerase and 
substrate binding capabilities of an enzyme. The very first step taken to establish a quantitative 
RfbP refolding assay is to establish a standard curve to relate the signal to the amount of native 
apo-RfbP formed. For this, the fluorescence of 1 µM riboflavin was determined with parameters 
designed to keep the fluorescence below two million counts per seconds (CPS), which is the 
upper limit for the linear detection range of the fluorimeter’s detector. Then apo-RfbP, which had 
been prepared as described in the Methods section, was added while keeping the total riboflavin 
concentration at 1 µM. As expected, the fluorescence signal of the free riboflavin decreased as 
the added apo-RfbP bound the free riboflavin (Fig 3.3.8). The results could be fitted in a linear 
fashion yielding a factor of 1983 CPS/nM to convert the decrease in the fluorescence signal into 
the decrease in the concentration of free riboflavin in solution, which is equal to the increase in 
concentration of native RfbP. In contrast, addition of either reduced carboxymethylated RfbP 
which is permanently unfolded, or the addition of human PDI did not decrease the fluorescence 
signal. As the next step, denatured and reduced RfbP at a final concentration of 1 µM was added 
to 1 µM riboflavin in a redox refolding buffer (see Methods 2.3.8), and the fluorescence was 
monitored. Initial experimental setups with human PDI at a concentration of 100 nM revealed no 
difference in fluorescence within a time frame of 20 minutes, when compared to a setup 
containing no PDI or even no RfbP. When the time frame was significantly extended to 9 hours, 
a linear decrease in fluorescence was visible after an initial reaction phase. In the linear phase, 
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the fluorescence of assays containing RfbP decreased significantly stronger compared to just the 
free riboflavin. Thus, the additional decrease over the riboflavin only sample can only be 
attributed to the formation of native RfbP. When human PDI in varying concentrations was 
added to the refolding reaction, the rate increased, although it took near stoichiometric 
concentrations to achieve a significant increase in the refolding rate (Fig. 3.3.9).  
 
As the Michaelis-Menten kinetic is not applicable at those concentrations and, anyhow, the 
multi-step reaction of refolding cannot be described by this model, a simple model of the 
apparent rate comparison was used to fit the data. This model treats refolding as a pseudo-first-
order reaction (eq. 3.3.7) with the concentration of RfbP staying constant. The model expects a 
linear relationship between the 
concentration of the folding 
catalyst and kapp, which 
represents the reaction rate 
divided by the RfbP 
concentration. As can be seen, 
for each tested folding catalyst 
kapp increases with the 
concentration of the folding 
catalyst and the increase can 
be reasonably fitted with a 
linear equation (Fig 3.3.9 right 
panel). While this means that 
the kinetic parameters KM and 
vmax cannot be determined 
 RfbP refolding Inserted flap reduction 
Protein in % (yPDI) in % (yPDI) 
yPDI 100.0 ± 3.8 100.0 ± 4.8 
hPDI 158.5 ± 12. 078.2 ± 1.6 
cERp57 020.3 ± 1.2 06.89 ± 0.7 
yPDI SSSS 005.8 ± 0.2 --- 
 
Table 3.2 –  Comparison of the activities of selected folding 
catalysts 
The kapp data was plotted against the enzyme concentration 
and fitted with a linear model. The correlation factor obtained 
in this way was normalized (yPDI = 100%) for a comparison 
of the activities of the compared enzymes in both the RfbP 
refolding assay and the IFS reduction assay. 
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using this assay, a general folding capability can be assayed using the rate constant – as 
determined by the slope of the fitted kapp – as a measure. This allows a qualitative comparison 
between the folding catalysts. As can be seen by comparison, the general refolding capabilities of 
both human and yeast PDI are comparable (Table 3.3.1). As expected, the PDI SSSS mutant 
without active site cysteines showed barely any activity. Chicken ERp57 shows only a very low 
activity in the refolding of RfbP. This is in stark contrast to the results of the FSQ assay where 
ERp57 outperformed both PDI variants in the reduction of the low molecular weight substrate di-
E-GSSG.  
The third assay was developed by my collaboration partner Stefan Lorenz from the group of 
Prof. Franz X. Schmid at the University of Bayreuth. The substrate used for this assay is a 
mutant version of the inserted flap domain (IFD), which is part of the phage protein BGX3. This 
domain relies on the spatial proximity of its N and C termini to remain folded. In the BGX3 
protein, this is the case as the inserted flap domain is inserted into a loop of another domain and 
the fold of the parent domain ensures the spatial proximity of the IFD termini. When expressed 
and purified in isolation, the IFD remains unfolded. Only when a cysteine is introduced at each 
end of the polypeptide chain, the formation of a disulfide brings the termini together and triggers 
a spontaneous folding of the domain [105]. The introduced cysteines are the only cysteines 
present in this IFD mutant and thus there is only one intramolecular disulfide bond possible. 
Upon reduction of the disulfide bond the domain unfolds rapidly within 200 ms. The folding 
status of the domain can be determined by the fluorescence of the only tryptophan residue 
present in the mutant IFD. When excited, the emission spectrum of a tryptophan residue is 
influenced by the polarity of its microenvironment shifting to shorter wavelength in a 
hydrophobic environment.  
As of the writing of this thesis, the assay based on this redox sensitive substrate has not been 
published and I was asked to refrain from using this assay until it was published. Therefore it is 
only possible to describe and use the data gathered by myself together with Stefan Lorenz in the 
lab of Prof. Schmid. As a first step, the reduction of inserted flap substrate (IFS) by DTT was 
tested. For this 1 µM of IFS was added at time point zero into reduction buffer (100 mM 
potassium phosphate pH 7.0; 2 mM EDTA, 5 µM DTT) and the fluorescence was monitored. 
The excitation wavelength was 295 nm at which the fluorescence of tryptophan residues 
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dominates over the signal of tyrosine or phenylalanine residues. The emission was monitored at 
330 nm which is the emission maximum for tryptophan residues buried inside a folded protein 
whereas the emission maximum of a tryptophan surrounded by water is at 352 nm [109]. Over 
time the monitored fluorescence signal dropped as the IFS was reduced and unfolded. During the 
unfolding the tryptophan used as fluorescent probe becomes surrounded by water and shifts its 
emission spectrum to higher wavelengths (Fig 3.3.10 left panel). These data were fitted with a 
mono-exponential decay function expanded by a linear term to account for the bleaching of the 
fluorescent probe (eq. 3.3.8). The time constant t was used as an apparent rate constant to 
characterize the rate of the reaction. Preliminary experiments by Stefan Lorenz showed no effect 
of folding catalysts at catalytic concentrations. At stoichiometric concentrations, however, the 
rate constants increased, showing a linear dependency on the concentration of the folding 
catalyst (Fig 3.3.10 right panel). From the plot of the apparent rate constants against the 
Figure 3.37 – Reduction of the inserted flap domain substrate 
The inserted flap domain substrate, which is a mutant of the inserted flap domain of the phage 
protein BGX3 containing one cysteine at each the N and C terminus, was added to reduction 
buffer (100 mM potassium phosphate pH 7.0, 2 mM EDTA, 5 µM DTT) to a final 
concentration of 1 µM. The tryptophan fluorescence was monitored with an excitation 
wavelength of 295 nm and an emission wavelength of 330 nm. Upon reduction, the IFS 
unfolds placing the tryptophan in a polar environment, thus reducing the emission at 330 nm 
(left panel). The decrease in fluorescence was fitted with a mono-exponential decay function 
with the exponential factor being used as kapp. The experiment was repeated in the presence of 
the respective enzyme. The k values gained from each fit yielded a linear relation when 
plotted against the enzyme concentration (right panel). The correlation factor was then used to 
compare the catalytic abilities of the tested enzymes (Table 3.3.1). 
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concentration of folding catalyst the general catalytic ability for this reaction can be compared by 
a comparison of the slopes of the linear fit. As can be seen by a comparison of the slopes, human 
and yeast PDI both have comparable reductase activities for the inserted flap substrate (Table 
3.3.1). In contrast, the activity of ERp57 is significantly lower. These results are similar to the 
results gained from the RfbP assay. In both cases, ERp57 displayed only an activity that was 
barely above the background while the two PDI variants were similar in their activity and 
significantly accelerated the reaction. 
As outlined above, each of the three assays is ill-suited for the exact determination of the kinetic 
parameters KM and vmax. As established the fluorescent self-quenching assay suffers from purity 
issues of the substrate and the data processing is difficult. For very active proteins such as 
chicken ERp57, neither the current setup of the Fluoromax4 fluorimeter nor the Fluostar plate 
reader can gather enough data points to allow a fit of the linear portion of the reaction. For this a 
fluorimeter equipped with a stopped-flow system is needed to obtain data during the short initial 
period of the reaction. For proteins with low activity such as human or yeast PDI, the filter 
effects at higher substrate concentrations make it very difficult to properly fit a Michaelis-
Menten curve to the reaction velocities as such a fit is prone to error, if there are no data points at 
concentrations significantly higher than the KM. Yet the method has also shown its merit to 
compare the reductase ability of the active sites in a qualitative fashion. Likewise the refolding 
assay using the riboflavin binding protein as well as the reduction assay with the inserted flap 
substrate suffers from the low activity of the folding catalyst necessitating in both cases 
stoichiometric concentrations of the enzyme. This means that those two assays too are not 
suitable for the determination of KM and vmax, but they allow for an accurate comparison of 
activity. Nevertheless, the assays still represent very useful tools as each of the three methods 
probes a different set of functions and activities which can vary between different PDI family 
members. The activity of ERp57 greatly exceeds that of either human or yeast PDI when 
reducing a low molecular weight substrate. Yet it struggles to catalyze a refolding reaction. This 
indicates a problem with either substrate binding or isomerization as the FSQ assay has shown 
ERp57’s great oxidoreductase activity. Yet ERp57 is also a very weak catalyst for the reduction 
of the inserted flap substrate, suggesting that the substrate binding and recognition ability of 
ERp57 is very poor. This is perfectly in line with the literature where ERp57 has been shown to 
work in collaboration with lectins such as calnexin or calreticulin which are thought to handle 
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the substrate recognition [99]. This further demonstrates that the combination of these three 
assays is still a very powerful tool to dissect the activity and role of various PDI family members. 
 
 
  
- 122 - 
 
3.4 Substrate recognition of the PDI family 
With an estimated one third of all proteins undergoing oxidative folding [40], the PDI family has 
to interact with an extremely heterogeneous group of substrates. There have been studies 
reporting that PDI can attack native disulfide bonds in folded proteins [45, 110]. These results 
suggest that PDI might interact with folded and unfolded proteins alike, however, only members 
of the latter group would alter their conformation in the process. On the other hand those studies 
have been carried out under non-physiological redox conditions. Since chaperones in general are 
able to recognize hydrophobic residues and/or unstructured backbone regions associated with 
unfolded proteins [111], an alternative model would suggest that PDI selectively interacts with 
unfolded proteins relying on biochemical properties to discriminate the folding status of potential 
substrates. Using isothermal titration calorimetry (ITC), I investigated how PDI and selected 
family members interact with protein substrates. During an ITC experiment, PDI was added to 
potential substrate proteins like RNAse A or riboflavin binding protein (RfbP). I compared the 
interaction between PDI and substrates with respect to the folding status of the substrate as well 
as the redox status and domain architecture of the respective PDI family member. 
To investigate substrate recognition by members of the PDI family model substrates need to 
cover a range of molecular weights and, at the same time, contain a significant number of 
disulfide bonds. Selecting by those criteria, I chose bovine pancreatic trypsin inhibitor (BPTI), 
bovine pancreatic RNase A (RNase A) and riboflavin binding protein (RfbP) purified from 
chicken egg white that had already been employed in other studies as refolding substrates for 
PDI as well as bovine serum albumin (BSA) as a substrate with a higher molecular weight. All 
substrates were denatured and carboxymethylated as described in chapter 2.3.5 to generate 
modified and permanently unfolded substrates (denoted by ‘RCM’ for reduced 
carboxymethylated). Upon removal of guanidinium chloride through dialysis, RCM BPTI 
precipitated and could not be used in further experiments. RCM RNase A, RCM BSA and RCM 
RfbP, however, remained in solution up to concentrations of at least 150 µM in the presence of 
250 mM NaCl.  
To confirm that the substrates are unfolded even in the absence of denaturant I performed CD 
spectroscopy with samples dialyzed against 50 mM potassium phosphate buffer and 250 mM 
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NaCl. The modified forms of both RNase A and RfbP generated similar spectra that were 
consistent with a random coil conformation, thus indicating that both proteins are in the unfolded 
state [112]. As expected the unmodified proteins exhibited CD spectra that were consistent with 
folded proteins and also their known three-dimensional structures (Fig. 3.37 A). In contrast RCM 
BSA displayed a less pronounced change in the CD spectrum compared to native BSA 
(Fig. 3.37 B), probably indicating that the protein retained at least some features of its native 
conformation. For initial ITC experiments we therefore employed only RfbP and RNAseA to 
investigate in each case the differential interactions of PDI with either a folded or an unfolded 
substrate.  
To ensure a complete modification and uniformity of our modified substrate proteins, we tested 
samples of RfbP by native PAGE. We only observed a single band for RCM RfbP which 
migrated differently than unmodified RfbP (Fig. 3.38 A), suggesting that all thiol-groups had 
been modified. In order to account for possible aggregation, RCM RfbP was analyzed by 
dynamic light scattering (Fig. 3.38 B) and analytical size exclusion chromatography 
(Fig. 3.38 C). Neither method revealed significant amounts of aggregates and both methods 
indicated that RCM RfbP remains a monomeric protein. In general, our samples of the RCM-
modified substrate proteins only contained a single species and these homogenous proteins were 
used in the ITC experiments. In order to ensure that the modification had been complete we also 
loaded a sample where the excess of the modifying agent over the free thiols had been increased 
from 1:2 to 1:20. We could observe additional weakly defined bands, most likely representing 
modifications of histidine residues.  
 
In ITC control experiments I titrated native human PDI into a sample cell containing only buffer. 
Upon injection, there is a significant uptake of heat that is dependent on the concentration 
difference between the injectant and the current value in the cell (Figure S2). We have 
interpreted this signal to represent the dissociation of dimeric PDI upon dilution in the cell and 
could fit the heat from this experiment to a dissociation constant (KD) of 1.15 mM. This behavior 
is consistent with the observation of a dimeric form of PDI during the purification as well as with 
reports of homologous PDIs forming homodimers [113-115]. This background heat has been 
subtracted from all ITCs using a separate buffer run for each tested protein as reference (see 
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supplementary data Figure S2). When injecting PDI into cells containing native unmodified 
RfbP the heat release did not differ from the injections into buffer (Fig. 3.37 C), thus indicating 
that PDI does not interact with folded RfbP.  
In contrast, RCM RfbP elicited a different response (Fig. 3.37 D). After subtraction of the PDI 
dilution control, a substantial and complex heat signature remained which could not be fitted 
reasonably using a one site binding model. However, the data could be fit applying a two site 
Figure 3.38 – CD spectroscopy of model substrates and initial ITC experiments 
PDI only interacts with unfolded proteins. (A) CD spectra of RNAse (■,□) and RfbP (,○). 
Scans using native proteins are displayed with filled symbols, whereas scans using 
denatured reduced carboxymethylated (RCM) proteins are displayed with empty symbols. 
(B), CD spectra of native (filled) or RCM BSA (empty). (C-E), ITC experiments injecting 
human PDI into native RfbP (C), RCM RfbP (D), or RCM BSA (E). For every ITC 
displayed in this article, the lower panel of the graph has been corrected by subtracting the 
buffer control (see Figure S2).  
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Figure 3.39 – Effects of carboxymethylation 
(A) Native polyacrylamide gel electrophoresis of unmodified RfbP (lane 1), reduced and 
carboxymethylated (RCM) RfbP modified as described in chapter 2.3.5 (lane 2), and RfbP 
modified with a 10-fold greater excess of iodoacetic acid (lane 3). (B) Dynamic light 
scattering of a solution containing 10 µM RCM RfbP. Two peaks are detected; peak one 
(100% of the mass and 89% of the intensity) corresponds to a RCM RfbP monomer 
(calculated molecular weight of 26 kDa compared to an observed mass of 43 kDa) with a 
low polydispersity of 13.2%. (C) Size exclusion chromatography analysis on a Superdex 
200 10/100GL column. Only a very small amount (<5%) of the modified RCM RfbP forms 
an aggregate (arrow), eluting at the void volume of 8 mL. The modified protein has a higher 
apparent molecular weight, presumably due to an elongated form of the unfolded protein 
compared to the near-spherical shape of the native protein.  
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binding model resulting in: (1) One binding event that is characterized by a stoichiometry of 
approximately seven RfbP molecules to one molecule of human PDI. This binding is driven by 
an increase in entropy and is characterized by an affinity in the low micromolar range 
(Kd=1.6±0.8 µM) and at the same time is enthalpically opposed. (2) A second binding which is 
characterized by a stoichiometry of two PDI to one substrate molecule and is almost two orders 
of magnitude weaker (Kd=117±13µM) than the entropy driven binding. This binding process is 
driven by an increase in enthalpy but is entropically opposed. With two simultaneous binding 
processes within one signal, it is difficult to properly derive the thermodynamic parameters of 
each binding as the fitting process can converge to multiple, slightly differing local minima. 
Thus, from these initial experiments I could only conclude that human PDI can distinguish 
between the folded and unfolded states of a protein and interacts with denatured RfbP in a 
complex manner.  
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Figure 3.40 – Buffer correction of ITC experiments 
ITC control titrations. (A) ITC experiment in which wild-type human PDI is titrated into 
native RfbP illustrating the heat of dissociation of PDI upon dilution. (B) Titration of wild-
type human PDI into buffer only, illustrating that the resulting signal is identical to (A) and 
hence PDI does not interact with native RfpB. (C) For every ITC displayed in this thesis, the 
lower panel of the graph has been corrected by subtracting the buffer control. This can result 
in graphs where the raw data shows a heat release (C upper panel, which is identical to the 
upper panel of (A)) but the integration shows no signal relative to the background ((C) lower 
panel, resulting from the subtraction of the data shown in (B) from those shown in (A)). 
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I subsequently carried out ITC experiments with PDI and native and modified RNase A. The 
results only differ marginally from the results obtained with RfbP (Fig. 3.40). When we titrated 
PDI into a cell containing RCM BSA, the signal did not differ from the background (Fig. 3.37 E) 
despite the modification. This is consistent with the CD spectra of BSA which displayed only 
minor differences between the native and modified forms of this protein, thus confirming that 
PDI only interacts with denatured substrates. More importantly this behavior excludes the 
possibility of PDI specifically recognizing carboxymethylated cysteine residues.  
With PDI being able to recognize unfolded substrates, Iinvestigated selected members of the PDI 
family for comparison. The first paralog under investigation was ERp57, and just like PDI, 
ERp57 did not show any binding to native RfbP. However, this enzyme also did not interact with 
RCM RfbP since the heat signature did not differ from that of the dilution run (Fig. 3.41 A). The 
observed absence of a binding signal is in line with the previously published results indicating 
that ERp57 interacts with its substrates only indirectly via the lectins calnexin and calreticulin 
[116]. 
-0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
-4
-2
0
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
Po
w
er
 
in
 
µc
al
/s
ec
Molar Ratio of PDI to substrate
Q 
in
 
kc
al
/m
o
le
 
o
f i
n
jec
ta
n
t
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
-4
-2
0
0.0
0.2
0.4
0.6
0.8
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
Po
w
er
 
in
 
µc
al
/s
ec
Molar Ratio of PDI to substrate
Q 
in
 
kc
al
/m
o
le
 
o
f i
n
jec
ta
n
t
Figure 3.41 – RNAse A as binding partner for human PDI 
Binding of PDI to RNase A. Wild-type human PDI is titrated either into RCM RNase A (A), 
or native RNase A (B). This results in a biphasic binding or no interaction, respectively. 
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Figure 3.42 – Substrate binding of selected PDI family members 
Some PDI family members display only one binding mode. (A-C) ITC experiments with 
human ERp57 (A), human ERp27 (B) and human P5 (C) as titrant and RCM RfbP as 
substrate. (D), ITC tritration with P5 at a concentration of 500 µM and RCM RfbP at a 
concentration of 100 µM. 
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Human ERp27 is a family member lacking catalytic domains, yet it contains the bb’ core. When 
ERp27 was titrated into native RfbP, there was no visible difference from the buffer control (data 
not shown). In contrast, ERp27 generated a distinct heat signature when titrated into RCM RfbP 
(Fig. 3.41 B) indicating a binding very similar to the enthalpy-driven, second binding mode of 
human PDI while lacking the entropy-driven binding. With only one binding mode being 
present, the thermodynamic parameters of the binding could be fitted with confidence (see Table 
3.3), resulting in a Kd value of 168±17 µM.  
Human P5 (PDI_A6) also displayed the ability to distinguish between the folded and unfolded 
states of RfbP. As with all the other investigated proteins it showed no sign of binding to the 
native substrate (data not shown) but when titrated into RCM RfbP it displayed binding driven 
by entropy similar to the first binding mode of PDI (Fig. 3.41. C). To further investigate this 
binding, which under the initial conditions is only described by very few data points, the 
concentration of the titrant was reduced resulting in a run that ended with equimolar amounts of 
P5 and RCM RfbP. With more data points available for the fit, the thermodynamic parameters 
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Figure 3.43 – Influence of temperature on ITC results 
Comparison of ITC experiments at 10 °C and 25 °C. ERp27 (A) or P5 (B) were titrated into 
RfbP-RCM either at 25 °C (filled symbols) or 10 °C (empty symbols). Only the titrations at 
25 °C are displayed in each top panel. 
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could be determined with confidence yielding a dissociation constant of 4.7±0.3 µM 
(Fig. 3.41 D). 
To further test the different binding modes, additional experiments with ERp27 and P5 were 
performed at 10° C. I could observe similar signals at 10 °C compared to 25 °C when titrating 
ERp27 into RCM RfbP (Fig. 3.42 A). In contrast, P5 when titrated into RCM RfbP generated a 
less pronounced heat signature at the lower temperature (Fig. 3.42 B). This is in line with the 
contributions of the entropy term ‘-T∆S’. For ERp27 the contribution of the entropy is close to 
zero and therefore a change in temperature influences the observed enthalpy less than in the case 
of P5, where binding is driven by a change in entropy. Unfortunately, it is not possible to 
determine the binding enthalpies accurately enough to calculate the heat capacity of binding. 
With three members of the PDI family already showing three different binding behaviors 
towards an unfolded protein substrate, I characterized the binding behavior of four additional 
Protein Kd(µM) ∆H (kcal/mol) -T∆S 
(kcal/mol)# 
N* 
PDI (H) 78±10 -11.5±1.5 5.9 1.95±0.18 
PDI (S) 1.6±0.8 3.1±1.1 -11.0 0.15±0.01 
ERp57 n.d. n.d. n.d. n.d. 
PDIp 82±50 -15.7±0.7 10.2 1.84±0.05 
P5 4.7±0.3 14.0±0.4 -21.1 0.14±0.01 
ERp27 168±170 -7.4±0.9 2.2 1.90±0.16 
PDI a domain 5.2±1.3 6.3±2.9 -11.7 0.18±0.02 
PDI bb’ 
domains 
83±9_ -11.9±2.1 6.6 1.93±0.21 
 
Table 3.3 – Summary of thermodynamic parameters 
Binding parameters as fitted to the integrated heat signatures. PDI (H) and (S) represent the 
enthalpy-driven and entropy-driving binding modes of human PDI, respectively. (#) 
Contribution of entropy to the binding is calculated from the affinity and the observed 
enthalpy at T=298 K. Since this quantity is not directly determined experimentally, no 
standard deviations can be given. (*) Stoichiometry of the binding as derived from the ITC 
analysis. One molecule of substrate interacts with n PDI molecules. 
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family members, namely PDIp, PDIr, ERp18 and ERp46, in order to gain a more complete 
picture of substrate interaction of the PDI family. As shown in Figure 3.43, PDI is the only 
protein simultaneously displaying both binding behaviors, while there are multiple family 
members which exhibit either the entropy-driven (P5, PDIr and ERp18), or the enthalpic binding 
mode (PDIp and ERp27), or do not interact with substrate at all (ERp57 and ERp46). In all cases 
where binding could be detected, PDI family members were able to distinguish between the 
folded and unfolded states of their offered substrates. The affinity for the observed entropy-
driven binding modes was in a similar range with Kd values varying between 3 and 15 µM and a 
stoichiometry of approximately 6-8 substrates per PDI family member. In contrast, the enthalpy-
driven binding is more than one order of magnitude weaker (Kd values in the range from 60 to 
200 µM) with a stoichiometry of two enzyme molecules per substrate. 
The survey of the PDI family suggested a relationship between the binding mode and the domain 
structure of the investigated protein. In all cases where an entropy-driven binding event was 
observed, the enzyme in question contained at least one a-type domain. In contrast, occurrences 
of enthalpy-driven binding correlated precisely with the presence of at least one b-type domain 
Figure 3.44 – Domain architecture and binding modes of PDI family members 
Summary of binding modes (H=enthalpy-driven and S=entropy-driven) together with the 
domain architectures of the respective PDI family member (n.d. means no binding could be 
detected). Under the heading ITC the raw ITC data are displayed 
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Figure 3.45 – Correlation between binding behavior and domain architecture 
Mapping of binding modes to the domains of human PDI. (A) ITC analysis of the bb’ 
fragment of human PDI (A136-K352) and its interaction with RCM RfbP. (B) ITC 
experiment injecting either the a domain (E1-P135; filled symbols) or the a’ domain (K366-
D476; open symbols) into RCM RfbP. The displayed raw data in the upper panel correspond 
to the filled symbols. (C) ITC experiment injecting either the N-terminal half (E1-L234; 
empty symbols) or the C-terminal half (P235-L508; filled symbols) into RCM RfbP. The raw 
data displayed in the upper panel correspond to the filled symbols. (D) ITC experiment with 
the mobility restricted mutant of yeast PDI and RCM RfbP. For comparison the data using 
the yeast PDI wild-type has been added to the lower panel (open symbols). 
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with a hydrophobic cleft, however, there were also cases (ERp57, ERp46, PDIr and PDIp) where 
no binding could be observed despite the presence of appropriate domains.  
To better understand the contribution of a-type and b-type domains to substrate binding we 
therefore tested multiple truncations of human PDI for their interactions with the RfbP substrate. 
The first construct to be analyzed featured the bb’ domain core of PDI. When titrated into RCM 
RfbP the bb’ domains only displayed an enthalpy-driven binding with thermodynamic 
parameters similar to the enthalpic component of the full-length protein (Fig. 3.44 A). In 
contrast, the a domain interacts with RCM RfbP, and this binding event is driven by entropy. 
Surprisingly the a’ domain does not bind RCM RfbP at all (Fig. 3.44 B). When I split PDI into 
its N- and C-terminal halves, the N-terminal part containing the a and b domains displayed only 
entropy-driven binding while the C-terminal part showed enthalpic binding (Fig. 3.44 C). 
Together these experiments mapped the entropy driven binding to the isolated a domain, whereas 
the b’ domain is solely responsible for the enthalpy-driven binding.  
In order to be fully functional, PDI requires its domains to be flexible with respect to each other, 
as has been previously shown for yeast PDI (12). As soon as the domain flexibility was restricted 
by the introduction of additional disulfide bonds, tethering the a and a’ domain to the bb’ core, in 
vitro and in vivo catalysis of disulfide bond formation was greatly diminished, or entirely 
abolished. When I titrated a mobility-restricted mutant containing the mutations E123C, S247C, 
N306C and D441C into RCM RfbP, no binding could be observed (Fig. 3.44 D). This is in line 
with a model suggesting that the opening and closing of the a-type domains allows access to the 
substrate-binding site (12). 
Based on biochemical experiments and the structures of the bb’ domains from human PDI as 
well as full-length PDI of S. cerevisiae a substrate binding site in the b’ domain has been 
identified which is formed by a hydrophobic cleft in the b’ domain [63, 89, 117, 118]. Sequence 
and structural comparisons of the b’ domains of several PDI family members [97] revealed that 
the hydrophobic cleft is occluded by a network of hydrogen bonds in ERp57 and ERp72. Based 
on the structural alignment I introduced three point mutations (F249Q/F260Y/I301E) into the b’ 
domain of human PDI. When I titrated this hydrophobic cleft mutant into RCM RfbP no binding 
was evident in the ITC (Fig. 3.45 A) even though the general fold of PDI was unperturbed as 
judged by CD spectroscopy (data not shown).  
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Figure 3.46 – Factors influencing substrate binding in the a-type and b-type domains 
(A) ITC analysis with the hydrophobic cleft mutant of human PDI and RCM RfbP (raw data 
+ filled symbols). For comparison, the data of wild-type human PDI has been added to the 
bottom panel (open symbols). (B) ITC experiment with the a domain of human PDI (E1-
P135, raw data+filled symbols) pre-incubated with 5 mM reduced glutathione and then 
titrated into RCM RfbP. For comparison the data of the a domain under non-reducing 
conditions has been added (open symbols). (C) ITC experiment with human PDIp pre-
incubated with 5 mM oxidized glutathione and RCM RfbP. (D) ITC experiment in which 
human P5 at a concentration of 1 mM was titrated into 200 µM reduced glutathione. 
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For the a-type domains I focused on the Cys-X-X-Cys active site, as it is the defining feature of 
this domain. With redox active cysteines being the site of catalysis, I analyzed the impact of the 
redox status on the entropy-driven binding. I modified the ITC conditions to include 5 mM 
reduced glutathione in the buffer. This physiological reductant is also abundant in the cytoplasm 
as a redox buffer to keep proteins reduced. When I titrated the a domain of human PDI into 
unfolded substrate in the presence of reduced glutathione, I observed no binding (Fig. 3.45 B), 
whereas the same experiment carried out without reductant resulted in an entropy-driven binding 
as described above (Fig. 3.44 B). To further analyze the influence of the redox status we also 
tested reduced P5 for its ability to bind RCM RfbP and, in an analogous fashion, no binding 
could be observed (data not shown). When i tested PDIp for binding of RCM RfbP in the 
presence of 5 mM oxidized glutathione, no entropy-driven binding could be observed 
(Fig. 3.45 C) despite PDIp sharing 49.5% sequence identity. Thus, reduction of enzymes 
removes the entropy-driven binding, however, oxidation of enzymes that initially did not display 
entropy-driven binding such as PDIp does not result in an interaction with the substrate, 
indicating that these enzymes do not interact with substrates for reasons that are not connected to 
the redox status of their a-type domains and hence that there are two types of a-type domains. 
With the entropy-driven binding being redox dependent, it has been suggested (Lloyd Ruddock, 
personal communication) that the heat uptake upon injection of an a-type domain into modified 
substrate could be caused by residual unmodified thiols that attack the active site disulfide bond 
of oxidized a-type domains. If only a small portion of the substrate population would carry a free 
thiol, it would explain the unusual stoichiometry observed. To test this hypothesis I titrated P5 
into buffer containing reduced gluthathione. Despite the presence of free thiols in the substrate, 
no heat release could be observed (Fig. 3.45 D). Thus, I can exclude that the observed heat 
signature is the result of a disulfide bond exchange reaction. 
Members of the PDI family are key catalysts during the oxidative folding of newly synthesized 
proteins passing through the secretory pathway, and, whenever the PDI family network is 
severely compromised, cells suffer drastic effects[119-121]. Yet it is still unknown, how the 
functions of the different PDI family members are integrated to form the efficient processing 
network that is observed in higher eukaryotes. This study is the first to investigate substrate 
interactions of the PDI family using ITC, a method that yields more information about the 
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thermodynamic parameters describing the binding processes than the previously employed 
methods of pull-down and size exclusion chromatography experiments. In contrast to previous 
studies relying on peptides, I investigated substrate-binding using permanently unfolded full-
length proteins. The chosen proteins are well-characterized model proteins for oxidative folding 
studies such as RNase A [44, 122, 123] or RfbP [76].  
With those tools i tried to verify the hypothesis developed based on structural and biochemical 
data that substrates bind into the hydrophobic cleft of the b’ domain [65, 66, 124]. Against my 
expectations I observed not one but two separate interaction modes between the surveyed PDI 
family members and potential substrates. These binding modes are driven either by entropy or by 
enthalphy and could be structurally localized to the a-type domains and b-type domains, 
respectively. With the aid of truncation mutants of human PDI I could further narrow down the 
interaction sites to the a domain for the interaction dictated by an increase in entropy and to the 
b’ domain for the enthalpy-driven interaction.  
A comparison of the behavior of the different PDI family members revealed that every protein 
displaying entropy-driven binding contained a thioredoxin domain with a redox sensitive active 
site (a-type domain), while every protein with an enthalpy-driven binding contained a b-type 
domain which is characterized by the absence of an active site. Yet the inverse does not hold 
true. Not every a-type domain can facilitate an entropy-driven binding and not every b-type 
domain can facilitate an enthalpy-driven binding. As the binding capabilities of b-type domains 
have already been known, these domains have been extensively studied [65, 66, 125]. Based on a 
structural comparison of yPDI, ERp57 and ERp72 [97] which suggested that the binding is 
facilitated by a hydrophobic cleft in the b’ domain, I engineered an obstruction of this cleft by 
three hydrogen bonded side chains as it naturally occurs in ERp57 and ERp72. This triple mutant 
exhibited no binding at all, while its structure was not significantly altered as judged by CD 
spectroscopy (data not shown), thus demonstrating that the hydrophobic cleft is indeed 
responsible for this interaction.  
As stated above, the entropy-driven binding is exhibited by domains containing a Cys-X-X-Cys 
active site. Here, substrate binds in a redox dependent fashion, where the active site needs to be 
oxidized for the interaction to take place. Yet an oxidized active site on its own is not sufficient 
for binding as shown by the oxidation experiment of PDIp, which fails to bind substrates via the 
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entropy-driven mode despite being in the oxidized state. This suggests that there is an unknown 
structural feature that is responsible for binding, which is present in some a-type domains but not 
in others. This additional information will prove useful in analyzing the roles of single PDI 
family members. 
Questions still remain concerning the measured stoichiometries, especially in the case of the 
entropy-driven binding. The two PDI to one substrate ratio of the enthalpic binding can be 
explained by the larger size of the substrates, which presumably offer multiple binding sites. As 
the target substrates for the hydrophobic cleft have been suggested to contain either two 
consecutive aromatic residues, or two aromatic residues separated by a single non-aromatic 
residue [126], it is interesting to note that the amino acid sequence of the RfbP offers three such 
sites with two being in close spatial proximity, so that only one or the other could be bound. On 
the other hand, RNase A does not offer even a single site, yet it is recognized by b’ domains with 
a similar ratio, thus indicating an even broader recognition pattern.  
The binding of the a domain on the other hand shows a ratio of one PDI protein to six or more 
substrates. Given the limited surface of the a domain and the fact that the binding of multiple 
reduced substrates for oxidation would promote the formation of disulfide-linked aggregates 
which are connected via intermolecular bridges such a stoichiometry seems unlikely. The 
stoichiometry could also be interpreted as PDI selectively binding to only a fraction of the 
available substrate molecules. This appears to be a more appropriate interpretation, however, the 
question for the distinguishing feature of the bound substrate arises.  
When I tested substrate prepared with a more than tenfold excess of iodoacetic acid over free 
thiols, I could observe the appearance of additional molecular species in native PAGE 
experiments (Fig. 3.38 A). These most likely correspond to modifications of several histidine 
residues. This highly charged substrate was not recognized by either binding mode of PDI. Thus, 
it seems likely that the a domain actually recognizes unfolded proteins that are uncharged. When 
I prepared unfolded substrate using a twofold excess of IAA, most of the molecules are modified 
to an extent that renders them unrecognizable for the a domain. This results in the observed 
stoichiometry, where only a fraction of the offered substrate is permanently unfolded, yet not that 
strongly modified with charged groups as to abolish binding.  
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The redox sensitivity of substrate-binding by an a-type domain immediately suggests its 
involvement in the oxidase function of the protein. Since the binding only occurs with an 
oxidized active site, its only possible role is to bind unfolded substrate for the introduction of 
disulfide bonds. It has already been shown, that the a’ domain of PDI undergoes significant 
conformational changes depending on the redox status [89]. Given the high degree of homology 
between both active site domains, a similar mechanism seems likely for the a domain. On the 
other hand the isomerase activity displayed by many members of the PDI family is only possible 
when the active sites are in the reduced state. This means that isomerization of incorrectly 
disulfide-linked proteins is mostly facilitated with the help of the b’ domain binding site as the 
substrate-binding capability of an a-type domain is abolished upon reduction. Alternatively it is 
possible that within one protein the a-type domains capable of binding are predominantly in the 
oxidized form when present in their native ER redox environment. With the ‘twisted U’ shape 
adopted by PDI [63], ERp57 [68] and possibly other members of the PDI family, the a-type 
domains of one enzyme are in close spatial proximity. This would allow for one domain to bind 
substrate in need for isomerization and present it to a reduced active site of another domain 
within the same molecule. 
Up to this point PDI is the only protein investigated that simultaneously shows both modes of 
binding. This is in line with the central role in oxidative protein folding that has been attributed 
to this protein. With both forms of binding being present, the binding of the a domain will take 
precedence over the binding of the b’ domain due to the more than one order of magnitude 
higher binding affinity. Thus, the a domain binding is dominant when the protein is in the 
oxidized state, but as soon as PDI has oxidized its substrate, the b’ domain binding will take 
over. Interestingly the structure of Ero1α revealed a protruding β-hairpin [127] that has been 
suggested to bind to the hydrophobic cleft of the b’ domain of PDI. As the hydrophobic cleft 
becomes the dominant binding site upon reduction, it ensures that Ero1α can bind and reoxidize 
PDI for another cycle of catalysis. With this alternation of binding Ero1α can selectively prefer 
reduced over oxidized PDI, which has been shown previously [127]. 
The exact nature as well as location of substrate recognition still requires further investigation. 
Yet the addition of another binding site allows to further classify members of the PDI family 
depending on the number and kind of substrate-binding domains. The results of this part of the 
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project further underlines the central role of PDI itself for the oxidative folding as it is the only 
protein within its family to contain both modes of substrate binding. With the role of many PDI 
family members hinted at through their mode of binding, their function in and contribution to the 
network responsible for oxidative folding can hopefully be elucidated. 
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4. Synopsis & Outlook 
This project aimed to get a better understanding of the complex actions and interactions of the 
folding catalysts in the endoplasmic reticulum and the roles of specific PDI family member. This 
encompassed the development of new methods to characterize the activity and fuction of an 
investigated enzyme as well as a survey of the PDI family utilizing these methods. The different 
conformational or oligomeric states of PDI continue to be a topic in the literature since the first 
purifications of the protein. Despite multiple contradicting studies [64, 80-83], these potentially 
important mechanisms are still not fully recognized by the scientific community. The redox 
dependency gives a new angle to investigate the role of this mechanism, especially in regards to 
important topics like oxidative stress and the related fields of oxidizing damage and aging. While 
the results presented here suggest a functional role, it is very hard to determine the function of 
the different isoforms of PDI due to the necessity to maintain a strongly oxidative environment 
to prevent re-equilibration. This of course excludes the use of redox based assays. It might be 
possible to test the substrate binding capabilities using isothermal titration calorimetry (ITC), yet 
the strong oxidant hydrogen peroxide when tested, produced a very strong background heat that 
made it impossible to observe the actual binding reaction. While ITC based assays are by design 
not impossible to be executed under oxidative conditions, they would require extensive 
optimization of the technique. Thus the logical next step concerning the PDI isoforms is mass 
spectrometry to exclude either conformational or oligomeric changes. 
While there was little success with the initial goals of crystallizing human PDI and PDI-substrate 
co-crystals the partial results achieved can hopefully be utilized for another more optimized 
approach. From the expression and purification of a wide variety of PDI family members it 
became obvious, that besides stability, an extreme solubility is the hallmark trait of this protein 
family. As crystallization is a controlled form of precipitation, the high solubility inhibits the 
formation of crystals. Therefore the next steps in the crystallization of human PDI could be a 
reduction of surface entropy as well as potential modification of surface residues with 
hydrophobic groups to reduce solubility. Another problem is the high degree of flexibility which 
leads to a heterogeneous population of PDI molecules again preventing the formation of uniform 
crystals. For this purification under oxidizing conditions might work to create a uniform 
population of PDI molecules as described in the first part of the Results section. Utilizing a 
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combination of these tools could be the step needed to create diffracting crystals of human PDI. 
In addition, we were able to sove the structure of human ERp27. While ERp27 itself contains no 
active site, it can recognize unfolded proteins and bind them as shown by the ITC results 
presented in this thesis. In the structure, the substrate binding site is indicated by molecules of 
polyethylene glycol which partially bind to a hydrophobic cleft in the surface of the C terminal 
domain. This cleft is homologous to the known substrate binding site in PDI. It is known, that 
ERp27 interacts with ERp57 [71]. While attempts at molecular docking in silicio were not 
successful so far, we could show in collaboration with the group of Heike Hermanns that the 
expression of ERp27 is increased as a response to oxidative stress as part of the unfolded protein 
response. ERp57 has been shown to suffer from poor substrate recognition by both poor results 
in refolding and reduction assays in the literature [107, 108] as well as from the results of the 
activity assays and ITC measurements presented in this thesis (Chapter 3.3 & 3.4). Therefore 
ERp27 might work as another adaptor protein in addition to the known adaptors calnexin and 
calreticulin [99] to enable ERp57 to perform as a folding catalyst.  
Despite my failure to determine the kinetic parameters of PDI family members, the results from 
the established assays can be used for a better characterization. Especially in connectionwith the 
established ITC assay, different specializations of PDI family members can now be investigated 
further. This is an interesting prospect when looking at the ERp27-ERp57 interplay, as it might 
give a clue how ERp27 differs from the already known adaptor proteins calnexin and 
calreticulin. Especially the use of RfbP in both a refolding assay and the ITC assay can open up 
possibilities for a further characterization due to the glycosylation that RfbP carries when 
purified from chicken eggs. This is an important feature as both calnexin and calreticulin belong 
to the lectins – a class of proteins known to recognize proteoglycans. Classic refolding substrates 
mostly do not contain proteoglycans and standard recombinant substrates will nett contain them 
due to the inability of E. coli to glycosylate. RfbP in contrast can be easily deglycosylated by 
PNGaseF to create substrates with and without glycosylations for comparison. As the ER is not 
only the location for oxidative protein folding but also the location for N-linked glycosylation, a 
specialization of specific PDI family members for glycosylated or non-glycosylated proteins is a 
likely possibility. With four different activity assays – three based on fluorescence and another 
one based on ITC – available now for a qualitative analysis of the different activities, an in-depth 
characterization of the PDI family would further our understanding of the specifics of each 
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protein. Such a general study would provide starting points for further investigations to unravel 
the relations in the ER folding network. 
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